



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) **Date de dépôt PCT/PCT Filing Date:** 2022/10/21
(87) **Date publication PCT/PCT Publication Date:** 2023/04/27
(85) **Entrée phase nationale/National Entry:** 2024/04/16
(86) **N° demande PCT/PCT Application No.:** US 2022/078498
(87) **N° publication PCT/PCT Publication No.:** 2023/070082
(30) **Priorités/Priorities:** 2021/10/22 (US63/270,849);
2022/02/09 (US63/308,289); 2022/05/25 (US63/345,654)

(51) **Cl.Int./Int.Cl.** **A61K 31/713** (2006.01),
A61K 38/00 (2006.01), **A61K 45/06** (2006.01),
A61P 35/00 (2006.01), **C12N 15/113** (2010.01)
(71) **Demandeur/Applicant:**
ARROWHEAD PHARMACEUTICALS, INC., US
(72) **Inventeurs/Inventors:**
NICHOLAS, ANTHONY, US;
PEI, TAO, US;
BUSH, ERIK W., US;
YUAN, TINGTING, US
(74) **Agent:** LAVERY, DE BILLY, LLP

(54) **Titre : AGENTS D'ARNI POUR L'INHIBITION DE L'EXPRESSION DE LA METALLOPROTEINASE MATRICIELLE 7 (MMP7),
COMPOSITIONS DE CEUX-CI, ET PROCEDES D'UTILISATION**
(54) **Title: RNAI AGENTS FOR INHIBITING EXPRESSION OF MATRIX METALLOPROTEINASE 7(MMP7), COMPOSITIONS
THEREOF, AND METHODS OF USE**

(57) **Abrégé/Abstract:**

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a matrix metalloproteinase 7 (MMP7) gene. The MMP7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MMP7 gene. Pharmaceutical compositions that include one or more MMP7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MMP7 RNAi agents to pulmonary cells, in vivo, provides for inhibition of MMP7 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as idiopathic pulmonary fibrosis (IPF).



Date Submitted: 2024/04/16

CA App. No.: 3235224

Abstract:

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a matrix metalloproteinase 7 (MMP7) gene. The MMP7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MMP7 gene. Pharmaceutical compositions that include one or more MMP7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MMP7 RNAi agents to pulmonary cells, in vivo, provides for inhibition of MMP7 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as idiopathic pulmonary fibrosis (IPF).

RNAI AGENTS FOR INHIBITING EXPRESSION OF MATRIX METALLOPROTEINASE 7(MMP7), COMPOSITIONS THEREOF, AND METHODS OF USE

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to United States Provisional Patent Application Serial No. 63/270,849, filed on 22 October 2021, United States Provisional Patent Application Serial No. 63/308,289, filed on 9 February 2022, and United States Provisional Patent Application Serial No. 63/345,654, filed on 25 May 2022, the contents of each of which are incorporated herein by reference in their entirety.

SEQUENCE LISTING

[0002] This application contains a Sequence Listing which has been submitted in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy is named 30673_WO_SequenceListing.xml and is 3,575 kb in size.

FIELD OF THE INVENTION

[0003] The present disclosure relates to RNA interference (RNAi) agents, e.g., double stranded RNAi agents, for inhibition of Matrix Metalloproteinase 7 (“MMP7” or “Matrilysin”) gene expression, compositions that include MMP7 RNAi agents, and methods of use thereof.

BACKGROUND

[0004] Matrix Metalloproteinase 7 (“MMP7” or “Matrilysin”) is the smallest (28 kDa) member of the metalloproteinase (MMP) family of 24 related secreted zinc-dependent endopeptidases with diverse substrates and functions, being able to degrade components of the extracellular matrix (for example, elastin, proteoglycans, type IV collagen, fibronectin, entactin/nidogen, and the core protein of proteoglycans) as well as cleaving and modulating the activity non-extracellular matrix substrates like cytokines. (Fujishima, Shiomi et al., *Arch Pathol Lab Med* 134(8): 1136-1142 (2010); Craig, Zhang et al., *Am J Respir Cell Mol Biol* 53(5): 585-600 (2015)). These functional roles in extracellular matrix remodeling and regulation of cytokine signaling have linked members of the MMP family to common

pathogenic mechanisms contributing to cancer, chronic inflammation, and fibrosis. Despite their attractiveness as drug targets, however, the development of highly selective small molecule MMP inhibitors has been challenging due to the shared structural similarity of the zinc-dependent catalytic domain among family members (Vandenbroucke and Libert, *Nat Rev Drug Discov* 13(12): 904-927 (2014); Fields, *Cells* 8(9) (2019)).

[0005] MMP7 is constitutively expressed and secreted by epithelial cells throughout the body (including the skin, lung, and glandular epithelia of the liver, intestine, pancreas, salivary gland, and reproductive tract), where it plays a role in epithelial repair (Pilcher, Wang et al., *Ann N Y Acad Sci* 878:12-24 (1999)). Increased MMP7 expression has been linked to pathogenic fibrosis of the lung (Rosas, Richards et al., *PLoS Med* 5(4): e93 (2008)), liver (Hung, Chang et al., *Hepatology* 50(4): 1184-1193 (2009); Roeb, *Matrix Biol* 68-69: 463-473 (2018); Nomden, Beljaars et al., *Front Med (Lausanne)* 7:617261 (2020); Irvine, Okano et al., *Sci Rep* 11(1):2858 (2021)), and kidney (Ke, Fan et al., *Front Physiol* 8:21 (2017); Zhang, Ren et al., *Kidney Blood Press Res* 42(3): 541-552 (2017); Tan, Li et al., *JCI Insight* 4(24) (2019)). MMP7 enzyme levels have been linked to pathogenic fibrosis via multiple potential mechanisms including promotion of epithelial-mesenchymal transition (EMT), extracellular matrix degradation, aberrant matrix repair, and tissue remodeling. MMP7 promotes fibrosis by cleaving E-cadherin to activate epithelial cells and proteolytically activating heparin-binding epidermal growth factor precursor (pro-HB-EGF) to release active HB-EGF, which promotes aberrant epithelial migration and human lung fibroblast proliferation (Zhang, Rice et al., *Am J Respir Cell Mol Biol* 24(2):123-131 (2001); McGuire, Li et al., *Am J Pathol* 162(6):1831-1843 (2003)). MMP7 is also known to promote fibroblast survival and resistance to apoptosis via cleavage of osteopontin and mFasL pathways (Agnihotri, Crawford et al., *J Biol Chem* 276(30):28261-28267 (2001); Mummler, Burgy et al., *FASEB J* 32(2):703-716 (2018); Nareznoi, Konikov-Rozenman et al., *Cells* 9(2) (2020)).

[0006] One specific type of fibrosis is idiopathic pulmonary fibrosis (IPF), a chronic lung disease that is often fatal, and for which the clinical course and rate of disease progression are relatively unpredictable (*Id.*). In patients with IPF, MMP7 expression is known to increase in peripheral blood, bronchoalveolar lavage fluid, and lung tissue (Zuo, Kaminski et al., *Proc Natl Acad Sci USA* 99(9): 6292-6297 (2002)). Serum MMP7 expression is a well validated serum biomarker for IPF, which correlates with IPF severity and progression (Song, Do et al., *Chest* 143(5):1422-1429 (2013); Tzouvelekis, Herazo-Maya et al.,

Respirology 22(3):486-493 (2017)). Consistent with its known mechanism, MMP7 modulates multiple pathways contributing to aberrant epithelial cell, fibroblast, and immune cell function in IPF. Significantly, MMP7 knockout mice are protected against bleomycin-mediated lung injury (a standard rodent model of IPF), demonstrating reduced pulmonary inflammation, fibrosis, and mortality, and thus suggesting a causative role for MMP7 in IPF (Craig, Zhang et al., *Am J Respir Cell Mol Biol* 53(5):585-600 (2015)).

[0007] Genome-Wide Association Studies (GWAS) have shown that gain of function MMP7 genetic variant rs11568818AA linked to IPF risk (Richards, Park et al., *Am J Physiol Lung Cell Mol Physiol* 302(8):L746-754 (2012)). Further, in such GWAS studies it is described that MMP7 genetic variants are associated with multiple cancer diseases and sclerosis (Moreno-Ortiz, Gutierrez-Angulo et al., *Genet Mol Res* 13(2):3537-3544 (2014); Fu, Chien et al., *Anticancer Res* 40(2):695-702 (2020)).

SUMMARY

[0008] There exists a need for novel RNA interference (RNAi) agents (termed RNAi agents, RNAi triggers, or triggers), *e.g.*, double stranded RNAi agents, that are able to selectively and efficiently inhibit the expression of a MMP7 gene, including for use as a therapeutic or medicament. Further, there exists a need for compositions of novel MMP7-specific RNAi agents for the treatment of diseases or disorders associated with pathological inflammation (such as IPF) and/or disorders that can be mediated at least in part by a reduction in MMP7 gene expression.

[0009] The nucleotide sequences and chemical modifications of the MMP7 RNAi agents disclosed herein, as well as their combination with certain specific targeting ligands suitable for selectively and efficiently delivering the MMP7 RNAi agents to relevant pulmonary cells *in vivo*, differ from what is previously disclosed or known in the art. The MMP7 RNAi agents disclosed herein provide for highly potent and efficient inhibition of the expression of a MMP7 gene.

[0010] In general, the present disclosure features MMP7 gene-specific RNAi agents, compositions that include MMP7 RNAi agents, and methods for inhibiting expression of a MMP7 gene *in vitro* and/or *in vivo* using the MMP7 RNAi agents and compositions that include MMP7 RNAi agents described herein. The MMP7 RNAi agents described herein are able to selectively and efficiently decrease expression of a MMP7 gene, and thereby

decrease the amount of MMP7 available which is believed to be pro-fibrotic through potentially multiple mechanisms including by cleaving E-cadherin to activate epithelial cells and proteolytically activating heparin-binding epidermal growth factor precursor (pro-HB-EGF) to release active HB-EGF, which promotes aberrant epithelial migration and human lung fibroblast proliferation, and well as cleaving and activating other pro-fibrotic substrates such as osteopontin and membrane bound Fas ligand (mFasL).

[0011] The described MMP7 RNAi agents can be used in methods for therapeutic treatment (including preventative or prophylactic treatment) of symptoms and diseases including, but not limited to, idiopathic pulmonary fibrosis (IPF), asthma, various other types of fibrosis, chronic inflammation, interstitial lung diseases (ILD), infectious disease (for example, SARS-COV-2), acute lung injury (for example, acute respiratory distress syndrome (ARDS)), pulmonary hypertension, various cancers, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), fatty liver disease, biliary atresia, and chronic kidney disease (CKD).

[0012] In one aspect, the disclosure features RNAi agents for inhibiting expression of a MMP7 gene, wherein the RNAi agent includes a sense strand (also referred to as a passenger strand) and an antisense strand (also referred to as a guide strand). The sense strand and the antisense strand can be partially, substantially, or fully complementary to each other. The length of the RNAi agent sense strands described herein each can be 12 to 49 nucleotides in length. The length of the RNAi agent antisense strands described herein each can be 18 to 30 nucleotides in length. In some embodiments, the sense and antisense strands are independently 18 to 26 nucleotides in length. The sense and antisense strands can be either the same length or different lengths. In some embodiments, the sense and antisense strands are independently 21 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 21 to 24 nucleotides in length. In some embodiments, both the sense strand and the antisense strand are 21 nucleotides in length. In some embodiments, the antisense strands are independently 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In some embodiments, the sense strands are independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 nucleotides in length. The RNAi agents described herein, upon delivery to a cell expressing MMP7 such as a pulmonary cell, inhibit the expression of one or more MMP7 gene variants *in vivo* and/or *in vitro*.

[0013] The MMP7 RNAi agents disclosed herein target a human MMP7 gene (*see, e.g.*, SEQ ID NO:1). In some embodiments, the MMP7 RNAi agents disclosed herein target a portion of an MMP7 gene having the sequence of any of the sequences disclosed in Table 1.

[0014] In another aspect, the disclosure features compositions, including pharmaceutical compositions, that include one or more of the disclosed MMP7 RNAi agents that are able to selectively and efficiently decrease expression of an MMP7 gene. The compositions that include one or more MMP7 RNAi agents described herein can be administered to a subject, such as a human or animal subject, for the treatment (including prophylactic treatment or inhibition) of symptoms and diseases including, but not limited to, various pulmonary diseases including idiopathic pulmonary fibrosis (IPF), asthma, various other types of fibrosis, chronic inflammation, interstitial lung diseases (ILD), infectious disease (for example, SARS-COV-2), acute lung injury (for example, acute respiratory distress syndrome (ARDS)), pulmonary hypertension, various cancers, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), fatty liver disease, biliary atresia, and chronic kidney disease (CKD).

[0015] Examples of MMP7 RNAi agent sense strands and antisense strands that can be used in a MMP7 RNAi agent are provided in Tables 3, 4, 5, and 6. Examples of MMP7 RNAi agent duplexes are provided in Tables 7A, 7B, 8, 9, and 10. Examples of 19-nucleotide core stretch sequences that may consist of or may be included in the sense strands and antisense strands of certain MMP7 RNAi agents disclosed herein, are provided in Table 2.

[0016] In another aspect, the disclosure features methods for delivering MMP7 RNAi agents to epithelial cells in a subject, such as a mammal, *in vivo*. Also described herein are compositions for use in such methods. In some embodiments, disclosed herein are methods for delivering MMP7 RNAi agents to pulmonary cells (epithelial cells, macrophages, smooth muscle, endothelial cells) to a subject *in vivo*. In some embodiments, the subject is a human subject.

[0017] The methods disclosed herein include the administration of one or more MMP7 RNAi agents to a subject, e.g., a human or animal subject, by any suitable means known in the art. The pharmaceutical compositions disclosed herein that include one or more MMP7 RNAi agents can be administered in a number of ways depending upon whether local or systemic treatment is desired. Administration can be, but is not limited to, for example, intravenous, intraarterial, subcutaneous, intraperitoneal, subdermal (e.g., via an implanted

device), and intraparenchymal administration. In some embodiments, the pharmaceutical compositions described herein are administered by inhalation (such as dry powder inhalation or aerosol inhalation), intranasal administration, intratracheal administration, or oropharyngeal aspiration administration.

[0018] In some embodiments, it is desired that the MMP7 RNAi agents described herein inhibit the expression of an MMP7 gene in the pulmonary epithelium, for which the administration is by inhalation (e.g., by an inhaler device, such as a metered-dose inhaler, or a nebulizer such as a jet or vibrating mesh nebulizer, or a soft mist inhaler).

[0019] The one or more MMP7 RNAi agents can be delivered to target cells or tissues using any oligonucleotide delivery technology known in the art. In some embodiments, a MMP7 RNAi agent is delivered to cells or tissues by covalently linking the RNAi agent to a targeting group. In some embodiments, the targeting group can include a cell receptor ligand, such as an integrin targeting ligand. Integrins are a family of transmembrane receptors that facilitate cell-extracellular matrix (ECM) adhesion. In particular, integrin α v- β 6 (α v β 6) is an epithelial-specific integrin that is known to be a receptor for ECM proteins and the TGF- β latency-associated peptide (LAP), and is expressed in various cells and tissues. Integrin α v β 6 is known to be highly upregulated in injured pulmonary epithelium. In some embodiments, the MMP7 RNAi agents described herein are linked to an integrin targeting ligand that has affinity for integrin α v β 6. As referred to herein, an “ α v β 6 integrin targeting ligand” is a compound that has affinity for integrin α v β 6, which can be utilized as a ligand to facilitate the targeting and delivery of an RNAi agent to which it is attached to the desired cells and/or tissues (i.e., to cells expressing integrin α v β 6). In some embodiments, multiple α v β 6 integrin targeting ligands or clusters of α v β 6 integrin targeting ligands are linked to a MMP7 RNAi agent. In some embodiments, the MMP7 RNAi agent- α v β 6 integrin targeting ligand conjugates are selectively internalized by lung epithelial cells, either through receptor-mediated endocytosis or by other means.

[0020] Examples of targeting groups useful for delivering MMP7 RNAi agents that include α v β 6 integrin targeting ligands are disclosed, for example, in International Patent Application Publication No. WO 2018/085415 and International Patent Application Publication No. WO 2019/089765, the contents of each of which are incorporated by reference herein in their entirety.

[0021] A targeting group can be linked to the 3' or 5' end of a sense strand or an antisense strand of a MMP7 RNAi agent. In some embodiments, a targeting group is linked to the 3'

or 5' end of the sense strand. In some embodiments, a targeting group is linked to the 5' end of the sense strand. In some embodiments, a targeting group is linked internally to a nucleotide on the sense strand and/or the antisense strand of the RNAi agent. In some embodiments, one or more targeting ligands are linked internally to one or more nucleotides on the sense strand of the RNAi agent. In some embodiments, a targeting group is linked to the RNAi agent via a linker.

[0022] In another aspect, the disclosure features compositions that include one or more MMP7 RNAi agents that have the duplex structures disclosed in Tables 7A, 7B, 8, 9, and 10.

[0023] The use of MMP7 RNAi agents provides methods for therapeutic (including prophylactic) treatment of diseases or disorders for which a reduction in MMP7 can provide a therapeutic benefit. The MMP7 RNAi agents disclosed herein can be used to treat various pulmonary diseases various pulmonary diseases including idiopathic pulmonary fibrosis (IPF), asthma, various other types of fibrosis, chronic inflammation, interstitial lung diseases (ILD), infectious disease (for example, SARS-COV-2), acute lung injury (for example, acute respiratory distress syndrome (ARDS)), pulmonary hypertension, various cancers, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), fatty liver disease, biliary atresia, and chronic kidney disease (CKD). In some embodiments, the MMP7 RNAi agents disclosed herein can be used to treat a pulmonary inflammatory disease or condition. MMP7 RNAi agents can be used to treat, for example, IPF or other types of pulmonary fibrosis. Such methods of treatment include administration of a MMP7 RNAi agent to a human being or animal for which a reduction in MMP7 levels is desired.

[0024] As used herein, the terms “oligonucleotide” and “polynucleotide” mean a polymer of linked nucleosides each of which can be independently modified or unmodified.

[0025] As used herein, an “RNAi agent” (also referred to as an “RNAi trigger”) means a composition that contains an RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecule that is capable of degrading or inhibiting (e.g., degrades or inhibits under appropriate conditions) translation of messenger RNA (mRNA) transcripts of a target mRNA in a sequence specific manner. As used herein, RNAi agents may operate through the RNA interference mechanism (i.e., inducing RNA interference through interaction with the RNA interference pathway machinery (RNA-induced silencing complex or RISC) of mammalian cells), or by any alternative mechanism(s) or pathway(s). While it is believed that RNAi agents, as that term is used herein, operate primarily through the RNA

interference mechanism, the disclosed RNAi agents are not bound by or limited to any particular pathway or mechanism of action. RNAi agents disclosed herein are comprised of a sense strand and an antisense strand, and include, but are not limited to: short (or small) interfering RNAs (siRNAs), double stranded RNAs (dsRNA), micro RNAs (miRNAs), short hairpin RNAs (shRNA), and dicer substrates. The antisense strand of the RNAi agents described herein is at least partially complementary to the mRNA being targeted (i.e. MMP7 mRNA). RNAi agents can include one or more modified nucleotides and/or one or more non-phosphodiester linkages.

[0026] As used herein, the terms “silence,” “reduce,” “inhibit,” “down-regulate,” or “knockdown” when referring to expression of a given gene, mean that the expression of the gene, as measured by the level of RNA transcribed from the gene or the level of polypeptide, protein, or protein subunit translated from the mRNA in a cell, group of cells, tissue, organ, or subject in which the gene is transcribed, is reduced when the cell, group of cells, tissue, organ, or subject is treated with the RNAi agents described herein as compared to a second cell, group of cells, tissue, organ, or subject that has not or have not been so treated.

[0027] As used herein, the terms “sequence” and “nucleotide sequence” mean a succession or order of nucleobases or nucleotides, described with a succession of letters using standard nomenclature.

[0028] As used herein, a “base,” “nucleotide base,” or “nucleobase,” is a heterocyclic pyrimidine or purine compound that is a component of a nucleotide, and includes the primary purine bases adenine and guanine, and the primary pyrimidine bases cytosine, thymine, and uracil. A nucleobase may further be modified to include, without limitation, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. (*See, e.g., Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008*). The synthesis of such modified nucleobases (including phosphoramidite compounds that include modified nucleobases) is known in the art.

[0029] As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleobase or nucleotide sequence (e.g., RNAi agent sense strand or targeted mRNA) in relation to a second nucleobase or nucleotide sequence (e.g., RNAi agent antisense strand or a single-stranded antisense oligonucleotide), means the ability of an oligonucleotide or polynucleotide including the first nucleotide sequence to hybridize (form base pair hydrogen bonds under mammalian physiological conditions (or otherwise suitable

in vivo or *in vitro* conditions)) and form a duplex or double helical structure under certain standard conditions with an oligonucleotide that includes the second nucleotide sequence. The person of ordinary skill in the art would be able to select the set of conditions most appropriate for a hybridization test. Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimics, at least to the extent that the above hybridization requirements are fulfilled. Sequence identity or complementarity is independent of modification. For example, a and Af, as defined herein, are complementary to U (or T) and identical to A for the purposes of determining identity or complementarity.

[0030] As used herein, “perfectly complementary” or “fully complementary” means that in a hybridized pair of nucleobase or nucleotide sequence molecules, all (100%) of the bases in a contiguous sequence of a first oligonucleotide will hybridize with the same number of bases in a contiguous sequence of a second oligonucleotide. The contiguous sequence may comprise all or a part of a first or second nucleotide sequence.

[0031] As used herein, “partially complementary” means that in a hybridized pair of nucleobase or nucleotide sequence molecules, at least 70%, but not all, of the bases in a contiguous sequence of a first oligonucleotide will hybridize with the same number of bases in a contiguous sequence of a second oligonucleotide. The contiguous sequence may comprise all or a part of a first or second nucleotide sequence.

[0032] As used herein, “substantially complementary” means that in a hybridized pair of nucleobase or nucleotide sequence molecules, at least 85%, but not all, of the bases in a contiguous sequence of a first oligonucleotide will hybridize with the same number of bases in a contiguous sequence of a second oligonucleotide. The contiguous sequence may comprise all or a part of a first or second nucleotide sequence.

[0033] As used herein, the terms “complementary,” “fully complementary,” “partially complementary,” and “substantially complementary” are used with respect to the nucleobase or nucleotide matching between the sense strand and the antisense strand of an RNAi agent, or between the antisense strand of an RNAi agent and a sequence of an MMP7 mRNA.

[0034] As used herein, the term “substantially identical” or “substantial identity,” as applied to a nucleic acid sequence means the nucleotide sequence (or a portion of a nucleotide sequence) has at least about 85% sequence identity or more, e.g., at least 90%, at least 95%, or at least 99% identity, compared to a reference sequence. Percentage of sequence identity

is determined by comparing two optimally aligned sequences over a comparison window. The percentage is calculated by determining the number of positions at which the same type of nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The inventions disclosed herein encompass nucleotide sequences substantially identical to those disclosed herein.

[0035] As used herein, the terms “treat,” “treatment,” and the like, mean the methods or steps taken to provide relief from or alleviation of the number, severity, and/or frequency of one or more symptoms of a disease in a subject. As used herein, “treat” and “treatment” may include the prevention, management, prophylactic treatment, and/or inhibition or reduction of the number, severity, and/or frequency of one or more symptoms of a disease in a subject.

[0036] As used herein, the phrase “introducing into a cell,” when referring to an RNAi agent, means functionally delivering the RNAi agent into a cell. The phrase “functional delivery,” means delivering the RNAi agent to the cell in a manner that enables the RNAi agent to have the expected biological activity, e.g., sequence-specific inhibition of gene expression.

[0037] Unless stated otherwise, use of the symbol  as used herein means that any group or groups may be linked thereto that is in accordance with the scope of the inventions described herein.

[0038] As used herein, the term “isomers” refers to compounds that have identical molecular formulae, but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images are termed “enantiomers,” or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is termed a “chiral center.”

[0039] As used herein, unless specifically identified in a structure as having a particular conformation, for each structure in which asymmetric centers are present and thus give rise to enantiomers, diastereomers, or other stereoisomeric configurations, each structure disclosed herein is intended to represent all such possible isomers, including their optically

pure and racemic forms. For example, the structures disclosed herein are intended to cover mixtures of diastereomers as well as single stereoisomers.

[0040] As used in a claim herein, the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. When used in a claim herein, the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.

[0041] The person of ordinary skill in the art would readily understand and appreciate that the compounds and compositions disclosed herein may have certain atoms (e.g., N, O, or S atoms) in a protonated or deprotonated state, depending upon the environment in which the compound or composition is placed. Accordingly, as used herein, the structures disclosed herein envisage that certain functional groups, such as, for example, OH, SH, or NH, may be protonated or deprotonated. The disclosure herein is intended to cover the disclosed compounds and compositions regardless of their state of protonation based on the environment (such as pH), as would be readily understood by the person of ordinary skill in the art. Correspondingly, compounds described herein with labile protons or basic atoms should also be understood to represent salt forms of the corresponding compound. Compounds described herein may be in a free acid, free base, or salt form. Pharmaceutically acceptable salts of the compounds described herein should be understood to be within the scope of the invention.

[0042] As used herein, the term “linked” or “conjugated” when referring to the connection between two compounds or molecules means that two compounds or molecules are joined by a covalent bond. Unless stated, the terms “linked” and “conjugated” as used herein may refer to the connection between a first compound and a second compound either with or without any intervening atoms or groups of atoms.

[0043] As used herein, the term “including” is used to herein mean, and is used interchangeably with, the phrase “including but not limited to.” The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless the context clearly indicates otherwise.

[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein

are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0045] Other objects, features, aspects, and advantages of the invention will be apparent from the following detailed description, accompanying figures, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0046] **FIG. 1.** Chemical structure representation of the tridentate $\alpha\beta6$ epithelial cell targeting ligand referred to herein as Tri-SM6.1- $\alpha\beta6$ -(TA14).

[0047] **FIG. 2.** Chemical structure representation of the peptide $\alpha\beta6$ epithelial cell targeting ligand referred to herein as $\alpha\beta6$ -pep1.

[0048] **FIG. 3.** MTT colorimetric assay for cell metabolic activity, demonstrating little cytotoxic effect of MMP7 RNAi agent, as described in Example 24.

[0049] **FIG. 4A.** Schematic diagram of the modified sense and antisense strands of the MMP7 RNAi agent conjugate having the structure of AC001651 (*see, e.g.*, Tables 8 and 10), having a tridentate $\alpha\beta6$ epithelial cell targeting ligand linked at the 5' end of the sense strand.

The following abbreviations are used in Figures 4A to 4F: a, c, g, and u are 2'-O-methyl modified nucleotides; Af, Cf, Gf, and Uf are 2'-fluoro modified nucleotides; o is a phosphodiester linkage; s is a phosphorothioate linkage; invAb is an inverted abasic residue (*see, e.g.*, Table 11); cPrpu is a 5'-cyclopropyl phosphonate-2'-O-methyluridine modified nucleotide (*see, e.g.*, Table 11); cPrpa is a 5'-cyclopropyl phosphonate-2'-O-methyladenosine modified nucleotide (*see, e.g.*, Table 11); Tri-SM6.1- $\alpha\beta6$ -(TA14) is the tridentate $\alpha\beta6$ epithelial cell targeting ligand having the structure shown in Fig. 1; and (TriAlk14) is the linking group as shown in Table 11, which is suitable for subsequent conjugation to targeting ligands (*See also*, Example 1 herein).

[0050] **FIG. 4B.** Schematic diagram of the modified sense and antisense strands of the MMP7 RNAi agent conjugate having the structure of AC001514 (*see, e.g.*, Tables 8 and 10), having a tridentate $\alpha\beta6$ epithelial cell targeting ligand linked at the 5' end of the sense strand.

[0051] **FIG. 4C.** Schematic diagram of the modified sense and antisense strands of the MMP7 RNAi agent conjugate having the structure of AC002023 (*see, e.g.*, Tables 8 and

10), having a tridentate $\alpha v\beta 6$ epithelial cell targeting ligand linked at the 5' end of the sense strand.

[0052] FIG. 4D. Schematic diagram of the modified sense and antisense strands of the MMP7 RNAi agent duplex having the structure of AD09887 (*see, e.g.*, Tables 8 and 10), having a (TriAlk14) linker at the 5' end of the sense strand.

[0053] FIG. 4E. Schematic diagram of the modified sense and antisense strands of the MMP7 RNAi agent duplex having the structure of AD09667 (*see, e.g.*, Tables 8 and 10), having a (TriAlk14) linker at the 5' end of the sense strand.

[0054] FIG. 4F. Schematic diagram of the modified sense and antisense strands of the MMP7 RNAi agent duplex having the structure of AD10441 (*see, e.g.*, Tables 8 and 10), having a (TriAlk14) linker at the 5' end of the sense strand.

DETAILED DESCRIPTION

RNAi Agents

[0055] Described herein are RNAi agents for inhibiting expression of the MMP7 gene (referred to herein as MMP7 RNAi agents or MMP7 RNAi triggers). Each MMP7 RNAi agent disclosed herein comprises a sense strand and an antisense strand. The sense strand can be 12 to 49 nucleotides in length. In some embodiments, the sense strand is 12 to 49 nucleotides in length. The antisense strand can be 18 to 49 nucleotides in length. The sense and antisense strands can be either the same length or they can be different lengths. In some embodiments, the sense and antisense strands are each independently 18 to 27 nucleotides in length. In some embodiments, both the sense and antisense strands are each 21-26 nucleotides in length. In some embodiments, the sense and antisense strands are each 21-24 nucleotides in length. In some embodiments, the sense and antisense strands are each independently 19-21 nucleotides in length. In some embodiments, the sense strand is about 19 nucleotides in length while the antisense strand is about 21 nucleotides in length. In some embodiments, the sense strand is about 21 nucleotides in length while the antisense strand is about 23 nucleotides in length. In some embodiments, a sense strand is 23 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, both the sense and antisense strands are each 21 nucleotides in length. In some embodiments, the RNAi agent sense strands are each independently 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 nucleotides in length. In some embodiments, the RNAi agent antisense strands

are each independently 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In some embodiments, the RNAi agent is double stranded and has a duplex length of about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides. In some embodiments, the RNAi agent is double stranded and has a duplex length of 19, 20, 21, 22, or 23 nucleotides.

[0056] Examples of nucleotide sequences used in forming MMP7 RNAi agents are provided in Tables 2, 3, 4, 5, 6, and 10. Examples of RNAi agent duplexes, that include the sense strand and antisense strand sequences in Tables 2, 3, 4, 5, 6, are shown in Tables 7A, 7B, 8, 9, and 10.

[0057] In some embodiments, the region of perfect, substantial, or partial complementarity between the sense strand and the antisense strand is 16-26 (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26) nucleotides in length and occurs at or near the 5' end of the antisense strand (e.g., this region may be separated from the 5' end of the antisense strand by 0, 1, 2, 3, or 4 nucleotides that are not perfectly, substantially, or partially complementary).

[0058] A sense strand of the MMP7 RNAi agents described herein includes at least 12 consecutive nucleotides that have at least 85% identity to a core stretch sequence (also referred to herein as a "core stretch" or "core sequence") of the same number of nucleotides in an MMP7 mRNA. In some embodiments, a sense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a core stretch sequence in the antisense strand, and thus the sense strand core stretch sequence is typically perfectly identical or at least about 85% identical to a nucleotide sequence of the same length (sometimes referred to, *e.g.*, as a target sequence) present in the MMP7 mRNA target. In some embodiments, this sense strand core stretch is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, this sense strand core stretch is 17 nucleotides in length. In some embodiments, this sense strand core stretch is 19 nucleotides in length. In some embodiments, this sense strand core stretch is 21 nucleotides in length.

[0059] An antisense strand of a MMP7 RNAi agent described herein includes at least 15 consecutive nucleotides that have at least 85% complementarity to a core stretch of the same number of nucleotides in an MMP7 mRNA and to a core stretch of the same number of nucleotides in the corresponding sense strand. In some embodiments, an antisense strand core stretch is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a nucleotide sequence (*e.g.*, target sequence) of the same length present in the MMP7 mRNA target. In some embodiments, this antisense strand core stretch is 17,

18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, this antisense strand core stretch is 19 nucleotides in length. In some embodiments, this antisense strand core stretch is 17 nucleotides in length. A sense strand core stretch sequence can be the same length as a corresponding antisense core sequence or it can be a different length.

[0060] The MMP7 RNAi agent sense and antisense strands anneal to form a duplex. A sense strand and an antisense strand of a MMP7 RNAi agent can be partially, substantially, or fully complementary to each other. Within the complementary duplex region, the sense strand core stretch sequence is at least 85% complementary or 100% complementary to the antisense core stretch sequence. In some embodiments, the sense strand core stretch sequence contains a sequence of at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 nucleotides that is at least 85% or 100% complementary to a corresponding 16, 17, 18, 19, 20, 21, 22, or 23 nucleotide sequence of the antisense strand core stretch sequence (i.e., the sense and antisense core stretch sequences of a MMP7 RNAi agent have a region of at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23 nucleotides that is at least 85% base paired or 100% base paired.)

[0061] In some embodiments, the antisense strand of a MMP7 RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2 or Table 3. In some embodiments, the sense strand of a MMP7 RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2, Table 4, Table 5, Table 6, or Table 10.

[0062] In some embodiments, the sense strand and/or the antisense strand can optionally and independently contain an additional 1, 2, 3, 4, 5, or 6 nucleotides (extension) at the 3' end, the 5' end, or both the 3' and 5' ends of the core stretch sequences. The antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sequence in the MMP7 mRNA. The sense strand additional nucleotides, if present, may or may not be identical to the corresponding sequence in the MMP7 mRNA. The antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sense strand's additional nucleotides, if present.

[0063] As used herein, an extension comprises 1, 2, 3, 4, 5, or 6 nucleotides at the 5' and/or 3' end of the sense strand core stretch sequence and/or antisense strand core stretch sequence. The extension nucleotides on a sense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the

corresponding antisense strand. Conversely, the extension nucleotides on an antisense strand may or may not be complementary to nucleotides, either core stretch nucleotides or extension nucleotides, in the corresponding sense strand. In some embodiments, both the sense strand and the antisense strand of an RNAi agent contain 3' and 5' extensions. In some embodiments, one or more of the 3' extension nucleotides of one strand base pairs with one or more 5' extension nucleotides of the other strand. In other embodiments, one or more of 3' extension nucleotides of one strand do not base pair with one or more 5' extension nucleotides of the other strand. In some embodiments, a MMP7 RNAi agent has an antisense strand having a 3' extension and a sense strand having a 5' extension. In some embodiments, the extension nucleotide(s) are unpaired and form an overhang. As used herein, an "overhang" refers to a stretch of one or more unpaired nucleotides located at a terminal end of either the sense strand or the antisense strand that does not form part of the hybridized or duplexed portion of an RNAi agent disclosed herein (*See, e.g.*, U.S. Patent No. 8,362,231).

[0064] In some embodiments, a MMP7 RNAi agent comprises an antisense strand having a 3' extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In other embodiments, a MMP7 RNAi agent comprises an antisense strand having a 3' extension of 1, 2, or 3 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprise nucleotides that are complementary to the corresponding MMP7 mRNA sequence. In some embodiments, one or more of the antisense strand extension nucleotides comprise nucleotides that are not complementary to the corresponding MMP7 mRNA sequence.

[0065] In some embodiments, a MMP7 RNAi agent comprises a sense strand having a 3' extension of 1, 2, 3, 4, or 5 nucleotides in length. In some embodiments, one or more of the sense strand extension nucleotides comprises adenosine, uracil, or thymidine nucleotides, AT dinucleotide, or nucleotides that correspond to or are the identical to nucleotides in the MMP7 mRNA sequence. In some embodiments, the 3' sense strand extension includes or consists of one of the following sequences, but is not limited to: T, UT, TT, UU, UUT, TTT, or TTTT (each listed 5' to 3').

[0066] A sense strand can have a 3' extension and/or a 5' extension. In some embodiments, a MMP7 RNAi agent comprises a sense strand having a 5' extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In some embodiments, one or more of the sense strand extension nucleotides comprise nucleotides that correspond to or are identical to nucleotides in the MMP7 mRNA sequence.

[0067] Examples of sequences used in forming MMP7 RNAi agents are provided in Tables 2, 3, 4, 5, 6, and 10. In some embodiments, a MMP7 RNAi agent antisense strand includes a sequence of any of the sequences in Tables 2, 3, or 10. In certain embodiments, a MMP7 RNAi agent antisense strand comprises or consists of any one of the modified sequences in Table 3. In some embodiments, a MMP7 RNAi agent antisense strand includes the sequence of nucleotides (from 5' end → 3' end) 1-17, 2-15, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, or 2-21, of any of the sequences in Tables 2 or 3. In some embodiments, a MMP7 RNAi agent sense strand includes the sequence of any of the sequences in Tables 2, 4, 5, or 6. In some embodiments, a MMP7 RNAi agent sense strand includes the sequence of nucleotides (from 5' end → 3' end) 1-18, 1-19, 1-20, 1-21, 2-19, 2-20, 2-21, 3-20, 3-21, or 4-21 of any of the sequences in Tables 2, 4, 5, or 6. In certain embodiments, a MMP7 RNAi agent sense strand comprises or consists of a modified sequence of any one of the modified sequences in Table 4, 5, 6, or 10.

[0068] In some embodiments, the sense and antisense strands of the RNAi agents described herein contain the same number of nucleotides. In some embodiments, the sense and antisense strands of the RNAi agents described herein contain different numbers of nucleotides. In some embodiments, the sense strand 5' end and the antisense strand 3' end of an RNAi agent form a blunt end. In some embodiments, the sense strand 3' end and the antisense strand 5' end of an RNAi agent form a blunt end. In some embodiments, both ends of an RNAi agent form blunt ends. In some embodiments, neither end of an RNAi agent is blunt-ended. As used herein a "blunt end" refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands are complementary (form a complementary base-pair).

[0069] In some embodiments, the sense strand 5' end and the antisense strand 3' end of an RNAi agent form a frayed end. In some embodiments, the sense strand 3' end and the antisense strand 5' end of an RNAi agent form a frayed end. In some embodiments, both ends of an RNAi agent form a frayed end. In some embodiments, neither end of an RNAi agent is a frayed end. As used herein a frayed end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands form a pair (i.e., do not form an overhang) but are not complementary (i.e. form a non-complementary pair). In some embodiments, one or more unpaired nucleotides at the end of one strand of a double stranded RNAi agent form an overhang. The unpaired nucleotides may be on the sense strand or the antisense strand, creating either 3' or 5' overhangs. In some embodiments, the

RNAi agent contains: a blunt end and a frayed end, a blunt end and 5' overhang end, a blunt end and a 3' overhang end, a frayed end and a 5' overhang end, a frayed end and a 3' overhang end, two 5' overhang ends, two 3' overhang ends, a 5' overhang end and a 3' overhang end, two frayed ends, or two blunt ends. Typically, when present, overhangs are located at the 3' terminal ends of the sense strand, the antisense strand, or both the sense strand and the antisense strand.

[0070] The MMP7 RNAi agents disclosed herein may also be comprised of one or more modified nucleotides. In some embodiments, substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand of the MMP7 RNAi agent are modified nucleotides. The MMP7 RNAi agents disclosed herein may further be comprised of one or more modified internucleoside linkages, e.g., one or more phosphorothioate linkages. In some embodiments, a MMP7 RNAi agent contains one or more modified nucleotides and one or more modified internucleoside linkages. In some embodiments, a 2'-modified nucleotide is combined with modified internucleoside linkage.

[0071] In some embodiments, a MMP7 RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid. In some embodiments, a MMP7 RNAi agent is prepared as a pharmaceutically acceptable salt. In some embodiments, a MMP7 RNAi agent is prepared as a pharmaceutically acceptable sodium salt. Such forms that are well known in the art are within the scope of the inventions disclosed herein.

Modified Nucleotides

[0072] Modified nucleotides, when used in various oligonucleotide constructs, can preserve activity of the compound in cells while at the same time increasing the serum stability of these compounds, and can also minimize the possibility of activating interferon activity in humans upon administration of the oligonucleotide construct.

[0073] In some embodiments, a MMP7 RNAi agent contains one or more modified nucleotides. As used herein, a "modified nucleotide" is a nucleotide other than a ribonucleotide (2'-hydroxyl nucleotide). In some embodiments, at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) of the nucleotides are modified nucleotides. As used herein, modified nucleotides can include, but are not limited to, deoxyribonucleotides, nucleotide mimics, abasic nucleotides, 2'-modified nucleotides, inverted nucleotides, modified nucleobase-comprising nucleotides, bridged nucleotides, peptide nucleic acids (PNAs), 2',3'-seco

nucleotide mimics (unlocked nucleobase analogues), locked nucleotides, 3'-O-methoxy (2' internucleoside linked) nucleotides, 2'-F-Arabino nucleotides, 5'-Methyl-2'-fluoro nucleotides, morpholino nucleotides (modified nucleotides with a morpholine ring), nucleotides where the typical 5-membered sugar ring of the nucleotide has been modified, vinyl phosphonate deoxyribonucleotides, vinyl phosphonate containing nucleotides, and cyclopropyl phosphonate containing nucleotides. 2'-modified nucleotides (*i.e.*, a nucleotide with a group other than a hydroxyl group at the 2' position of the five-membered sugar ring) include, but are not limited to, 2'-O-methyl nucleotides (also referred to as 2'-methoxy nucleotides), 2'-fluoro nucleotides (also referred to herein as 2'-deoxy-2'-fluoro nucleotides), 2'-deoxy nucleotides, 2'-methoxyethyl (2'-O-2-methoxyethyl) nucleotides (also referred to as 2'-MOE), 2'-amino nucleotides, 2'-halo nucleotides, and 2'-alkyl nucleotides. It is not necessary for all positions in a given compound to be uniformly modified. Conversely, more than one modification can be incorporated in a single MMP7 RNAi agent or even in a single nucleotide thereof. The MMP7 RNAi agent sense strands and antisense strands can be synthesized and/or modified by methods known in the art. Modification at one nucleotide is independent of modification at another nucleotide.

[0074] Modified nucleobases include synthetic and natural nucleobases, such as 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, (e.g., 2-aminopropyladenine, 5-propynyluracil, or 5-propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, inosine, xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl (e.g., 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) derivatives of adenine and guanine, 2-alkyl (e.g., 2-methyl, 2-ethyl, 2-isopropyl, or 2-n-butyl) and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, cytosine, 5-propynyl uracil, 5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-sulfhydryl, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (e.g., 5-bromo), 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

[0075] In some embodiments, the 5' and/or 3' end of the antisense strand can include abasic residues (Ab), which can also be referred to as an "abasic site" or "abasic nucleotide." An abasic residue (Ab) is a nucleotide or nucleoside that lacks a nucleobase at the 1' position of the sugar moiety. (*See, e.g.*, U.S. Patent No. 5,998,203). In some embodiments, an abasic

residue can be placed internally in a nucleotide sequence. In some embodiments, Ab or AbAb can be added to the 3' end of the antisense strand. In some embodiments, the 5' end of the sense strand can include one or more additional abasic residues (e.g., (Ab) or (AbAb)). In some embodiments, UUAb, UAb, or Ab are added to the 3' end of the sense strand. In some embodiments, an abasic (deoxyribose) residue can be replaced with a ribitol (abasic ribose) residue.

[0076] In some embodiments, all or substantially all of the nucleotides of an RNAi agent are modified nucleotides. As used herein, an RNAi agent wherein substantially all of the nucleotides present are modified nucleotides is an RNAi agent having four or fewer (i.e., 0, 1, 2, 3, or 4) nucleotides in both the sense strand and the antisense strand being ribonucleotides (i.e., unmodified). As used herein, a sense strand wherein substantially all of the nucleotides present are modified nucleotides is a sense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being unmodified ribonucleotides. As used herein, an antisense sense strand wherein substantially all of the nucleotides present are modified nucleotides is an antisense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the antisense strand being unmodified ribonucleotides. In some embodiments, one or more nucleotides of an RNAi agent is an unmodified ribonucleotide. Chemical structures for certain modified nucleotides are set forth in Table 11 herein.

Modified Internucleoside Linkages

[0077] In some embodiments, one or more nucleotides of a MMP7 RNAi agent are linked by non-standard linkages or backbones (i.e., modified internucleoside linkages or modified backbones). Modified internucleoside linkages or backbones include, but are not limited to, phosphorothioate groups (represented herein as a lower case "s"), chiral phosphorothioates, thiophosphates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, alkyl phosphonates (e.g., methyl phosphonates or 3'-alkylene phosphonates), chiral phosphonates, phosphinates, phosphoramidates (e.g., 3'-amino phosphoramidate, aminoalkylphosphoramidates, or thionophosphoramidates), thionoalkyl-phosphonates, thionoalkylphosphotriesters, morpholino linkages, boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of boranophosphates, or boranophosphates having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. In some embodiments, a modified internucleoside linkage or backbone lacks a phosphorus atom. Modified internucleoside linkages lacking a phosphorus atom include,

but are not limited to, short chain alkyl or cycloalkyl inter-sugar linkages, mixed heteroatom and alkyl or cycloalkyl inter-sugar linkages, or one or more short chain heteroatomic or heterocyclic inter-sugar linkages. In some embodiments, modified internucleoside backbones include, but are not limited to, siloxane backbones, sulfide backbones, sulfoxide backbones, sulfone backbones, formacetyl and thioformacetyl backbones, methylene formacetyl and thioformacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other backbones having mixed N, O, S, and CH₂ components.

[0078] In some embodiments, a sense strand of a MMP7 RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, an antisense strand of a MMP7 RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, or both the sense strand and the antisense strand independently can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages. In some embodiments, a sense strand of a MMP7 RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages, an antisense strand of a MMP7 RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages, or both the sense strand and the antisense strand independently can contain 1, 2, 3, or 4 phosphorothioate linkages.

[0079] In some embodiments, a MMP7 RNAi agent sense strand contains at least two phosphorothioate internucleoside linkages. In some embodiments, the phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3 from the 3' end of the sense strand. In some embodiments, one phosphorothioate internucleoside linkage is at the 5' end of the sense strand nucleotide sequence, and another phosphorothioate linkage is at the 3' end of the sense strand nucleotide sequence. In some embodiments, two phosphorothioate internucleoside linkage are located at the 5' end of the sense strand, and another phosphorothioate linkage is at the 3' end of the sense strand. In some embodiments, the sense strand does not include any phosphorothioate internucleoside linkages between the nucleotides, but contains one, two, or three phosphorothioate linkages between the terminal nucleotides on both the 5' and 3' ends and the optionally present inverted abasic residue terminal caps. In some embodiments, the targeting ligand is linked to the sense strand via a phosphorothioate linkage.

[0080] In some embodiments, a MMP7 RNAi agent antisense strand contains four phosphorothioate internucleoside linkages. In some embodiments, the four phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3 from

the 5' end of the antisense strand and between the nucleotides at positions 19-21, 20-22, 21-23, 22-24, 23-25, or 24-26 from the 5' end. In some embodiments, three phosphorothioate internucleoside linkages are located between positions 1-4 from the 5' end of the antisense strand, and a fourth phosphorothioate internucleoside linkage is located between positions 20-21 from the 5' end of the antisense strand. In some embodiments, a MMP7 RNAi agent contains at least three or four phosphorothioate internucleoside linkages in the antisense strand.

Capping Residues or Moieties

[0081] In some embodiments, the sense strand may include one or more capping residues or moieties, sometimes referred to in the art as a “cap,” a “terminal cap,” or a “capping residue.” As used herein, a “capping residue” is a non-nucleotide compound or other moiety that can be incorporated at one or more termini of a nucleotide sequence of an RNAi agent disclosed herein. A capping residue can provide the RNAi agent, in some instances, with certain beneficial properties, such as, for example, protection against exonuclease degradation. In some embodiments, inverted abasic residues (invAb) (also referred to in the art as “inverted abasic sites”) are added as capping residues (*see* Table 11). (See, e.g., F. Czauderna, *Nucleic Acids Res.*, 2003, 31(11), 2705-16). Capping residues are generally known in the art, and include, for example, inverted abasic residues as well as carbon chains such as a terminal C₃H₇ (propyl), C₆H₁₃ (hexyl), or C₁₂H₂₅ (dodecyl) groups. In some embodiments, a capping residue is present at either the 5' terminal end, the 3' terminal end, or both the 5' and 3' terminal ends of the sense strand. In some embodiments, the 5' end and/or the 3' end of the sense strand may include more than one inverted abasic deoxyribose moiety as a capping residue.

[0082] In some embodiments, one or more inverted abasic residues (invAb) are added to the 3' end of the sense strand. In some embodiments, one or more inverted abasic residues (invAb) are added to the 5' end of the sense strand. In some embodiments, one or more inverted abasic residues or inverted abasic sites are inserted between the targeting ligand and the nucleotide sequence of the sense strand of the RNAi agent. In some embodiments, the inclusion of one or more inverted abasic residues or inverted abasic sites at or near the terminal end or terminal ends of the sense strand of an RNAi agent allows for enhanced activity or other desired properties of an RNAi agent.

[0083] In some embodiments, one or more inverted abasic residues (invAb) are added to the 5' end of the sense strand. In some embodiments, one or more inverted abasic residues can be inserted between the targeting ligand and the nucleotide sequence of the sense strand of the RNAi agent. The inverted abasic residues may be linked via phosphate, phosphorothioate (e.g., shown herein as (invAb)s)), or other internucleoside linkages. In some embodiments, the inclusion of one or more inverted abasic residues at or near the terminal end or terminal ends of the sense strand of an RNAi agent may allow for enhanced activity or other desired properties of an RNAi agent. In some embodiments, an inverted abasic (deoxyribose) residue can be replaced with an inverted ribitol (abasic ribose) residue. In some embodiments, the 3' end of the antisense strand core stretch sequence, or the 3' end of the antisense strand sequence, may include an inverted abasic residue. The chemical structures for inverted abasic deoxyribose residues are shown in Table 11 below.

MMP7 RNAi Agents

[0084] The MMP7 RNAi agents disclosed herein are designed to target specific positions on a MMP7 gene (e.g., SEQ ID NO:1 (NM_002423.5)). As defined herein, an antisense strand sequence is designed to target a MMP7 gene at a given position on the gene when the 5' terminal nucleobase of the antisense strand is aligned with a position that is 21 nucleotides downstream (towards the 3' end) from the position on the gene when base pairing to the gene. For example, as illustrated in Tables 1 and 2 herein, an antisense strand sequence designed to target a MMP7 gene at position 303 requires that when base pairing to the gene, the 5' terminal nucleobase of the antisense strand is aligned with position 323 of a MMP7 gene.

[0085] As provided herein, a MMP7 RNAi agent does not require that the nucleobase at position 1 (5' → 3') of the antisense strand be complementary to the gene, provided that there is at least 85% complementarity (e.g., at least 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% complementarity) of the antisense strand and the gene across a core stretch sequence of at least 16 consecutive nucleotides. For example, for a MMP7 RNAi agent disclosed herein that is designed to target position 303 of a MMP7 gene, the 5' terminal nucleobase of the antisense strand of the of the MMP7 RNAi agent must be aligned with position 323 of the gene; however, the 5' terminal nucleobase of the antisense strand may be, but is not required to be, complementary to position 323 of a MMP7 gene, provided that there is at least 85% complementarity (e.g., at least 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,

96, 97, 98, 99, or 100% complementarity) of the antisense strand and the gene transcript across a core stretch sequence of at least 16 consecutive nucleotides. As shown by, among other things, the various examples disclosed herein, the specific site of binding of the gene by the antisense strand of the MMP7 RNAi agent (e.g., whether the MMP7 RNAi agent is designed to target a MMP7 gene at position 303, at position 418, at position 971, or at some other position) is an important factor to the level of inhibition achieved by the MMP7 RNAi agent. (See, e.g., Kamola et al., *The siRNA Non-seed Region and Its Target Sequences are Auxiliary Determinants of Off-Target Effects*, PLOS Computational Biology, 11(12), Figure 1 (2015)).

[0086] In some embodiments, the MMP7 RNAi agents disclosed herein target a MMP7 gene at or near the positions of the MMP7 sequence shown in Table 1. In some embodiments, the antisense strand of a MMP7 RNAi agent disclosed herein includes a core stretch sequence that is fully, substantially, or at least partially complementary to a target MMP7 19-mer sequence disclosed in Table 1.

Table 1. MMP7 19-mer mRNA Target Sequences (taken from *homo sapiens* matrix metalloproteinase 7 (MMP7) transcript, GenBank NM_002423.5 (SEQ ID NO:1))

SEQ ID No.	MMP7 19-mer Target Sequences (5' → 3')	Corresponding Positions of Sequence on SEQ ID NO: 1	Targeted Gene Position (as referred to herein)
2	AUGUGGAGUGCCAGAUUU	305-323	303
3	GUGGAGUGCCAGAUUUGC	307-325	305
4	UGGAGUGCCAGAUUUGCA	308-326	306
5	GAGUGCCAGAUUUGCAGA	310-328	308
6	AGUGCCAGAUUUGCAGAA	311-329	309
7	GUGCCAGAUUUGCAGAAU	312-330	310
8	UGCCAGAUUUGCAGAAUA	313-331	311
9	CAUUUGAUGGGCCAGGAAA	550-568	548
10	UGAUGGGCCAGGAAACACG	554-572	552
11	GGCUCAGGACUAUCUAAG	149-167	147
12	CUCAAGAGAUUUUAUCUCU	162-180	160
13	AGAGAUUUUAUCUCUAUGA	166-184	164
14	GAUUUUUAUCUCUAUGACUC	169-187	167
15	UGUGGAGUGCCAGAUUUA	306-324	304
16	AGUGCCAGAUUUGCAGAA	311-329	309
17	CAGAUUUGCAGAAUACUC	316-334	314
18	UUGCAGAAUACUCACUAUU	322-340	320
19	UGCAGAAUACUCACUAUUU	323-341	321
20	UACAGUGGAUCGAUUAGUG	416-434	414

SEQ ID No.	MMP7 19-mer Target Sequences (5' → 3')	Corresponding Positions of Sequence on SEQ ID NO: 1	Targeted Gene Position (as referred to herein)
21	ACAGUGGAUCGAUUAGUGU	417-435	415
22	GUGGAUCGAUUAGUGUCAA	420-438	418
23	GAGAUGCUCACUUCGAUGA	610-628	608
24	AUUAACUUCUGUAUGCUA	663-681	661
25	AGUGAUGUAUCCAACCUAU	737-755	735
26	GUAUCCAACCUAUGGAAAU	743-761	741
27	AAGGCAUUCAGAAACUAUA	802-820	800
28	GUUGCACAAUCAGAAUUGA	902-920	900
29	UUGCACAAUCAGAAUUGAU	903-921	901
30	CAAUCAGAAUUGAUAAAGCA	908-926	906
31	AAUCAGAAUUGAUAAAGCAA	909-927	907
32	GUCACCCUUUUUUAUUGCA	955-973	953
33	GCAGUUGGUUUUUGAAUGU	971-989	969
34	AGUUGGUUUUUGAAUGUCU	973-991	971
35	GUUGGUUUUUGAAUGUCUU	974-992	972
36	CUCCUUUUAAGGAUAAACU	996-1014	994

[0087] *Homo sapiens* matrix metalloproteinase 7 (MMP7), GenBank NM_002423.5 (SEQ ID NO:1), gene transcript (1119 bases):

1 accaaatcaa ccataggtcc aagaacaatt gtctctggac ggcagctatg cgactcacgg
61 tgctgtgtgc tgtgtgctg ctgcttgcca gcttgccct gccgtgcct caggaggcgg
121 gaggcattgag tgagctacag tgggaacagg ctcaggacta tctcaagaga tttatctct
181 atgactcaga aacaaaaaat gccaacagtt tagaagccaa actcaaggag atgcaaaaa
241 tctttggcct acctataact ggaatgttaa actcccgct catagaaata atgcagaagc
301 ccagatgtgg agtgccagat gttgcagaat actcactatt tccaaatagc ccaaaatgga
361 ctccaaagt ggtcacctac aggatcgat catatactcg agacttaccg catattacag
421 tggatcgatt agtgtcaaag gctttaaaca tgtggggcaa agagatcccc ctgcattca
481 ggaaagtgt atggggaact gctgacatca tgattggctt tgcgcgagga gctcatgggg
541 actctaccc atttgatggg ccaggaaaca cgctggtca tgcttttgcg cctgggacag
601 gtctcggagg agatgctcac ttcgatgagg atgaacgctg gacggatggt agcagtctag
661 ggattaaatt cctgtatgct gcaactcatg aacttggcca ttctttgggt atgggacatt
721 cctctgatec taatgcagtg atgtatccaa cctatggaaa tggagatccc caaaatttta
781 aactttccca gcatgatatt aaaggcattc agaaactata tggaaagaga agtaattcaa
841 gaaagaaata gaaacttcag gcagaacatc cattcattca ttattggat tgtatatcat
901 tttgcacaa tcagaattga taagcactgt tctccactc catttagcaa ttatgtcacc

961 cttttttatt gcagttgggt ttgaatgtc ttccactcct tllaaggata aactccttta
 1021 tgggtgtgact gtgtcttatt catctatact tgcagtgggt agatgtcaat aaatgttaca
 1081 tacacaaata aataaaatgt ttattccatg gtaaatttta

[0088] In some embodiments, a MMP7 RNAi agent includes an antisense strand wherein position 19 of the antisense strand (5'→3') is capable of forming a base pair with position 1 of a 19-mer target sequence disclosed in Table 1. In some embodiments, a MMP7 agent includes an antisense strand wherein position 1 of the antisense strand (5'→3') is capable of forming a base pair with position 19 of a 19-mer target sequence disclosed in Table 1.

[0089] In some embodiments, a MMP7 agent includes an antisense strand wherein position 2 of the antisense strand (5' → 3') is capable of forming a base pair with position 18 of a 19-mer target sequence disclosed in Table 1. In some embodiments, a MMP7 agent includes an antisense strand wherein positions 2 through 18 of the antisense strand (5' → 3') are capable of forming base pairs with each of the respective complementary bases located at positions 18 through 2 of the 19-mer target sequence disclosed in Table 1.

[0090] For the RNAi agents disclosed herein, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) can be perfectly complementary to a MMP7 gene, or can be non-complementary to a MMP7 gene. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) is a U, A, or dT. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) forms an A:U or U:A base pair with the sense strand.

[0091] In some embodiments, a MMP7 RNAi agent antisense strand comprises the sequence of nucleotides (from 5' end → 3' end) 2-18 or 2-19 of any of the antisense strand sequences in Table 2 or Table 3. In some embodiments, a MMP7 RNAi sense strand comprises the sequence of nucleotides (from 5' end → 3' end) 1-17, 1-18, or 2-18 of any of the sense strand sequences in Table 2, Table 4, Table 5, or Table 6.

[0092] In some embodiments, a MMP7 RNAi agent is comprised of (i) an antisense strand comprising the sequence of nucleotides (from 5' end → 3' end) 2-18 or 2-19 of any of the antisense strand sequences in Table 2 or Table 3, and (ii) a sense strand comprising the sequence of nucleotides (from 5' end → 3' end) 1-17 or 1-18 of any of the sense strand sequences in Table 2, Table 4, Table 5, or Table 6.

[0093] In some embodiments, the MMP7 RNAi agents include core 19-mer nucleotide sequences shown in the following Table 2.

Table 2. MMP7 RNAi Agent Antisense Strand and Sense Strand Core Stretch Base Sequences (N=any nucleobase; I = inosine (hypoxanthine nucleobase))

SEQ ID NO:.	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO:.	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
37	AACAUCUGGCACUCCACAU	187	AUGUGGAGUGCCCAUGUU	305-323	303
38	UACAUCUGGCACUCCACAU	188	AUGUGGAGUGCCCAUGUA	305-323	303
39	NACAUCUGGCACUCCACAU	189	AUGUGGAGUGCCCAUGUN	305-323	303
40	NACAUCUGGCACUCCACAN	190	NUGUGGAGUGCCCAUGUN	305-323	303
41	UCAACAUCUGGCACUCCAC	191	GUGGAGUGCCCAUGUUGA	307-325	305
42	ACAACAUCUGGCACUCCAC	192	GUGGAGUGCCCAUGUUGU	307-325	305
43	GCAACAUCUGGCACUCCAC	193	GUGGAGUGCCCAUGUUGC	307-325	305
44	NCAACAUCUGGCACUCCAC	194	GUGGAGUGCCCAUGUUGN	307-325	305
45	NCAACAUCUGGCACUCCAN	195	NUGGAGUGCCCAUGUUGN	307-325	305
46	UGCAACAUCUGGCACUCCA	196	UGGAGUGCCCAUGUUGCA	308-326	306
47	AGCAACAUCUGGCACUCCA	197	UGGAGUGCCCAUGUUGCU	308-326	306
48	NGCAACAUCUGGCACUCCA	198	UGGAGUGCCCAUGUUGCN	308-326	306
49	NGCAACAUCUGGCACUCCN	199	NGGAGUGCCCAUGUUGCN	308-326	306
50	UCUGCAACAUCUGGCACUC	200	GAGUGCCCAUGUUGCAGA	310-328	308
51	ACUGCAACAUCUGGCACUC	201	GAGUGCCCAUGUUGCAGU	310-328	308
52	NCUGCAACAUCUGGCACUC	202	GAGUGCCCAUGUUGCAGN	310-328	308
53	NCUGCAACAUCUGGCACUN	203	NAGUGCCCAUGUUGCAGN	310-328	308
54	UUCUGCAACAUCUGGCACU	204	AGUGCCCAUGUUGCAGAA	311-329	309
55	AUCUGCAACAUCUGGCACU	205	AGUGCCCAUGUUGCAGAU	311-329	309
56	NUCUGCAACAUCUGGCACU	206	AGUGCCCAUGUUGCAGAN	311-329	309

SEQ ID NO.:	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.:	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
57	NUCUGCAACAUCUGGCACN	207	NGUGCCAGAUGUUGCAGAN	311-329	309
58	AUUCUGCAACAUCUGGCAC	208	GUGCCAGAUGUUGCAGAAU	312-330	310
59	UUUCUGCAACAUCUGGCAC	209	GUGCCAGAUGUUGCAGAAA	312-330	310
60	NUUCUGCAACAUCUGGCAC	210	GUGCCAGAUGUUGCAGAAU	312-330	310
61	NUUCUGCAACAUCUGGCAN	211	NUGCCAGAUGUUGCAGAAU	312-330	310
62	UAUUCUGCAACAUCUGGCA	212	UGCCAGAUGUUGCAGAAUA	313-331	311
63	AAUUCUGCAACAUCUGGCA	213	UGCCAGAUGUUGCAGAAUU	313-331	311
64	NAUUCUGCAACAUCUGGCA	214	UGCCAGAUGUUGCAGAAUN	313-331	311
65	NAUUCUGCAACAUCUGGCN	215	NGCCAGAUGUUGCAGAAUN	313-331	311
66	UUUCCUGGCCCAUCAAAUG	216	CAUUUGAUGGCCCAGGAAA	550-568	548
67	AUUCUUGGCCCAUCAAAUG	217	CAUUUGAUGGCCCAGGAAU	550-568	548
68	NUUCCUGGCCCAUCAAAUG	218	CAUUUGAUGGCCCAGGAAU	550-568	548
69	NUUCCUGGCCCAUCAAAUN	219	NAUUUGAUGGCCCAGGAAU	550-568	548
70	UGUGUUUCCUGGCCCAUCA	220	UGAUGGCCCAGGAAACACA	554-572	552
71	AGUGUUUCCUGGCCCAUCA	221	UGAUGGCCCAGGAAACACU	554-572	552
72	CGUGUUUCCUGGCCCAUCA	222	UGAUGGCCCAGGAAACACG	554-572	552
73	NGUGUUUCCUGGCCCAUCA	223	UGAUGGCCCAGGAAACACN	554-572	552
74	NGUGUUUCCUGGCCCAUCN	224	NGAUGGCCCAGGAAACACN	554-572	552
75	UUUGAGAUAGUCCUGAGCC	225	GGCUCAGGACUAUCUCAAA	149-167	147
76	AUUGAGAUAGUCCUGAGCC	226	GGCUCAGGACUAUCUCAAU	149-167	147
77	CUUGAGAUAGUCCUGAGCC	227	GGCUCAGGACUAUCUCAAG	149-167	147
78	NUUGAGAUAGUCCUGAGCC	228	GGCUCAGGACUAUCUCAAN	149-167	147

SEQ ID NO.:	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.:	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
79	NUUGAGUAAGUCCUGAGCN	229	NGCUCAGGACUAUCUCAAN	149-167	147
80	AGAGAUAAAAUCUCUUGAG	230	CUCAAGAGAUUUUAUCUCU	162-180	160
81	UGAGAUAAAAUCUCUUGAG	231	CUCAAGAGAUUUUAUCUCA	162-180	160
82	NGAGAUAAAAUCUCUUGAG	232	CUCAAGAGAUUUUAUCUCN	162-180	160
83	NGAGAUAAAAUCUCUUGAN	233	NUCAAGAGAUUUUAUCUCN	162-180	160
84	UCAUAGAGAUAAAAUCUCU	234	AGAGAUUUUAUCUCUAUGA	166-184	164
85	ACAUAGAGAUAAAAUCUCU	235	AGAGAUUUUAUCUCUAUGU	166-184	164
86	NCAUAGAGAUAAAAUCUCU	236	AGAGAUUUUAUCUCUAUGN	166-184	164
87	NCAUAGAGAUAAAAUCUCN	237	NGAGAUUUUAUCUCUAUGN	166-184	164
88	UAGUCAUAGAGAUAAAAUC	238	GAUUUAUCUCUAUGACUA	169-187	167
89	AAGUCAUAGAGAUAAAAUC	239	GAUUUAUCUCUAUGACUU	169-187	167
90	GAGUCAUAGAGAUAAAAUC	240	GAUUUAUCUCUAUGACUC	169-187	167
91	NAGUCAUAGAGAUAAAAUC	241	GAUUUAUCUCUAUGACUN	169-187	167
92	NAGUCAUAGAGAUAAAAUN	242	NAUUUAUCUCUAUGACUN	169-187	167
93	UAACAUCUGGCACUCCACA	243	UGUGGAGUGCCAGAUUUA	306-324	304
94	AACAUCUGGCACUCCACA	244	UGUGGAGUGCCAGAUUUU	306-324	304
95	NAACAUCUGGCACUCCACA	245	UGUGGAGUGCCAGAUUUN	306-324	304
96	NAACAUCUGGCACUCCACN	246	NGUGGAGUGCCAGAUUUN	306-324	304
97	UUCUGCAACAUCUGGCACU	247	AGUGCCAGAUUUUGCAGAA	311-329	309
98	AUCUGCAACAUCUGGCACU	248	AGUGCCAGAUUUUGCAGAU	311-329	309
99	NUCUGCAACAUCUGGCACU	249	AGUGCCAGAUUUUGCAGAN	311-329	309
100	NUCUGCAACAUCUGGCACN	250	NGUGCCAGAUUUUGCAGAN	311-329	309

SEQ ID NO.:	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.:	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
101	UAGUAUUCUGCAACAUCUG	251	CAGAUGUUGCAGAAUACUA	316-334	314
102	AAGUAUUCUGCAACAUCUG	252	CAGAUGUUGCAGAAUACUU	316-334	314
103	GAGUAUUCUGCAACAUCUG	253	CAGAUGUUGCAGAAUACUC	316-334	314
104	NAGUAUUCUGCAACAUCUG	254	CAGAUGUUGCAGAAUACUN	316-334	314
105	NAGUAUUCUGCAACAUCUN	255	NAGAUGUUGCAGAAUACUN	316-334	314
106	AAUAGUGAGUAUUCUGCAA	256	UUGCAGAAUACUCACUAUU	322-340	320
107	UAUAGUGAGUAUUCUGCAA	257	UUGCAGAAUACUCACUAUA	322-340	320
108	NAUAGUGAGUAUUCUGCAA	258	UUGCAGAAUACUCACUAUN	322-340	320
109	NAUAGUGAGUAUUCUGCAN	259	NUGCAGAAUACUCACUAUN	322-340	320
110	AAUAGUGAGUAUUCUGCA	260	UGCAGAAUACUCACUAUUU	323-341	321
111	UAAUAGUGAGUAUUCUGCA	261	UGCAGAAUACUCACUAUUA	323-341	321
112	NAUAGUGAGUAUUCUGCA	262	UGCAGAAUACUCACUAUUN	323-341	321
113	NAUAGUGAGUAUUCUGCN	263	NGCAGAAUACUCACUAUUN	323-341	321
114	UACUAAUCGAUCCACUGUA	264	UACAGUGGAUCCGAUUAGUA	416-434	414
115	AACUAAUCGAUCCACUGUA	265	UACAGUGGAUCCGAUUAGUU	416-434	414
116	CACUAAUCGAUCCACUGUA	266	UACAGUGGAUCCGAUUAGUG	416-434	414
117	NACUAAUCGAUCCACUGUA	267	UACAGUGGAUCCGAUUAGUN	416-434	414
118	NACUAAUCGAUCCACUGUN	268	NACAGUGGAUCCGAUUAGUN	416-434	414
119	ACACUAAUCGAUCCACUGU	269	ACAGUGGAUCCGAUUAGUGU	417-435	415
120	UCACUAAUCGAUCCACUGU	270	ACAGUGGAUCCGAUUAGUGA	417-435	415
121	NCACUAAUCGAUCCACUGU	271	ACAGUGGAUCCGAUUAGUGN	417-435	415
122	NCACUAAUCGAUCCACUGN	272	NCAGUGGAUCCGAUUAGUGN	417-435	415

SEQ ID NO.:	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.:	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
123	UUGACACUAAUCCGAUCCAC	273	GUGGAUCGAUUAGUGUCA	420-438	418
124	AUGACACUAAUCCGAUCCAC	274	GUGGAUCGAUUAGUGUCAU	420-438	418
125	NUGACACUAAUCCGAUCCAC	275	GUGGAUCGAUUAGUGUCAN	420-438	418
126	NUGACACUAAUCCGAUCCAN	276	NUGGAUCGAUUAGUGUCAN	420-438	418
127	UUGACACUAAUCCGAUCCAC	277	GUGGAUCGAUUAGUIUCA	420-438	418
128	AUGACACUAAUCCGAUCCAC	278	GUGGAUCGAUUAGUIUCAU	420-438	418
129	NUGACACUAAUCCGAUCCAC	279	GUGGAUCGAUUAGUIUCAN	420-438	418
130	NUGACACUAAUCCGAUCCAN	280	NUGGAUCGAUUAGUIUCAN	420-438	418
131	UCAUCGAAGUGAGCAUCUC	281	GAGAUGCUCACUUCGAUGA	610-628	608
132	ACAUCGAAGUGAGCAUCUC	282	GAGAUGCUCACUUCGAUGU	610-628	608
133	NCAUCGAAGUGAGCAUCUC	283	GAGAUGCUCACUUCGAUGN	610-628	608
134	NCAUCGAAGUGAGCAUCUN	284	NAGAUGCUCACUUCGAUGN	610-628	608
135	UAGCAUACAGGAAGUUAU	285	AUUAACUUCUUGUAUGCUA	663-681	661
136	AAGCAUACAGGAAGUUAU	286	AUUAACUUCUUGUAUGCUU	663-681	661
137	NAGCAUACAGGAAGUUAU	287	AUUAACUUCUUGUAUGCUN	663-681	661
138	NAGCAUACAGGAAGUUAAN	288	NUUAACUUCUUGUAUGCUN	663-681	661
139	AUAGGUUGGAUACAUACU	289	AGUGAUGUAUCCCAACCUAU	737-755	735
140	UUAGGUUGGAUACAUACU	290	AGUGAUGUAUCCCAACCUAA	737-755	735
141	NUAGGUUGGAUACAUACU	291	AGUGAUGUAUCCCAACCUAN	737-755	735
142	NUAGGUUGGAUACAUACAN	292	NGUGAUGUAUCCCAACCUAN	737-755	735
143	AUUUCCAUAAGGUUGGAUAC	293	GUAUCCAACCUAUGGAAA	743-461	741
144	UUUUCCAUAAGGUUGGAUAC	294	GUAUCCAACCUAUGGAAAA	743-461	741

SEQ ID NO.:	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.:	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
145	NUUCCAUAGGUUGAUAC	295	GUAUCCAACCUAUGGAAAN	743-746	741
146	NUUCCAUAGGUUGAUAN	296	NUAUCCAACCUAUGGAAAN	743-746	741
147	UAUAGUUUCUGAAUGCCUU	297	AAGGCAUUCAGAAACUAUA	802-820	800
148	AAUAGUUUCUGAAUGCCUU	298	AAGGCAUUCAGAAACUAUU	802-820	800
149	NAUAGUUUCUGAAUGCCUU	299	AAGGCAUUCAGAAACUAUN	802-820	800
150	NAUAGUUUCUGAAUGCCUN	300	NAGGCAUUCAGAAACUAUN	802-820	800
151	UCAAUUCUGAUUGGCAAC	301	GUUGCACAUAUCAGAAUUGA	902-920	900
152	ACA AUUCUGAUUGGCAAC	302	GUUGCACAUAUCAGAAUUGU	902-920	900
153	NCA AUUCUGAUUGGCAAC	303	GUUGCACAUAUCAGAAUUGN	902-920	900
154	NCA AUUCUGAUUGGCAAN	304	NUUGCACAUAUCAGAAUUGN	902-920	900
155	AUCA AUUCUGAUUGGCAA	305	UUGCACAUAUCAGAAUUGAU	903-921	901
156	UUCA AUUCUGAUUGGCAA	306	UUGCACAUAUCAGAAUUGAA	903-921	901
157	NUCA AUUCUGAUUGGCAA	307	UUGCACAUAUCAGAAUUGAN	903-921	901
158	NUCA AUUCUGAUUGGCGAN	308	NUGCACAUAUCAGAAUUGAN	903-921	901
159	UGCUUAUCA AUUCUGAUUG	309	CAUUCAGAAUUGAUUAGCA	908-926	906
160	AGCUUAUCA AUUCUGAUUG	310	CAUUCAGAAUUGAUUAGCU	908-926	906
161	NGCUUAUCA AUUCUGAUUG	311	CAUUCAGAAUUGAUUAGCN	908-926	906
162	NGCUUAUCA AUUCUGAUUN	312	NAUUCAGAAUUGAUUAGCN	908-926	906
163	UUGCUUAUCA AUUCUGAUU	313	AAUUCAGAAUUGAUUAGCAA	909-927	907
164	AUGCUUAUCA AUUCUGAUU	314	AAUUCAGAAUUGAUUAGCAU	909-927	907
165	NUGCUUAUCA AUUCUGAUU	315	AAUUCAGAAUUGAUUAGCAN	909-927	907
166	NUGCUUAUCA AUUCUGAUN	316	NAUUCAGAAUUGAUUAGCAN	909-927	907

SEQ ID NO:	Antisense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO:	Sense Strand Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	Corresponding Positions of Identified Sequence on SEQ ID NO: 1	Targeted Gene Position
167	UGCAAUAAAAAAGGGUGAC	317	GUCACCCUUUUUUAUUGCA	955-973	953
168	AGCAAUAAAAAAGGGUGAC	318	GUCACCCUUUUUUAUUGCU	955-973	953
169	NGCAAUAAAAAAGGGUGAC	319	GUCACCCUUUUUUAUUGCN	955-973	953
170	NGCAAUAAAAAAGGGUGAN	320	NUCACCCUUUUUUAUUGCN	955-973	953
171	ACAUUCAAAAAACCAACUGC	321	GCAGUUGGUUUUUUGAAUGU	971-989	969
172	UCAUUCAAAAAACCAACUGC	322	GCAGUUGGUUUUUUGAAUGA	971-989	969
173	NCAUUCAAAAAACCAACUGC	323	GCAGUUGGUUUUUUGAAUGN	971-989	969
174	NCAUUCAAAAAACCAACUGN	324	NCAGUUGGUUUUUUGAAUGN	971-989	969
175	AGACAUUCAAAAAACCAACU	325	AGUUGGUUUUUUGAAUGUCU	973-991	971
176	UGACAUUCAAAAAACCAACU	326	AGUUGGUUUUUUGAAUGUCA	973-991	971
177	NGACAUUCAAAAAACCAACU	327	AGUUGGUUUUUUGAAUGUCN	973-991	971
178	NGACAUUCAAAAAACCAACN	328	NGUUGGUUUUUUGAAUGUCN	973-991	971
179	AAGACAUUCAAAAAACCAAC	329	GUUGGUUUUUUGAAUGUCUU	974-992	972
180	UAGACAUUCAAAAAACCAAC	330	GUUGGUUUUUUGAAUGUCUA	974-992	972
181	NAGACAUUCAAAAAACCAAC	331	GUUGGUUUUUUGAAUGUCUN	974-992	972
182	NAGACAUUCAAAAAACCAAN	332	NUUGGUUUUUUGAAUGUCUN	974-992	972
183	AGUUUAUCCUUAAAAAGGAG	333	CUCCUUUUAAGGAUAAACU	996-1014	994
184	UGUUUAUCCUUAAAAAGGAG	334	CUCCUUUUAAGGAUAAACA	996-1014	994
185	NGUUUAUCCUUAAAAAGGAG	335	CUCCUUUUAAGGAUAAACN	996-1014	994
186	NGUUUAUCCUUAAAAAGGAN	336	NUCCUUUUAAGGAUAAACN	996-1014	994

[0094] The MMP7 RNAi agent sense strands and antisense strands that comprise or consist of the nucleotide sequences in Table 2 can be modified nucleotides or unmodified nucleotides. In some embodiments, the MMP7 RNAi agents having the sense and antisense strand sequences that comprise or consist of any of the nucleotide sequences in Table 2 are all or substantially all modified nucleotides.

[0095] In some embodiments, the antisense strand of a MMP7 RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2. In some embodiments, the sense strand of a MMP7 RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2.

[0096] As used herein, each N listed in a sequence disclosed in Table 2 may be independently selected from any and all nucleobases (including those found on both modified and unmodified nucleotides). In some embodiments, an N nucleotide listed in a sequence disclosed in Table 2 has a nucleobase that is complementary to the N nucleotide at the corresponding position on the other strand. In some embodiments, an N nucleotide listed in a sequence disclosed in Table 2 has a nucleobase that is not complementary to the N nucleotide at the corresponding position on the other strand. In some embodiments, an N nucleotide listed in a sequence disclosed in Table 2 has a nucleobase that is the same as the N nucleotide at the corresponding position on the other strand. In some embodiments, an N nucleotide listed in a sequence disclosed in Table 2 has a nucleobase that is different from the N nucleotide at the corresponding position on the other strand.

[0097] Certain modified MMP7 RNAi agent sense and antisense strands are provided in Table 3, Table 4, Table 5, Table 6, and Table 10. Certain modified MMP7 RNAi agent antisense strands, as well as their underlying unmodified nucleobase sequences, are provided in Table 3. Certain modified MMP7 RNAi agent sense strands, as well as their underlying unmodified nucleobase sequences, are provided in Tables 4, 5, and 6. In forming MMP7 RNAi agents, each of the nucleotides in each of the underlying base sequences listed in Tables 3, 4, 5, and 6, as well as in Table 2, above, can be a modified nucleotide.

[0098] The MMP7 RNAi agents described herein are formed by annealing an antisense strand with a sense strand. A sense strand containing a sequence listed in Table 2, Table 4, Table 5, or Table 6 can be hybridized to any antisense strand containing a sequence listed in Table 2 or Table 3, provided the two sequences have a region of at least 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.

[0099] In some embodiments, a MMP7 RNAi agent antisense strand comprises a nucleotide sequence of any of the sequences in Table 2 or Table 3.

[0100] In some embodiments, a MMP7 RNAi agent comprises or consists of a duplex having the nucleobase sequences of the sense strand and the antisense strand of any of the sequences in Table 2, Table 3, Table 4, Table 5, Table 6, or Table 10.

[0101] Examples of antisense strands containing modified nucleotides are provided in Table 3. Examples of sense strands containing modified nucleotides are provided in Tables 4, 5 and 6.

[0102] As used in Tables 3, 4, 5, 6, and 10, the following notations are used to indicate modified nucleotides, targeting groups, and linking groups:

A	=	adenosine-3'-phosphate
C	=	cytidine-3'-phosphate
G	=	guanosine-3'-phosphate
U	=	uridine-3'-phosphate
I	=	inosine-3'-phosphate
a	=	2'-O-methyladenosine-3'-phosphate
as	=	2'-O-methyladenosine-3'-phosphorothioate
c	=	2'-O-methylcytidine-3'-phosphate
cs	=	2'-O-methylcytidine-3'-phosphorothioate
g	=	2'-O-methylguanosine-3'-phosphate
gs	=	2'-O-methylguanosine-3'-phosphorothioate
i	=	2'-O-methylinosine-3'-phosphate
is	=	2'-O-methylinosine-3'-phosphorothioate
t	=	2'-O-methyl-5-methyluridine-3'-phosphate
ts	=	2'-O-methyl-5-methyluridine-3'-phosphorothioate
u	=	2'-O-methyluridine-3'-phosphate
us	=	2'-O-methyluridine-3'-phosphorothioate
Af	=	2'-fluoroadenosine-3'-phosphate
Afs	=	2'-fluoroadenosine-3'-phosphorothioate
Cf	=	2'-fluorocytidine-3'-phosphate
Cfs	=	2'-fluorocytidine-3'-phosphorothioate
Gf	=	2'-fluoroguanosine-3'-phosphate
Gfs	=	2'-fluoroguanosine-3'-phosphorothioate
Tf	=	2'-fluoro-5'-methyluridine-3'-phosphate
Tfs	=	2'-fluoro-5'-methyluridine-3'-phosphorothioate
Uf	=	2'-fluorouridine-3'-phosphate
Ufs	=	2'-fluorouridine-3'-phosphorothioate
dT	=	2'-deoxythymidine-3'-phosphate

A _{UNA}	=	2',3'-seco-adenosine-3'-phosphate
A _{UNAS}	=	2',3'-seco-adenosine-3'-phosphorothioate
C _{UNA}	=	2',3'-seco-cytidine-3'-phosphate
C _{UNAS}	=	2',3'-seco-cytidine-3'-phosphorothioate
G _{UNA}	=	2',3'-seco-guanosine-3'-phosphate
G _{UNAS}	=	2',3'-seco-guanosine-3'-phosphorothioate
U _{UNA}	=	2',3'-seco-uridine-3'-phosphate
U _{UNAS}	=	2',3'-seco-uridine-3'-phosphorothioate
a _{2N}	=	see Table 11
a _{2Ns}	=	see Table 11
(invAb)	=	inverted abasic deoxyribonucleotide-5'-phosphate, see Table 11
(invAb)s	=	inverted abasic deoxyribonucleotide-5'-phosphorothioate, see Table 11
s	=	phosphorothioate linkage
p	=	terminal phosphate (as synthesized)
vpdN	=	vinyl phosphonate deoxyribonucleotide
cPrpa	=	5'-cyclopropyl phosphonate-2'-O-methyladenosine-3'-phosphate (see Table 11)
cPrpas	=	5'-cyclopropyl phosphonate-2'-O-methyladenosine-3'-phosphorothioate (see Table 11)
cPrpu	=	5'-cyclopropyl phosphonate-2'-O-methyluridine-3'-phosphate (see Table 11)
cPrpus	=	5'-cyclopropyl phosphonate-2'-O-methyluridine-3'-phosphorothioate (see Table 11)
(Alk-SS-C6)	=	see Table 11
(C6-SS-Alk)	=	see Table 11
(C6-SS-C6)	=	see Table 11
(6-SS-6)	=	see Table 11
(C6-SS-Alk-Me)	=	see Table 11
(NII2-C6)	=	see Table 11
(TriAlk14)	=	see Table 11
(TriAlk14)s	=	see Table 11
-C6-	=	see Table 11
-C6s-	=	see Table 11
-L6-C6-	=	see Table 11
-L6-C6s-	=	see Table 11
-Alk-cyHex-	=	see Table 11
-Alk-cyHexs-	=	see Table 11
(TA14)	=	see Table 11 (structure of (TriAlk14)s after conjugation)

(TA14)s = see Table 11 (structure of (TriAlk14)s after conjugation)

[0103] As the person of ordinary skill in the art would readily understand, unless otherwise indicated by the sequence (such as, for example, by a phosphorothioate linkage “s”), when present in an oligonucleotide, the nucleotide monomers are mutually linked by 5'-3'-phosphodiester bonds. As the person of ordinary skill in the art would clearly understand, the inclusion of a phosphorothioate linkage as shown in the modified nucleotide sequences disclosed herein replaces the phosphodiester linkage typically present in oligonucleotides. Further, the person of ordinary skill in the art would readily understand that the terminal nucleotide at the 3' end of a given oligonucleotide sequence would typically have a hydroxyl (-OH) group at the respective 3' position of the given monomer instead of a phosphate moiety *ex vivo*. Additionally, for the embodiments disclosed herein, when viewing the respective strand 5' → 3', the inverted abasic residues are inserted such that the 3' position of the deoxyribose is linked at the 3' end of the preceding monomer on the respective strand (*see, e.g., Table 11*). Moreover, as the person of ordinary skill would readily understand and appreciate, while the phosphorothioate chemical structures depicted herein typically show the anion on the sulfur atom, the inventions disclosed herein encompass all phosphorothioate tautomers (e.g., where the sulfur atom has a double-bond and the anion is on an oxygen atom). Unless expressly indicated otherwise herein, such understandings of the person of ordinary skill in the art are used when describing the MMP7 RNAi agents and compositions of MMP7 RNAi agents disclosed herein.

[0104] Certain examples of targeting groups and linking groups used with the MMP7 RNAi agents disclosed herein are included in the chemical structures provided below in Table 11. Each sense strand and/or antisense strand can have any targeting groups or linking groups listed herein, as well as other targeting or linking groups, conjugated to the 5' and/or 3' end of the sequence.

Table 3. MMP7 RNAi Agent Antisense Strand Sequences

AS Strand ID	Modified Antisense Strand (5' → 3')	SEQ ID NO.	Underlying Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.
AM08523-AS	asAfsasAfuCfuGfgCfaCfuCfcAfcAfuCfsu	337	AACAUCUGGCACUCCACAUCU	629
AM08525-AS	asAfsasAfuCfuGfgCfaCfuCfcAfcAfuCfsu	338	AACAUCUGGCACUCCACAUCG	630
AM08527-AS	usCfsasAfcAfuCfuGfgCfaCfuCfcAfcAfsu	339	UCAACAUCUGGCACUCCACAUCU	631
AM08529-AS	usCfsasAfcAfuCfuGfgCfaCfuCfcAfcAfsu	340	UCAACAUCUGGCACUCCACAUCG	632
AM08531-AS	usGfsasAfaCfaUfcUfgGfcAfcUfcCfaCfsa	341	UGCAACAUCUGGCACUCCACA	633
AM08533-AS	usGfsasAfaCfaUfcUfgGfcAfcUfcCfaCfsu	342	UGCAACAUCUGGCACUCCACAUCG	634
AM08535-AS	usCfsusGfcAfaCfaUfcUfgGfcAfcUfcCfsa	343	UCUGCAACAUCUGGCACUCCA	635
AM08537-AS	usCfsusGfcAfaCfaUfcUfgGfcAfcUfcCfsu	344	UCUGCAACAUCUGGCACUCCG	636
AM08539-AS	usUfsasUfgCfaAfcAfuCfuGfgCfaCfuCfsc	345	UUCUGCAACAUCUGGCACUCC	637
AM08541-AS	asUfsusCfuGfcAfaCfaUfcUfgGfcAfcUfsc	346	AUUCUGCAACAUCUGGCACUC	638
AM08543-AS	usAfsusUfcUfgCfaAfcAfuCfuGfgCfaCfsu	347	UAUUCUGCAACAUCUGGCACUC	639
AM08545-AS	usAfsusUfcUfgCfaAfcAfuCfuGfgCfaCfsu	348	UAUUCUGCAACAUCUGGCACG	640
AM08547-AS	usUfsusCfcUfgGfcCfaAfuCfaUfaUfgGfsg	349	UUUCCUGGCCCAUCAAUUGGG	641
AM08549-AS	usGfsusGfuUfuCfcUfgGfcCfcAfuCfaAfsu	350	UGUGUUUCCUGGCCCAUCAAG	642
AM08789-AS	usCfsusUfcUfuUfgUfuUfaUfgAfgUfcGfsu	351	UCUUUUUUUUUUAGAGUCGU	643
AM08791-AS	asAfsasAfaCfuUfcUfgCfaUfuUfcCfcUfsc	352	AAGAUAUUCUGCAUUUCCUUC	644
AM08793-AS	usUfsasAfuCfuAfcUfaUfgAfaCfcGfaGfsg	353	UUGAUUAUAUAAGAACCGAGG	645
AM08797-AS	asCfsasAfaCfaGfgAfaGfuUfcAfcUfcCfsu	354	ACAAACAGGAAGUUCACUCCU	646
AM08801-AS	usAfsasAfgUfaCfaAfgGfaAfgAfaAfgGfsa	355	UACAGUACAAGGAAGAAAGGA	647
AM08803-AS	usGfsasCfaUfuUfaUfuGfcUfgGfuGfuCfsu	356	UGACAUUUUAUUGCUGGUGUCU	648
AM08805-AS	usGfsasCfaUfuUfaUfuGfcUfgGfuGfuCfsu	357	UGACAUUUUAUUGCUGGUGUCG	649
AM08807-AS	usGfsasCfaUfuUfaUfuGfcUfgAfuGfuCfsu	358	UGACAUUUUAUUGCUGAUUGUCG	650
AM12367-AS	usUfsusGfaGfaUfaGfuCfcUfgAfgCfcUfsg	359	UUUGAGAUAGUCCUGAGCCUG	651
AM12369-AS	asGfsasGfaUfaAfaAfuCfuCfuUfgAfgAfsu	360	AGAGAUAAAUAUCUCUUGAGAC	652
AM12371-AS	usCfsasUfaGfaGfaUfaAfaAfuCfuCfuUfsg	361	UCAUAGAGAUAAAUAUCUCUUG	653
AM12373-AS	usAfsasUfcAfuAfgAfaAfaAfaUfcUfsc	362	UAGUCAUAGAGAUAAAUAUCUC	654

AM12375-AS	usAfsasCfaUfcUfgGfcAfcUfcCfaCfaUfsc	363	UAAACUCUGGCACUCCACAUC	655
AM12378-AS	usAfsasUfaUfuCfuGfcAfaCfaUfcUfgGfsc	364	UAGUAAUUCUGCAACAUUGGC	656
AM12380-AS	asAfsusAfgUfgAfgUfaUfuCfuGfcAfaCfsc	365	AAUAGUGAGUAUUCUGCAACC	657
AM12382-AS	asAfsasUfaGfuGfaGfuAfuUfcUfgCfaAfscc	366	AAAUAGUGAGUAUUCUGCAAC	658
AM12384-AS	usAfsasUfaAfuCfuGfcAfaCfaUfcUfgUfaAfscc	367	UACUAAUCCGAUCCACUGUAAC	659
AM12386-AS	asCfsasCfuAfaUfcGfaUfcCfaCfaGfuGfuAfscc	368	ACACUAAUCCGAUCCACUGUAC	660
AM12388-AS	usUfsasAfcAfcUfaAfuCfuGfcAfaCfaUfcUfgGfsc	369	UUGACACUAAUCCGAUCCACUG	661
AM12390-AS	usCfsasUfcGfaAfgUfgAfgCfaUfcUfcCfsu	370	UCAUCGAAGUGAGCAUCUCCU	662
AM12392-AS	usAfsasCfaUfaCfaGfaGfaGfuUfaAfuCfsc	371	UAGCAUACAGGAAGUUAUCC	663
AM12394-AS	asUfsasGfgUfuGfgAfuAfcAfuCfaCfuGfsc	372	AUAGGUUGGAUACAUACACUGC	664
AM12396-AS	asUfsusUfcCfaUfaGfgUfuGfgAfuAfcAfscc	373	AUUUCCAUAGGUUGGAUACAC	665
AM12398-AS	usCfsasUfuUfaAfuAfuCfaUfcCfuGfgGfsc	374	UCCUUAAUAUACAUCCUGGGA	666
AM12400-AS	usAfsasAfgUfuUfcUfgAfaUfgCfcUfuUfsc	375	UAUAGUUUCUGAAUGCCUUUC	667
AM12402-AS	usCfsasAfuUfcUfgAfuUfgUfgCfaAfcAfscc	376	UCAAUUCUGAAUUGUGCAACAC	668
AM12404-AS	asUfsasAfaUfuCfuGfaUfuGfuGfcAfaCfsc	377	AUCAAUUCUGAAUUGUGCAACC	669
AM12406-AS	usGfsasUfuAfuCfaAfuUfcUfgAfuUfgUfsc	378	UGCUUAUCAUUCUGAUUGUG	670
AM12408-AS	usUfsasCfuUfaUfcAfaUfuCfuGfaUfuGfsc	379	UUGCUUAUCAUUCUGAUUGC	671
AM12410-AS	usGfsasAfaUfaAfaAfaAfgGfgUfgAfcAfscc	380	UGCAAUAAUAAAGGGUGACAC	672
AM12412-AS	asCfsasUfuCfaAfaAfaCfaCfaCfuGfcAfscc	381	ACAUUCAAAUAAACCAACUGCAC	673
AM12414-AS	asGfsasCfaUfuCfaAfaAfaCfaCfaCfuGfsc	382	AGACAUUCAAAACCAACUGC	674
AM12416-AS	asAfsasAfcAfuUfcAfaAfaAfaCfaAfcUfsc	383	AAGACAUUCAAAACCAACUG	675
AM12418-AS	asGfsasUfuAfuCfcUfuAfaAfaAfaAfgUfgUfsc	384	AGUUUAUCCUUAAAGGAGUG	676
AM12875-AS	cPrpusAfsasCfaUfcUfgGfcAfcUfcCfaCfaUfsc	385	UAAACUUCUGGCACUCCACAUC	655
AM12877-AS	cPrpuAfacaucugcAfcUfcCfaacasc	386	UAAACUUCUGGCACUCCACAUC	655
AM13076-AS	usCfsasAfuUfcUfgAfuUfgUfgCfaAfcAfscc	387	UCAAUUCUGAAUUGUGCAACAG	677
AM13077-AS	cPrpusCfsasAfuUfcUfgAfuUfgUfgCfaAfcAfscc	388	UCAAUUCUGAAUUGUGCAACAC	668
AM13079-AS	usCfsasaucugauUfgUfgCfaacasc	389	UCAAUUCUGAAUUGUGCAACAC	668
AM13081-AS	usCfsasAfuucugauUfgUfgCfaacasc	390	UCAAUUCUGAAUUGUGCAACAC	668
AM13082-AS	usCfsasAfuUfcugauUfgUfgCfaacasc	391	UCAAUUCUGAAUUGUGCAACAC	668
AM13083-AS	usCfsasAfuUfcugauUfgUfgCfaAfcasc	392	UCAAUUCUGAAUUGUGCAACAC	668

AM13212-AS	usUfsgsacacUfaAfuCfGfAfuCfcausg	393	UUGACACUAUUCGAUCCACUG	661
AM13215-AS	usCfscsuuaAfuAfuCfaUfcCfugggsa	394	UCCUUAAUAUCAUCCUGGA	666
AM13241-AS	asGfisascaucaaAfaCfcAfacugsc	395	AGACAUUCAAAAACCAACUGC	674
AM13244-AS	asGfisascauucAfaaAfaCfcAfacugsc	396	AGACAUUCAAAAACCAACUGC	674
AM13245-AS	asGfisascauucCfAfaaAfaCfcAfacugsc	397	AGACAUUCAAAAACCAACUGC	674
AM13246-AS	asUfisasgguugauAfcAfuCfacugsc	398	AUAGGUUGGAUACAUACUGC	664
AM13247-AS	asUfisasgguUUNAggaUfcAfuCfacugsc	399	AUAGGUUGGAUACAUACUGC	664
AM13400-AS	usAfsgsuauucgcAfaCfaUfcugsc	400	UAGUAUUCUGCAACAUCUGGC	656
AM13402-AS	usAfsgsuauUUNAcugcAfaCfaUfcugsc	401	UAGUAUUCUGCAACAUCUGGC	656
AM13403-AS	usAfsgsuaUUNA UfcugcAfaCfaUfcugsc	402	UAGUAUUCUGCAACAUCUGGC	656
AM13405-AS	asGfissuuaucuuAfaAfaGfgagug	403	AGUUUAUCCUUAAAAGGAGUG	676
AM13407-AS	asGfissuUfuaucuuAfaAfaGfgagug	404	AGUUUAUCCUUAAAAGGAGUG	676
AM13409-AS	asGfissuUfuaucuuAfaAfaGfgagug	405	AGUUUAUCCUUAAAAGGAGUC	678
AM14108-AS	cPrpuGfacaucAfaaAfaCfcAfacugsc	406	UGACAUUCAAAAACCAACUGC	679
AM14109-AS	cPrpuUfGacacUfaAfuCfGfAfuCfcausg	407	UUGACACUAUUCGAUCCACUG	661
AM14110-AS	cPrpasGfisasCfaUfuCfaAfaAfaCfcAfaCfuGfsc	408	AGACAUUCAAAAACCAACUGC	674
AM14112-AS	cPrpusGfisasCfaUfuCfaAfaAfaCfcAfaCfuGfsc	409	UGACAUUCAAAAACCAACUGC	679
AM14113-AS	cPrpuGfAfaCfaUfuCfaAfaAfaCfcAfaCfuGfsc	410	UGACAUUCAAAAACCAACUGC	679
AM14117-AS	cPrpusUfsgsAfcAfcUfaAfuCfGfAfuCfcaUfsg	411	UUGACACUAUUCGAUCCACUG	661
AM14118-AS	cPrpuUfGfAfcAfcUfaAfuCfGfAfuCfcaUfsg	412	UUGACACUAUUCGAUCCACUG	661
AM14119-AS	cPrpusUfsgsacacUfaAfuCfGfAfuCfcausg	413	UUGACACUAUUCGAUCCACUG	661
AM14121-AS	usAfsascaucuggcAfcUfcCfacauc	414	UAACAUCUGGCACUCCACAUC	655
AM14122-AS	cPrpusAfsascaucuggcAfcUfcCfacauc	415	UAACAUCUGGCACUCCACAUC	655
AM14124-AS	cPrpusUfisasGfgUfuGfgAfuAfcAfuCfaCfuGfsc	416	UUAGGUUGGAUACAUACUGC	680
AM14125-AS	usUfisasGfgUfuggauAfcAfuCfcaCfugsc	417	UUAGGUUGGAUACAUACUGC	680
AM14126-AS	cPrpusUfisasGfgUfuggauAfcAfuCfcaCfugsc	418	UUAGGUUGGAUACAUACUGC	680
AM14127-AS	cPrpuUfaGfgUfuggauAfcAfuCfcaCfugsc	419	UUAGGUUGGAUACAUACUGC	680
AM14129-AS	cPrpusGfissuUfuaucuuAfaAfaGfgagug	420	UGUUUAUCCUUAAAAGGAGUG	681
AM14130-AS	cPrpuGfuUfuaucuuAfaAfaGfgagug	421	UGUUUAUCCUUAAAAGGAGUG	681
AM14131-AS	cPrpusGfissuUfuAfuCfcUfuAfaAfaGfgAfgUfsg	422	UGUUUAUCCUUAAAAGGAGUG	681

AM14114-AS	cPrpasGfsascauucAfaaAfaCfcAfacugsc	423	AGACAUUCAAAAACCAACUCG	674
AM14116-AS	cPrpusGfsascauucAfaaAfaCfcAfacugsc	424	UGACAUUCAAAAACCAACUCG	679
AM14651-AS	usUfsasGfgUfuGfgAfuAfcAfuCfaCfuGfsc	425	UUAGGUUGGAUACAUCACUCG	680
AM14652-AS	cPrpasUfsasGfgUfuGfgAfuAfcAfuCfaCfuGfsc	426	AUAGGUUGGAUACAUCACUCG	664
AM14653-AS	asUfsagguuggauAfcAfuCfacugsc	427	AUAGGUUGGAUACAUCACUCG	664
AM14654-AS	cPrpasUfsagguuggauAfcAfuCfacugsc	428	AUAGGUUGGAUACAUCACUCG	664
AM14655-AS	cPrpasUfsaGfguuggauAfcAfuCfacugsc	429	AUAGGUUGGAUACAUCACUCG	664
AM14656-AS	cPrpaUfaGfguuggauAfcAfuCfacugsc	430	AUAGGUUGGAUACAUCACUCG	664
AM14657-AS	cPrpasUfsagGfguuggauAfcAfuCfacugsc	431	AUAGGUUGGAUACAUCACUCG	664
AM14658-AS	cPrpasUfsagguUfgguAfcAfuCfacugsc	432	AUAGGUUGGAUACAUCACUCG	664
AM14659-AS	cPrpasUfsagguGfguAfcAfuCfacugsc	433	AUAGGUUGGAUACAUCACUCG	664
AM14888-AS	cPrpasUfsasgguuggauAfcAfuCfacugsc	434	AUAGGUUGGAUACAUCACUCG	664
AM14889-AS	cPrpaUfagguuggauAfcAfuCfacugsc	435	AUAGGUUGGAUACAUCACUCG	664
AM15155-AS	cPrpaGfacaucAfaaAfaCfcAfacugsc	436	AGACAUUCAAAAACCAACUCG	674

Table 4. MMP7 Agent Sense Strand Sequences (Shown Without Linkers, Conjugates, or Capping Moieties)

Strand ID	Modified Sense Strand (5' → 3')	SEQ ID NO.	Underlying Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.
AM08522-SS-NL	asgauguggAfGfUfgccagauguu	458	AGAUGUGGAGUGCCAGAUUU	682
AM08524-SS-NL	csgauguggAfGfUfgccagauguu	459	CGAUGUGGAGUGCCAGAUUU	683
AM08526-SS-NL	asuguggagUfGfCfcagauguuga	460	AUGUGGAGUGCCAGAUUGA	684
AM08528-SS-NL	csugugggagUfGfCfcagauguuga	461	CUGUGGAGUGCCAGAUUGA	685
AM08530-SS-NL	usgugggaguGfCfcfagauguugca	462	UGUGGAGUGCCAGAUUGCA	686
AM08532-SS-NL	csugugggaguGfCfcfagauguugca	463	CGUGGAGUGCCAGAUUGCA	687
AM08534-SS-NL	usggagugcCfAfGfauuguucaga	464	UGGAGUGCCAGAUUGCAGA	688
AM08536-SS-NL	csggagugcCfAfGfauuguucaga	465	CGGAGUGCCAGAUUGCAGA	689
AM08538-SS-NL	gsggagugccAfGfAfuguuugcagaa	466	GGAGUGCCAGAUUGCAGAA	690
AM08540-SS-NL	gsagugccaGfAfUfguugcagaa	467	GAGUGCCAGAUUGCAGAAU	691
AM08542-SS-NL	asgugccagAfUfGfuuugcagaaua	468	AGUGCCAGAUUGCAGAAUA	692
AM08544-SS-NL	csugugccagAfUfGfuuugcagaaua	469	CGUGCCAGAUUGCAGAAUA	693
AM08546-SS-NL	csccauuugAfUfGfggccaggaaa	470	CCCAUUUGAUGGGCCAGGAAA	694
AM08548-SS-NL	csuuugauggGfCfCfaggaaacaca	471	CUUGAUGGGCCAGGAAACACA	695
AM12366-SS-NL	caggcucaGfGfAfcauaucaaa	472	CAGGCU CAGGACUAUCUCAAA	696
AM12368-SS-NL	guucucaagAfGfAfuuuuauucucu	473	GUCUCAAGAGAUUUUAUCUCU	697
AM12370-SS-NL	ca 2NagagauUfUfUfaucucuauaga	474	CAAGAGAUUUUAUCUCUAUGA	698
AM12372-SS-NL	ggagauuuuAfUfCfucuaugacua	475	GAGAUUUUAUCUCUAUGACUA	699
AM12374-SS-NL	gauguggaGfUfGfccagauguua	476	GAUGUGGAGUGCCAGAUUUUA	700
AM12376-SS-NL	ggagugcccAfGfAfuguuicagaa	477	GGAGUGCCAGAUUGUUCAGAA	701
AM12377-SS-NL	ggccagaugUfUfGfcagaaucua	478	GCCAGAUUGCAGAAUACUA	702
AM12379-SS-NL	ggguugccagAfAfUfucucacuaau	479	GGUUGCAGAAUACUCACUAUU	703
AM12381-SS-NL	sguugccagaAfUfAfucucacuaauu	480	GUUGCAGAAUACUCACUAUUU	704
AM12383-SS-NL	guuacaguGfGfAfucagaaucua	481	GUUACAGUGGAUCCGAUUUAGUA	705

Strand ID	Modified Sense Strand (5' → 3')	SEQ ID NO.	Underlying Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.
AM12385-SS-NL	guacagugGfAfUfcgaauiugu	482	GUACAGUGGAUCGAUUAUUGU	706
AM12387-SS-NL	caguggauCfGfAfuaguiucaa	483	CAGUGGAUCGAUUAGUIUCA	707
AM12389-SS-NL	aggagauGfUfCfagucianga	484	AGGAGAUCCUCACUUCIAUGA	708
AM12391-SS-NL	ggauuaacUfUfCfcgunguagua	485	GGAUUAACUUCUUGUAUGCUA	709
AM12393-SS-NL	gcagugauGfUfAfuccaaccuau	486	GCAGUGAUGUAUCCAACCUAU	710
AM12395-SS-NL	guguaaccAfAfCfcuauggaau	487	GUGUAUCCAACCUAUGGAAAU	711
AM12397-SS-NL	ucccaggaUfGfAfuaauaaagga	488	UCCCAGGAUGAUUAAAAGGA	712
AM12399-SS-NL	gaaaggcaUfUfCfagaacuua	489	GAAAGGCAUUCAGAAACUAUA	713
AM12401-SS-NL	guguuagcaCfAfAfucagaauga	490	GUGUUGCACAAUCAGAAUUGA	714
AM12403-SS-NL	gguuagcacAfAfUfcagaaugau	491	GGUUGCACAAUCAGAAUUGAU	715
AM12405-SS-NL	cacaaucaGfAfAfugauaagca	492	CACAUCAGAAUUGAUAAAGCA	716
AM12407-SS-NL	gcaaucagAfAfUfugauaagcaa	493	GCAAUUCAGAAUUGAUAAAGCAA	717
AM12409-SS-NL	gugucaccCfUfUfuuuuauugca	494	GUGUCACCCUUUUUUAUUGCA	718
AM12411-SS-NL	gugcaguuGfGfUfuuuuagauugu	495	GUGCAGUUGGUUUUUUGAAUGU	719
AM12413-SS-NL	gcaguuaggUfUfUfuugaauugcu	496	GCAGUUGGUUUUUUGAAUGUCU	720
AM12415-SS-NL	caguuaggUfUfUfugaauugcuu	497	CAGUUGGUUUUUUGAAUGUCUU	721
AM12417-SS-NL	cacuccuuUfUfAfaggaauaacu	498	CACUCCUUUUAAGGAUAAACU	722
AM12874-SS-NL	gsauggugaGfUfGfccagauuuua	499	GAUGUGGAGUGCCAGAUUUUA	700
AM12876-SS-NL	gsauggugaGfuGfcCfagauguaa	500	GAUGUGGAGUGCCAGAUUUUA	700
AM13075-SS-NL	cuguuagcaCfAfAfucagaauga	501	CUGUUGCACAAUCAGAAUUGA	723
AM13078-SS-NL	guguuagCfaCfaAfucagaauga	502	GUGUUGCACAAUCAGAAUUGA	714
AM13080-SS-NL	guguuagcaCfaAfAfCfagaauuga	503	GUGUUGCACAAUCAGAAUUGA	714
AM13084-SS-NL	guguuagcaCfaAfucagaauga	504	GUGUUGCACAAUCAGAAUUGA	714
AM13210-SS-NL	caguggauCfGfAfuagugucuaa	505	CAGUGGAUCGAUUAGUGUCA	724
AM13211-SS-NL	caguggAfUfCfGfAfuagugucuaa	506	CAGUGGAUCGAUUAGUGUCA	724

Strand ID	Modified Sense Strand (5' → 3')	SEQ ID NO.	Underlying Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.
AM13213-SS-NL	caguggauCfGfAfuUfagugucaa	507	CAGUGGAUCGAUUAGUGUCA	724
AM13214-SS-NL	caguggauCfGfAfuUfaguiucaa	508	CAGUGGAUCGAUUAGUIUCA	707
AM13216-SS-NL	ucccaggaUfGfAfuAfuuaagga	509	UCCCAGGAUGAUUAAAAGGA	712
AM13217-SS-NL	ucccaggaUfGfAfuAfuuaagga	510	UCCCAGGAUGAUUAAAAGGA	712
AM13218-SS-NL	ucccaggaUfGfAfuA 2Nuuaagga	511	UCCCAGGAUGAUUAAAAGGA	712
AM13242-SS-NL	gcagugggUfuUfuUfgaugucu	512	GCAGUUGGUUUUUGAAUGUCU	720
AM13243-SS-NL	gcagugggUfuUfuUfgaugucu	513	GCAGUUGGUUUUUGAAUGUCU	720
AM13248-SS-NL	gcagugauGfuAfUfccaacuu	514	GCAGUGAUGUAUCCAACCUAU	710
AM13249-SS-NL	gcagugAfuGfuAfuccaaccuu	515	GCAGUGAUGUAUCCAACCUAU	710
AM13250-SS-NL	gcagugauGfuAfUfccaacuu	516	GCAGUGAUGUAUCCAACCUAU	710
AM13399-SS-NL	gccagaugUfuGfcAfgaauacua	517	GCCAGAUUUGCAGAAUACUA	702
AM13401-SS-NL	gccagaUfgUfuGfcagaaucua	518	GCCAGAUUUGCAGAAUACUA	702
AM13404-SS-NL	cacuccUfuUfuAfaggaauaacu	519	CACUCCUUUUAAGGAUAAACU	722
AM13406-SS-NL	cacuccuuUfuAfAfaggauaacu	520	CACUCCUUUUAAGGAUAAACU	722
AM13408-SS-NL	gcacuccuuUfuAfAfaggauaacu	521	GACUCCUUUUAAGGAUAAACU	725
AM13762-SS-NL	gscagugggUfuUfuUfgaugucu	522	GCAGUUGGUUUUUGAAUGUCU	720
AM13763-SS-NL	gscagugggUfuUfuUfuaugaugucu	523	GCAGUUGGUUUUUGAAUGUCU	720
AM13764-SS-NL	csaguggauCfGfAfuUfagugucaa	524	CAGUGGAUCGAUUAGUGUCA	724
AM13765-SS-NL	csaguggauCfGfAfuUfaguiucaa	525	CAGUGGAUCGAUUAGUIUCA	707
AM14107-SS-NL	gscagugggUfuUfuUfgaugucua	526	GCAGUUGGUUUUUGAAUGUCA	726
AM14111-SS-NL	gcagugggUfuUfuUfuaugauguca	527	GCAGUUGGUUUUUGAAUGUCA	726
AM14120-SS-NL	gauguggaGfuGfcCfagauguaa	528	GAUGUGGAGUGCCAGAUUUUA	700
AM14123-SS-NL	gcagugauGfuAfuccaaccuaa	529	GCAGUGAUGUAUCCAACCUAA	727
AM14128-SS-NL	cacuccuuUfuAfAfaggauaaca	530	CACUCCUUUUAAGGAUAAACA	728
AM14115-SS-NL	gcagugggUfuUfuUfgaugucua	531	GCAGUUGGUUUUUGAAUGUCA	726

Strand ID	Modified Sense Strand (5' → 3')	SEQ ID NO.	Underlying Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.
AM14553-SS-NL	gscagugauGfuAfuCfcaaccuau	532	GCAGUGAUGUAUCCAACCUAU	710
AM14890-SS-NL	gscsaguuggUfuUfuUfgaauquesu	533	GCAGUUGGUUUUUUGAAUGUCU	720
AM14892-SS-NL	gsCfsasguuggUfuUfuGfaAfuguesu	534	GCAGUUGGUUUUUUGAAUGUCU	720
AM15418-SS-NL	gscguuggUfuUfuUfgaanguca	535	GCGUUGGUUUUUUGAAUGUCA	729
AM15419-SS-NL	gscaguugggUfuUfuUfgaanguca	536	GCAGUUGGUUUUUUGAAUGUCA	730
AM15420-SS-NL	gscaguugggUfuUfuUfgaanguca	526	GCAGUUGGUUUUUUGAAUGUCA	726
AM16013-SS-NL	gscaguugggUfuUfuUfgaanguca	526	GCAGUUGGUUUUUUGAAUGUCA	726

a. 2N=2-aminoadenosine nucleotide; I = hypoxanthine (inosine) nucleotide

Table 5. MMP7 Agent Sense Strand Sequences (Shown With Linkers and and Capping Groups (see Table 11 for structure information.))

Strand ID	Modified Sense Strand (5' → 3')	SEQ ID NO.	Underlying Base Sequence (5' → 3') (Shown as an Unmodified Nucleotide Sequence)	SEQ ID NO.
AM08522-SS	(NH2-C6)asgaugggAfGfUfgccagauguus(invAb)	539	AGAUGGAGUGCCAGAUUU	682
AM08524-SS	(NH2-C6)esgaugggAfGfUfgccagauguus(invAb)	540	CGAUGGAGUGCCAGAUUU	683
AM08526-SS	(NH2-C6)asugugggAfGfCfcagauguus(invAb)	541	AUGUGGAGUGCCAGAUUU	684
AM08528-SS	(NH2-C6)esugugggAfGfCfcagauguus(invAb)	542	CUGUGGAGUGCCAGAUUU	685
AM08530-SS	(NH2-C6)usugugggAfGfCfcagauguus(invAb)	543	UGUGGAGUGCCAGAUUU	686
AM08532-SS	(NH2-C6)esugugggAfGfCfcagauguus(invAb)	544	CGUGGAGUGCCAGAUUU	687
AM08534-SS	(NH2-C6)usugugggAfGfCfcagauguus(invAb)	545	UGUGGAGUGCCAGAUUU	688
AM08536-SS	(NH2-C6)esugugggAfGfCfcagauguus(invAb)	546	CGUGGAGUGCCAGAUUU	689
AM08538-SS	(NH2-C6)usugugggAfGfCfcagauguus(invAb)	547	UGUGGAGUGCCAGAUUU	690
AM08540-SS	(NH2-C6)esugugggAfGfCfcagauguus(invAb)	548	CGUGGAGUGCCAGAUUU	691
AM08542-SS	(NH2-C6)usugugggAfGfCfcagauguus(invAb)	549	UGUGGAGUGCCAGAUUU	692
AM08544-SS	(NH2-C6)esugugggAfGfCfcagauguus(invAb)	550	CGUGGAGUGCCAGAUUU	693
AM08546-SS	(NH2-C6)usugugggAfGfCfcagauguus(invAb)	551	UGUGGAGUGCCAGAUUU	694
AM08548-SS	(NH2-C6)esugugggAfGfCfcagauguus(invAb)	552	CGUGGAGUGCCAGAUUU	695
AM12366-SS	(NAG37)s(invAb)scaggcucaGfGfAfcuaucuaas(invAb)	553	CAGGCUCAGGACUUAUCUCAA	696
AM12368-SS	(NAG37)s(invAb)sgucuaagAfGfAfcuaucuaas(invAb)	554	GUCUCAAGAGAUUUUAUCUCU	697
AM12370-SS	(NAG37)s(invAb)sc2NagagauUfUfAfcuaucuaas(invAb)	555	CAAGAGAUUUUAUCUCUAUGA	698
AM12372-SS	(NAG37)s(invAb)sgagauuuAfUfCfucuaugacuas(invAb)	556	GAGAUUUUAUCUCUAUGACUA	699
AM12374-SS	(NAG37)s(invAb)sgauguggaGfUfGfcagauguus(invAb)	557	GAUGUGGAGUGCCAGAUUU	700
AM12376-SS	(NAG37)s(invAb)sggagugccAfGfAfcuaucuaas(invAb)	558	GGAGUGCCAGAUUUUAUCAGAA	701
AM12377-SS	(NAG37)s(invAb)sgccagaugUfUfGfcagaucuaas(invAb)	559	GCCAGAUUUUAUCUCUAUCUA	702
AM12379-SS	(NAG37)s(invAb)sgguugcagAfUfAfcuaucuaas(invAb)	560	GGUUGCAGAAUUAUCUCUAUU	703
AM12381-SS	(NAG37)s(invAb)sguugcagaAfUfAfcuaucuaas(invAb)	561	GUUGCAGAAUUAUCUCUAUU	704
AM12383-SS	(NAG37)s(invAb)sguacaguGfGfAfcuaucuaas(invAb)	562	GUUACAGUGGAGUCCAGAUUU	705
AM12385-SS	(NAG37)s(invAb)sguacaguGfAfcuaucuaas(invAb)	563	GUACAGUGGAGUCCAGAUUU	706

AM12387-SS	(NAG37)s(inv Ab)scaguggauCfGfAfuaguiucaas(inv Ab)	564	CAGUGGAUCGAUUAGUIUCA	707
AM12389-SS	(NAG37)s(inv Ab)scagaggauCfUfCfauuciugaas(inv Ab)	565	AGGAGAUUGCUCACUUCIAUGA	708
AM12391-SS	(NAG37)s(inv Ab)sggauiaacUfUfCfeguauucaas(inv Ab)	566	GGAUUAACUUCUUGUAUGCUA	709
AM12393-SS	(NAG37)s(inv Ab)sgcagugauGfUfAfuccaaccuauas(inv Ab)	567	GCAGUGAUGUAUCCAAACCUAU	710
AM12395-SS	(NAG37)s(inv Ab)sguguauccAfAfCfauuaggaauas(inv Ab)	568	GUGUAUCCAAACCUAUGGAAA	711
AM12397-SS	(NAG37)s(inv Ab)succcaggaUfGfAfuauuaaggaas(inv Ab)	569	UCCAGGAUGAUUUAAAGGA	712
AM12399-SS	(NAG37)s(inv Ab)sgaaaggcaUfUfCfagaacuaauas(inv Ab)	570	GAAAGGCAUUCAGAAACUAUA	713
AM12401-SS	(NAG37)s(inv Ab)sguguugcaCfAfAfucagaauugaas(inv Ab)	571	GUGUUGCACAAUUCAGAAUUGA	714
AM12403-SS	(NAG37)s(inv Ab)sgguugcacAfAfUfcagaauugaas(inv Ab)	572	GGUUGCACAAUUCAGAAUUGAU	715
AM12405-SS	(NAG37)s(inv Ab)scacaaucaGfAfAfuaugaauagcaas(inv Ab)	573	CACAAUCAGAAUUGAUAAAGCA	716
AM12407-SS	(NAG37)s(inv Ab)sgcaauacagAfAfUfugaauagcaas(inv Ab)	574	GCAUUCAGAAUUGAUAAAGCAA	717
AM12409-SS	(NAG37)s(inv Ab)sgugucaccCfUfUfuuuuaugcaas(inv Ab)	575	GUGUCACCCUUUUUUUAUUGCA	718
AM12411-SS	(NAG37)s(inv Ab)sgugcaguuGfGfUfuuuugaugus(inv Ab)	576	GUGCAGUUGGUUUUUUGAAUGU	719
AM12413-SS	(NAG37)s(inv Ab)sgcaguuggUfUfUfuuugaugucus(inv Ab)	577	GCAGUUGGUUUUUUGAAUGUCU	720
AM12415-SS	(NAG37)s(inv Ab)scaguugguUfUfUfugaugucuuas(inv Ab)	578	CAGUUGGUUUUUUGAAUGUCUU	721
AM12417-SS	(NAG37)s(inv Ab)scacuccuuUfUfAfaggaauaauas(inv Ab)	579	CACUCCUUUUAAAGGAUAAACU	722
AM12874-SS	(TriAlk14)gsauguggaGfUfGfccagauguuas(inv Ab)	580	GAUGUGGAGUGCCAGAUUUUA	700
AM12876-SS	(TriAlk14)gsauguggaGfUfGfcCfagauguuas(inv Ab)	581	GAUGUGGAGUGCCAGAUUUUA	700
AM13075-SS	(NAG37)s(inv Ab)scuguugcaCfAfAfucagaauugaas(inv Ab)	582	CUGUUGCACAAUUCAGAAUUGA	723
AM13078-SS	(NAG37)s(inv Ab)sguguugCfAfAfucagaauugaas(inv Ab)	583	GUGUUGCACAAUUCAGAAUUGA	714
AM13080-SS	(NAG37)s(inv Ab)sguguugcaCfAfAfucagaauugaas(inv Ab)	584	GUGUUGCACAAUUCAGAAUUGA	714
AM13084-SS	(NAG37)s(inv Ab)sguguugcaCfAfAfucagaauugaas(inv Ab)	585	GUGUUGCACAAUUCAGAAUUGA	714
AM13210-SS	(NAG37)s(inv Ab)scaguggauCfGfAfuagguucaas(inv Ab)	586	CAGUGGAUCGAUUAGUGUCA	724
AM13211-SS	(NAG37)s(inv Ab)scaguggAfUfCfAfuagguucaas(inv Ab)	587	CAGUGGAUCGAUUAGUGUCA	724
AM13213-SS	(NAG37)s(inv Ab)scaguggauCfGfAfuagguucaas(inv Ab)	588	CAGUGGAUCGAUUAGUGUCA	724
AM13214-SS	(NAG37)s(inv Ab)scaguggauCfGfAfuagguucaas(inv Ab)	589	CAGUGGAUCGAUUAGUIUCA	707
AM13216-SS	(NAG37)s(inv Ab)succcaggaUfGfAfuuaaggaas(inv Ab)	590	UCCAGGAUGAUUUAAAGGA	712
AM13217-SS	(NAG37)s(inv Ab)succcaggaUfGfAfuuaaggaas(inv Ab)	591	UCCAGGAUGAUUUAAAGGA	712

AM13218-SS	(NAG37)s(inv Ab)succaggaUfGfAfua 2Nuuaaggas(inv Ab)	592	UCCAGGAUGAUUUAAAGGA	712
AM13242-SS	(NAG37)s(inv Ab)sgcaguuggUfuUfuUfgaagucus(inv Ab)	593	GCAGUUGGUUUUUUGAAUGUCU	720
AM13243-SS	(NAG37)s(inv Ab)sgcaguuggUfuUfuUfgaagucus(inv Ab)	594	GCAGUUGGUUUUUUGAAUGUCU	720
AM13248-SS	(NAG37)s(inv Ab)sgcagugauGfuAfufccaacuaus(inv Ab)	595	GCAGUGAUGUAUCCAAACCUAU	710
AM13249-SS	(NAG37)s(inv Ab)sgcagugAfufGfuAfuccaaccuaus(inv Ab)	596	GCAGUGAUGUAUCCAAACCUAU	710
AM13250-SS	(NAG37)s(inv Ab)sgcagugauGfuAfufcaacuaus(inv Ab)	597	GCAGUGAUGUAUCCAAACCUAU	710
AM13399-SS	(NAG37)s(inv Ab)sgccagaUfuGfcAfgaauacuas(inv Ab)	598	GCCAGAUUGUUGCAGAAUACUA	702
AM13401-SS	(NAG37)s(inv Ab)sgccagaUfgUfuGfcagaauacuas(inv Ab)	599	GCCAGAUUGUUGCAGAAUACUA	702
AM13404-SS	(NAG37)s(inv Ab)scacuccUfuUfuAfaggauaaacuas(inv Ab)	600	CACUCCUUUUAAAGGAUAAACU	722
AM13406-SS	(NAG37)s(inv Ab)scacuccuUfuAfAfaggauaaacuas(inv Ab)	601	CACUCCUUUUAAAGGAUAAACU	722
AM13408-SS	(NAG37)s(inv Ab)sgacuccuUfuUfuAfaggauaaacuas(inv Ab)	602	GACUCCUUUUAAAGGAUAAACU	725
AM13762-SS	(TriAlk14)gscaguuggUfuUfuUfgaagucus(inv Ab)	603	GCAGUUGGUUUUUUGAAUGUCU	720
AM13763-SS	(TriAlk14)gscaguuggUfuUfuUfgaagucus(inv Ab)	604	GCAGUUGGUUUUUUGAAUGUCU	720
AM13764-SS	(TriAlk14)csaguuggauCfGfAfufagugucuas(inv Ab)	605	CAGUGGAUCGAUUAGUGUCA	724
AM13765-SS	(TriAlk14)csaguuggauCfGfAfufaguinucuas(inv Ab)	606	CAGUGGAUCGAUUAGUUCUA	707
AM14107-SS	(TriAlk14)gscaguuggUfuUfuUfgaagucus(inv Ab)	607	GCAGUUGGUUUUUUGAAUGUCA	726
AM14111-SS	(NAG37)s(inv Ab)sgcaguuggUfuUfuUfgaagucuas(inv Ab)	608	GCAGUUGGUUUUUUGAAUGUCA	726
AM14120-SS	(NAG37)s(inv Ab)sgauguggaGfuGfcCfagauguuas(inv Ab)	609	GAUGUGGAGUGCCAGAGUUA	700
AM14123-SS	(NAG37)s(inv Ab)sgcagugauGfUfAfuccaaccuaas(inv Ab)	610	GCAGUGAUGUAUCCAAACCUAA	727
AM14128-SS	(NAG37)s(inv Ab)scacuccuUfuUfuAfaggauaaacuas(inv Ab)	611	CACUCCUUUUAAAGGAUAAACA	728
AM14115-SS	(NAG37)s(inv Ab)sgcaguuggUfuUfuUfgaagucuas(inv Ab)	612	GCAGUUGGUUUUUUGAAUGUCA	726
AM14553-SS	(TriAlk14)gscagugauGfuAfufcaacuaus(inv Ab)	613	GCAGUGAUGUAUCCAAACCUAU	710
AM14890-SS	(inv Ab)sgscsaguuggUfuUfuUfgaagucsu	614	GCAGUUGGUUUUUUGAAUGUCU	720
AM15418-SS	(TriAlk14)gscguuggUfuUfuUfgaagucuas(inv Ab)	615	GCGUUGGUUUUUUGAAUGUCA	729
AM15419-SS	(TriAlk14)gscaguuggUfuUfuUfgaagucuas(inv Ab)	616	GCAGUUGGUUUUUUGAAUGUCA	730
AM15420-SS	(TriAlk14)gscaguuggUfuUfuUfgaagucua(inv Ab)	617	GCAGUUGGUUUUUUGAAUGUCA	726

a. 2N=2-aminoadenosine nucleotide; I = hypoxanthine (inosine) nucleotide

Table 6. MMP7 Agent Sense Strand Sequences (Shown with Targeting Ligand Conjugate. The structure of $\alpha\gamma\beta 6$ -SM6.1 is shown in Table 11, and the structure of Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14) is shown in FIG. 1.)

Strand ID	Modified Sense Strand (5' → 3')	SEQ ID NO.	Corresponding Sense Strand AM Number Without Linker or Conjugate (See Table 4)
CS001585	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gsauguggaGfUfGfcagauguuas(invAb)	618	AM12874-SS
CS001588	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gsauguggaGfuGfcCfagauguuas(invAb)	619	AM12876-SS
CS001941	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscaguuggUfuUfuUfgaagucuc(invAb)	620	AM13762-SS
CS001944	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscaguuggUfUfUfuugaagucuc(invAb)	621	AM13763-SS
CS001945	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-csaguggauCfGAfuUfagugucaas(invAb)	622	AM13764-SS
CS001947	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-csaguggauCfGAfuUfaguiucaas(invAb)	623	AM13765-SS
CS002396	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscagugauGfuAfuCfcaaccuaus(invAb)	624	AM14553-SS
CS002805	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscguuggUfuUfuUfgaagucuc(invAb)	625	AM15418-SS
CS002806	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscaguugggUfuUfuUfgaagucuc(invAb)	626	AM15419-SS
CS002807	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscaguuggUfuUfuUfgaagucuc(invAb)	627	AM15420-SS
CS002133	Tri-SM6.1- $\alpha\gamma\beta 6$ -(TA14)-gscaguuggUfuUfuUfgaagucuc(invAb)	628	AM14107-SS

[0105] The MMP7 RNAi agents disclosed herein are formed by annealing an antisense strand with a sense strand. A sense strand containing a sequence listed in Table 2, Table 4, Table 5, or Table 6 can be hybridized to any antisense strand containing a sequence listed in Table 2 or Table 3, provided the two sequences have a region of at least 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.

[0106] As shown in Table 5 above, certain of the example MMP7 RNAi agent nucleotide sequences are shown to further include reactive linking groups at one or both of the 5' terminal end and the 3' terminal end of the sense strand. For example, many of the MMP7 RNAi agent sense strand sequences shown in Table 5 above have a (TriAlk14) linking group at the 5' end of the nucleotide sequence. Other linking groups, such as an (NH₂-C6) linking group or a (6-SS-6) or (C6-SS-C6) linking group, may be present as well or alternatively in certain embodiments. Such reactive linking groups are positioned to facilitate the linking of targeting ligands, targeting groups, and/or PK/PD modulators to the MMP7 RNAi agents disclosed herein. Linking or conjugation reactions are well known in the art and provide for formation of covalent linkages between two molecules or reactants. Suitable conjugation reactions for use in the scope of the inventions herein include, but are not limited to, amide coupling reaction, Michael addition reaction, hydrazone formation reaction, inverse-demand Diels-Alder cycloaddition reaction, oxime ligation, and Copper (I)- catalyzed or strain-promoted azide-alkyne cycloaddition reaction.

[0107] In some embodiments, targeting ligands, such as the integrin targeting ligands shown in the examples and figures disclosed herein, can be synthesized as activated esters, such as tetrafluorophenyl (TFP) esters, which can be displaced by a reactive amino group (e.g., NH₂-C₆) to attach the targeting ligand to the MMP7 RNAi agents disclosed herein. In some embodiments, targeting ligands are synthesized as azides, which can be conjugated to a propargyl (e.g., TriAlk14) or DBCO group, for example, via Copper (I)- catalyzed or strain-promoted azide-alkyne cycloaddition reaction.

[0108] Additionally, certain of the nucleotide sequences can be synthesized with a dT nucleotide at the 3' terminal end of the sense strand, followed by (3' → 5') a linker (e.g., C6-SS-C6). The linker can, in some embodiments, facilitate the linkage to additional components, such as, for example, a PK/PD modulator or one or more targeting ligands. As described herein, the disulfide bond of C6-SS-C6 is first reduced, removing the dT from the molecule, which can then facilitate the conjugation of the desired PK/PD modulator. The terminal dT nucleotide therefore is not a part of the fully conjugated construct.

[0109] In some embodiments, the antisense strand of a MMP7 RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 3 or Table 10. In some embodiments, the sense strand of a MMP7 RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 4, Table 5, Table 6, or Table 10.

[0110] In some embodiments, a MMP7 RNAi agent antisense strand comprises a nucleotide sequence of any of the sequences in Table 2 or Table 3. In some embodiments, a MMP7 RNAi agent antisense strand comprises the sequence of nucleotides (from 5' end → 3' end) 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, or 2-24 of any of the sequences in Table 2, Table 3, or Table 10. In certain embodiments, a MMP7 RNAi agent antisense strand comprises or consists of a modified sequence of any one of the modified sequences in Table 3 or Table 10.

[0111] In some embodiments, a MMP7 RNAi agent sense strand comprises the nucleotide sequence of any of the sequences in Table 2 or Table 4. In some embodiments, a MMP7 RNAi agent sense strand comprises the sequence of nucleotides (from 5' end → 3' end) 1-17, 2-17, 3-17, 4-17, 1-18, 2-18, 3-18, 4-18, 1-19, 2-19, 3-19, 4-19, 1-20, 2-20, 3-20, 4-20, 1-21, 2-21, 3-21, 4-21, 1-22, 2-22, 3-22, 4-22, 1-23, 2-23, 3-23, 4-23, 1-24, 2-24, 3-24, or 4-24, of any of the sequences in Table 2, Table 4, Table 5, Table 6, or Table 10. In certain embodiments, a MMP7 RNAi agent sense strand comprises or consists of a modified sequence of any one of the modified sequences in Table 3 or Table 10.

[0112] For the RNAi agents disclosed herein, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) can be perfectly complementary to a MMP7 gene, or can be non-complementary to a MMP7 gene. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) is a U, A, or dT (or a modified version of U, A or dT). In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) forms an A:U or U:A base pair with the sense strand.

[0113] In some embodiments, a MMP7 RNAi agent antisense strand comprises the sequence of nucleotides (from 5' end → 3' end) 2-18 or 2-19 of any of the antisense strand sequences in Table 2, Table 3, or Table 10. In some embodiments, a MMP7 RNAi sense strand comprises the sequence of nucleotides (from 5' end → 3' end) 1-17 or 1-18 of any of the sense strand sequences in Table 2, Table 4, Table 5, Table 6, or Table 10.

[0114] In some embodiments, a MMP7 RNAi agent includes (i) an antisense strand comprising the sequence of nucleotides (from 5' end → 3' end) 2-18 or 2-19 of any of the

antisense strand sequences in Table 2, Table 3, or Table 10, and (ii) a sense strand comprising the sequence of nucleotides (from 5' end → 3' end) 1-17 or 1-18 of any of the sense strand sequences in Table 2, Table 4, Table 5, Table 6, or Table 10.

[0115] A sense strand containing a sequence listed in Table 2 or Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 2 or Table 3 provided the two sequences have a region of at least 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence. In some embodiments, the MMP7 RNAi agent has a sense strand consisting of the modified sequence of any of the modified sequences in Table 4, Table 5, Table 6, or Table 10, and an antisense strand consisting of the modified sequence of any of the modified sequences in Table 3 or Table 10. Certain representative sequence pairings are exemplified by the Duplex ID Nos. shown in Tables 7A, 7B, 8, and 9.

[0116] In some embodiments, a MMP7 RNAi agent comprises, consists of, or consists essentially of a duplex represented by any one of the Duplex ID Nos. presented herein. In some embodiments, a MMP7 RNAi agent consists of any of the Duplex ID Nos. presented herein. In some embodiments, a MMP7 RNAi agent comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, a MMP7 RNAi agent comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group, linking group, and/or other non-nucleotide group wherein the targeting group, linking group, and/or other non-nucleotide group is covalently linked (i.e., conjugated) to the sense strand or the antisense strand. In some embodiments, a MMP7 RNAi agent includes the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, a MMP7 RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group, linking group, and/or other non-nucleotide group, wherein the targeting group, linking group, and/or other non-nucleotide group is covalently linked to the sense strand or the antisense strand.

[0117] In some embodiments, a MMP7 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Tables 2, 7A, 7B, 8, 9, or 10, and comprises a targeting group. In some embodiments, a MMP7 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Tables 2, 7A, 7B, 8, 9, or 10, and comprises one or more $\alpha\text{v}\beta 6$ integrin targeting ligands.

[0118] In some embodiments, a MMP7 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Tables 2, 7A, 7B, 8, 9, or 10, and comprises a targeting group that is an integrin targeting ligand. In some embodiments, a MMP7 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Tables 2, 7A, 7B, 8, 9, or 10, and comprises one or more $\alpha\text{v}\beta 6$ integrin targeting ligands or clusters of $\alpha\text{v}\beta 6$ integrin targeting ligands (e.g., a tridentate $\alpha\text{v}\beta 6$ integrin targeting ligand).

[0119] In some embodiments, a MMP7 RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand/sense strand duplexes of Tables 7A, 7B, 8, 9, and 10.

[0120] In some embodiments, a MMP7 RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand/sense strand duplexes of Tables 7A, 7B, 8, 9, and 10, and comprises an integrin targeting ligand.

[0121] In some embodiments, a MMP7 RNAi agent comprises, consists of, or consists essentially of any of the duplexes of Tables 7A, 7B, 8, 9, and 10.

[0122] Table 7A. MMP7 RNAi Agent Duplexes with Corresponding Sense and Antisense Strand ID Numbers and Sequence ID numbers for the modified and unmodified nucleotide sequences. (Shown without Linking Agents or Conjugates)

AS ID	AS modified SEQ ID NO:	AS unmodified SEQ ID NO:	SS ID	SS modified SEQ ID NO:	SS unmodified SEQ ID NO:
AM08523-AS	337	629	AM08522-SS-NL	458	682
AM08525-AS	338	630	AM08524-SS-NL	459	683
AM08527-AS	339	631	AM08526-SS-NL	460	684
AM08529-AS	340	632	AM08528-SS-NL	461	685
AM08531-AS	341	633	AM08530-SS-NL	462	686
AM08533-AS	342	634	AM08532-SS-NL	463	687
AM08535-AS	343	635	AM08534-SS-NL	464	688
AM08537-AS	344	636	AM08536-SS-NL	465	689
AM08539-AS	345	637	AM08538-SS-NL	466	690
AM08541-AS	346	638	AM08540-SS-NL	467	691
AM08543-AS	347	639	AM08542-SS-NL	468	692
AM08545-AS	348	640	AM08544-SS-NL	469	693
AM08547-AS	349	641	AM08546-SS-NL	470	694
AM08549-AS	350	642	AM08548-SS-NL	471	695
AM12367-AS	359	651	AM12366-SS-NL	472	696
AM12369-AS	360	652	AM12368-SS-NL	473	697
AM12371-AS	361	653	AM12370-SS-NL	474	698
AM12373-AS	362	654	AM12372-SS-NL	475	699
AM12375-AS	363	655	AM12374-SS-NL	476	700
AM08539-AS	345	637	AM12376-SS-NL	477	701
AM12378-AS	364	656	AM12377-SS-NL	478	702
AM12380-AS	365	657	AM12379-SS-NL	479	703
AM12382-AS	366	658	AM12381-SS-NL	480	704
AM12384-AS	367	659	AM12383-SS-NL	481	705
AM12386-AS	368	660	AM12385-SS-NL	482	706
AM12388-AS	369	661	AM12387-SS-NL	483	707
AM12390-AS	370	662	AM12389-SS-NL	484	708
AM12392-AS	371	663	AM12391-SS-NL	485	709
AM12394-AS	372	664	AM12393-SS-NL	486	710
AM12396-AS	373	665	AM12395-SS-NL	487	711
AM12398-AS	374	666	AM12397-SS-NL	488	712
AM12400-AS	375	667	AM12399-SS-NL	489	713
AM12402-AS	376	668	AM12401-SS-NL	490	714
AM12404-AS	377	669	AM12403-SS-NL	491	715
AM12406-AS	378	670	AM12405-SS-NL	492	716
AM12408-AS	379	671	AM12407-SS-NL	493	717
AM12410-AS	380	672	AM12409-SS-NL	494	718
AM12412-AS	381	673	AM12411-SS-NL	495	719
AM12414-AS	382	674	AM12413-SS-NL	496	720
AM12416-AS	383	675	AM12415-SS-NL	497	721
AM12418-AS	384	676	AM12417-SS-NL	498	722
AM12375-AS	363	655	AM12874-SS-NL	499	700
AM12875-AS	385	655	AM12874-SS-NL	499	700
AM12877-AS	386	655	AM12876-SS-NL	500	700
AM13076-AS	387	677	AM13075-SS-NL	501	723
AM13077-AS	388	668	AM12401-SS-NL	490	714
AM13079-AS	389	668	AM13078-SS-NL	502	714
AM13079-AS	389	668	AM13080-SS-NL	503	714

AM13081-AS	390	668	AM13080-SS-NL	503	714
AM13082-AS	391	668	AM13080-SS-NL	503	714
AM13083-AS	392	668	AM13080-SS-NL	503	714
AM13083-AS	392	668	AM13084-SS-NL	504	714
AM13083-AS	392	668	AM13078-SS-NL	502	714
AM12388-AS	369	661	AM13210-SS-NL	505	724
AM13212-AS	393	661	AM13211-SS-NL	506	724
AM13212-AS	393	661	AM13213-SS-NL	507	724
AM13212-AS	393	661	AM13214-SS-NL	508	707
AM13215-AS	394	666	AM12397-SS-NL	488	712
AM13215-AS	394	666	AM13216-SS-NL	509	712
AM13215-AS	394	666	AM13217-SS-NL	510	712
AM13215-AS	394	666	AM13218-SS-NL	511	712
AM13241-AS	395	674	AM12413-SS-NL	496	720
AM13241-AS	395	674	AM13242-SS-NL	512	720
AM13244-AS	396	674	AM13243-SS-NL	513	720
AM13244-AS	396	674	AM13242-SS-NL	512	720
AM13245-AS	397	674	AM13243-SS-NL	513	720
AM13246-AS	398	664	AM12393-SS-NL	486	710
AM13247-AS	399	664	AM12393-SS-NL	486	710
AM13246-AS	398	664	AM13248-SS-NL	514	710
AM13246-AS	398	664	AM13249-SS-NL	515	710
AM13246-AS	398	664	AM13250-SS-NL	516	710
AM13400-AS	400	656	AM13399-SS-NL	517	702
AM13400-AS	400	656	AM13401-SS-NL	518	702
AM13402-AS	401	656	AM13399-SS-NL	517	702
AM13403-AS	402	656	AM13399-SS-NL	517	702
AM13405-AS	403	676	AM13404-SS-NL	519	722
AM13405-AS	403	676	AM13406-SS-NL	520	722
AM13407-AS	404	676	AM12417-SS-NL	498	722
AM13409-AS	405	678	AM13408-SS-NL	521	725
AM13241-AS	395	674	AM13762-SS-NL	522	720
AM13244-AS	396	674	AM13762-SS-NL	522	720
AM13241-AS	395	674	AM13763-SS-NL	523	720
AM13212-AS	393	661	AM13764-SS-NL	524	724
AM13212-AS	393	661	AM13765-SS-NL	525	707
AM14108-AS	406	679	AM14107-SS-NL	526	726
AM14109-AS	407	661	AM13764-SS-NL	524	724
AM14110-AS	408	674	AM12413-SS-NL	496	720
AM14112-AS	409	679	AM14111-SS-NL	527	726
AM14113-AS	410	679	AM14111-SS-NL	527	726
AM14117-AS	411	661	AM13210-SS-NL	505	724
AM14118-AS	412	661	AM13210-SS-NL	505	724
AM14119-AS	413	661	AM13213-SS-NL	507	724
AM14109-AS	407	661	AM13213-SS-NL	507	724
AM12875-AS	385	655	AM12374-SS-NL	476	700
AM14121-AS	414	655	AM14120-SS-NL	528	700
AM14122-AS	415	655	AM14120-SS-NL	528	700
AM12877-AS	386	655	AM14120-SS-NL	528	700
AM14124-AS	416	680	AM14123-SS-NL	529	727
AM14125-AS	417	680	AM14123-SS-NL	529	727

AM14126-AS	418	680	AM14123-SS-NL	529	727
AM14127-AS	419	680	AM14123-SS-NL	529	727
AM14129-AS	420	681	AM14128-SS-NL	530	728
AM14130-AS	421	681	AM14128-SS-NL	530	728
AM14131-AS	422	681	AM14128-SS-NL	530	728
AM14114-AS	423	674	AM13242-SS-NL	512	720
AM14116-AS	424	679	AM14115-SS-NL	531	726
AM14108-AS	406	679	AM14115-SS-NL	531	726
AM13246-AS	398	664	AM14553-SS-NL	532	710
AM14651-AS	425	680	AM14123-SS-NL	526	727
AM14652-AS	426	664	AM12393-SS-NL	486	710
AM14653-AS	427	664	AM13250-SS-NL	516	710
AM14654-AS	428	664	AM13250-SS-NL	516	710
AM14655-AS	429	664	AM13250-SS-NL	516	710
AM14656-AS	430	664	AM13250-SS-NL	516	710
AM14657-AS	431	664	AM13250-SS-NL	516	710
AM14658-AS	432	664	AM13250-SS-NL	516	710
AM14659-AS	433	664	AM13250-SS-NL	516	710
AM14888-AS	434	664	AM13250-SS-NL	516	710
AM14889-AS	435	664	AM13250-SS-NL	516	710
AM14888-AS	434	664	AM14553-SS-NL	532	710
AM14889-AS	435	664	AM14553-SS-NL	532	710
AM14116-AS	424	679	AM14107-SS-NL	526	726
AM15155-AS	436	674	AM13762-SS-NL	522	720
AM14114-AS	423	674	AM13762-SS-NL	522	720
AM14108-AS	406	679	AM15418-SS-NL	535	729
AM14108-AS	406	679	AM15419-SS-NL	536	730
AM14108-AS	406	679	AM15420-SS-NL	537	726
AM14655-AS	429	664	AM14553-SS-NL	532	710
AM14657-AS	431	664	AM14553-SS-NL	532	710
AM14108-AS	406	679	AM16013-SS-NL	538	726
AM14116-AS	424	679	AM16013-SS-NL	538	726

[0123] Table 7B. MMP7 RNAi Agent Duplexes with Corresponding Sense and Antisense Strand ID Numbers and Sequence ID numbers for the modified and unmodified nucleotide sequences.

[0124] Duplex	AS ID	AS modified SEQ ID NO:	AS unmodified SEQ ID NO:	SS ID	SS modified SEQ ID NO:	SS unmodified SEQ ID NO:
AD06348	AM08523-AS	337	629	AM08522-SS	539	682
AD06349	AM08525-AS	338	630	AM08524-SS	540	683
AD06350	AM08527-AS	339	631	AM08526-SS	541	684
AD06351	AM08529-AS	340	632	AM08528-SS	542	685
AD06352	AM08531-AS	341	633	AM08530-SS	543	686
AD06353	AM08533-AS	342	634	AM08532-SS	544	687
AD06354	AM08535-AS	343	635	AM08534-SS	545	688
AD06355	AM08537-AS	344	636	AM08536-SS	546	689
AD06356	AM08539-AS	345	637	AM08538-SS	547	690
AD06357	AM08541-AS	346	638	AM08540-SS	548	691
AD06358	AM08543-AS	347	639	AM08542-SS	549	692
AD06359	AM08545-AS	348	640	AM08544-SS	550	693
AD06360	AM08547-AS	349	641	AM08546-SS	551	694
AD06361	AM08549-AS	350	642	AM08548-SS	552	695
AD08797	AM12367-AS	359	651	AM12366-SS	553	696
AD08798	AM12369-AS	360	652	AM12368-SS	554	697
AD08799	AM12371-AS	361	653	AM12370-SS	555	698
AD08800	AM12373-AS	362	654	AM12372-SS	556	699
AD08801	AM12375-AS	363	655	AM12374-SS	557	700
AD08802	AM08539-AS	345	637	AM12376-SS	558	701
AD08803	AM12378-AS	364	656	AM12377-SS	559	702
AD08804	AM12380-AS	365	657	AM12379-SS	560	703
AD08805	AM12382-AS	366	658	AM12381-SS	561	704
AD08806	AM12384-AS	367	659	AM12383-SS	562	705
AD08807	AM12386-AS	368	660	AM12385-SS	563	706
AD08808	AM12388-AS	369	661	AM12387-SS	564	707
AD08809	AM12390-AS	370	662	AM12389-SS	565	708
AD08810	AM12392-AS	371	663	AM12391-SS	566	709
AD08811	AM12394-AS	372	664	AM12393-SS	567	710
AD08812	AM12396-AS	373	665	AM12395-SS	568	711
AD08813	AM12398-AS	374	666	AM12397-SS	569	712
AD08814	AM12400-AS	375	667	AM12399-SS	570	713
AD08815	AM12402-AS	376	668	AM12401-SS	571	714
AD08816	AM12404-AS	377	669	AM12403-SS	572	715
AD08817	AM12406-AS	378	670	AM12405-SS	573	716
AD08818	AM12408-AS	379	671	AM12407-SS	574	717
AD08819	AM12410-AS	380	672	AM12409-SS	575	718
AD08820	AM12412-AS	381	673	AM12411-SS	576	719
AD08821	AM12414-AS	382	674	AM12413-SS	577	720
AD08822	AM12416-AS	383	675	AM12415-SS	578	721
AD08823	AM12418-AS	384	676	AM12417-SS	579	722
AD09128	AM12375-AS	363	655	AM12874-SS	580	700
AD09129	AM12875-AS	385	655	AM12874-SS	580	700
AD09130	AM12877-AS	386	655	AM12876-SS	581	700
AD09242	AM13076-AS	387	677	AM13075-SS	582	723
AD09243	AM13077-AS	388	668	AM12401-SS	571	714
AD09244	AM13079-AS	389	668	AM13078-SS	583	714
AD09245	AM13079-AS	389	668	AM13080-SS	584	714

AD09246	AM13081-AS	390	668	AM13080-SS	584	714
AD09247	AM13082-AS	391	668	AM13080-SS	584	714
AD09248	AM13083-AS	392	668	AM13080-SS	584	714
AD09249	AM13083-AS	392	668	AM13084-SS	585	714
AD09250	AM13083-AS	392	668	AM13078-SS	583	714
AD09330	AM12388-AS	369	661	AM13210-SS	586	724
AD09331	AM13212-AS	393	661	AM13211-SS	587	724
AD09332	AM13212-AS	393	661	AM13213-SS	588	724
AD09333	AM13212-AS	393	661	AM13214-SS	589	707
AD09334	AM13215-AS	394	666	AM12397-SS	569	712
AD09335	AM13215-AS	394	666	AM13216-SS	590	712
AD09336	AM13215-AS	394	666	AM13217-SS	591	712
AD09337	AM13215-AS	394	666	AM13218-SS	592	712
AD09349	AM13241-AS	395	674	AM12413-SS	577	720
AD09350	AM13241-AS	395	674	AM13242-SS	593	720
AD09351	AM13244-AS	396	674	AM13243-SS	594	720
AD09352	AM13244-AS	396	674	AM13242-SS	593	720
AD09353	AM13245-AS	397	674	AM13243-SS	594	720
AD09354	AM13246-AS	398	664	AM12393-SS	567	710
AD09355	AM13247-AS	399	664	AM12393-SS	567	710
AD09356	AM13246-AS	398	664	AM13248-SS	595	710
AD09357	AM13246-AS	398	664	AM13249-SS	596	710
AD09358	AM13246-AS	398	664	AM13250-SS	597	710
AD09441	AM13400-AS	400	656	AM13399-SS	598	702
AD09442	AM13400-AS	400	656	AM13401-SS	599	702
AD09443	AM13402-AS	401	656	AM13399-SS	598	702
AD09444	AM13403-AS	402	656	AM13399-SS	598	702
AD09445	AM13405-AS	403	676	AM13404-SS	600	722
AD09446	AM13405-AS	403	676	AM13406-SS	601	722
AD09447	AM13407-AS	404	676	AM12417-SS	579	722
AD09448	AM13409-AS	405	678	AM13408-SS	602	725
AD09666	AM13241-AS	395	674	AM13762-SS	603	720
AD09667	AM13244-AS	396	674	AM13762-SS	603	720
AD09668	AM13241-AS	395	674	AM13763-SS	604	720
AD09669	AM13212-AS	393	661	AM13764-SS	605	724
AD09670	AM13212-AS	393	661	AM13765-SS	606	707
AD09887	AM14108-AS	406	679	AM14107-SS	607	726
AD09888	AM14109-AS	407	661	AM13764-SS	605	724
AD09889	AM14110-AS	408	674	AM12413-SS	577	720
AD09890	AM14112-AS	409	679	AM14111-SS	608	726
AD09891	AM14113-AS	410	679	AM14111-SS	608	726
AD09892	AM14117-AS	411	661	AM13210-SS	586	724
AD09893	AM14118-AS	412	661	AM13210-SS	586	724
AD09894	AM14119-AS	413	661	AM13213-SS	588	724
AD09895	AM14109-AS	407	661	AM13213-SS	588	724
AD09896	AM12875-AS	385	655	AM12374-SS	557	700
AD09897	AM14121-AS	414	655	AM14120-SS	609	700
AD09898	AM14122-AS	415	655	AM14120-SS	609	700
AD09899	AM12877-AS	386	655	AM14120-SS	609	700
AD09900	AM14124-AS	416	680	AM14123-SS	610	727
AD09901	AM14125-AS	417	680	AM14123-SS	610	727

AD09902	AM14126-AS	418	680	AM14123-SS	610	727
AD09903	AM14127-AS	419	680	AM14123-SS	610	727
AD09904	AM14129-AS	420	681	AM14128-SS	611	728
AD09905	AM14130-AS	421	681	AM14128-SS	611	728
AD09906	AM14131-AS	422	681	AM14128-SS	611	728
AD09907	AM14114-AS	423	674	AM13242-SS	593	720
AD09908	AM14116-AS	424	679	AM14115-SS	612	726
AD09909	AM14108-AS	406	679	AM14115-SS	612	726
AD10212	AM13246-AS	398	664	AM14553-SS	613	710
AD10284	AM14651-AS	425	680	AM14123-SS	610	727
AD10285	AM14652-AS	426	664	AM12393-SS	567	710
AD10286	AM14653-AS	427	664	AM13250-SS	597	710
AD10287	AM14654-AS	428	664	AM13250-SS	597	710
AD10288	AM14655-AS	429	664	AM13250-SS	597	710
AD10289	AM14656-AS	430	664	AM13250-SS	597	710
AD10290	AM14657-AS	431	664	AM13250-SS	597	710
AD10291	AM14658-AS	432	664	AM13250-SS	597	710
AD10292	AM14659-AS	433	664	AM13250-SS	597	710
AD10438	AM14888-AS	434	664	AM13250-SS	597	710
AD10439	AM14889-AS	435	664	AM13250-SS	597	710
AD10441	AM14888-AS	434	664	AM14553-SS	613	710
AD10442	AM14889-AS	435	664	AM14553-SS	613	710
AD10637	AM14116-AS	424	679	AM14107-SS	607	726
AD10638	AM15155-AS	436	674	AM13762-SS	603	720
AD10639	AM14114-AS	423	674	AM13762-SS	603	720
AD10815	AM14108-AS	406	679	AM15418-SS	615	729
AD10816	AM14108-AS	406	679	AM15419-SS	616	730
AD10817	AM14108-AS	406	679	AM15420-SS	617	726
AD10879	AM14655-AS	429	664	AM14553-SS	613	710
AD10880	AM14657-AS	431	664	AM14553-SS	613	710

[0125] Table 8. MMP7 RNAi Agent Duplexes with Corresponding Sense and Antisense Strand ID Numbers and Sequence ID numbers for the modified and unmodified nucleotide sequences. (Shown with Targeting Ligand Conjugates)

Duplex	AS ID	AS modified SEQ ID NO:	AS unmodified SEQ ID NO:	SS ID	SS modified SEQ ID NO:	SS unmodified SEQ ID NO:
AC001271	AM12375-AS	363	655	CS001585	618	700
AC001272	AM12875-AS	385	655	CS001585	618	700
AC001273	AM12877-AS	386	655	CS001588	619	700
AC001513	AM13241-AS	395	674	CS001941	620	720
AC001514	AM13244-AS	396	674	CS001941	620	720
AC001515	AM13241-AS	395	674	CS001944	621	720

Duplex	AS ID	AS modified SEQ ID NO:	AS unmodified SEQ ID NO:	SS ID	SS modified SEQ ID NO:	SS unmodified SEQ ID NO:
AC001516	AM13212-AS	393	661	CS001945	622	724
AC001517	AM13212-AS	393	661	CS001947	623	707
AC001651	AM14108-AS	406	679	CS002133	628	726
AC001652	AM14109-AS	407	661	CS001945	622	724
AC001875	AM13246-AS	398	664	CS002396	624	710
AC002023	AM14888-AS	434	664	CS002396	624	710
AC002024	AM14889-AS	435	664	CS002396	624	710
AC002085	AM14116-AS	424	679	CS002133	628	726
AC002086	AM15155-AS	436	674	CS001941	620	720
AC002087	AM14114-AS	423	674	CS001941	620	720
AC002217	AM14655-AS	429	664	CS002396	624	710
AC002218	AM14657-AS	431	664	CS002396	624	710
AC002219	AM14108-AS	406	679	CS002805	625	729
AC002220	AM14108-AS	406	679	CS002806	626	730
AC002221	AM14108-AS	406	679	CS002807	627	726

[0126] Table 9. Conjugate Duplex ID Numbers Referencing Position Targeted On MMP7 (MMP7) Gene

Duplex	AS ID	SS ID	Duplex	Targeted MMP7 Gene Position (Of SEQ ID NO:1)
AC001271	AM12375-AS	CS001585	AD09128	304
AC001272	AM12875-AS	CS001585	AD09129	304
AC001273	AM12877-AS	CS001588	AD09130	304
AC001513	AM13241-AS	CS001941	AD09666	971
AC001514	AM13244-AS	CS001941	AD09667	971
AC001515	AM13241-AS	CS001944	AD09668	971
AC001516	AM13212-AS	CS001945	AD09669	418
AC001517	AM13212-AS	CS001947	AD09670	418
AC001651	AM14108-AS	CS002133	AD09887	971
AC001652	AM14109-AS	CS001945	AD09888	418
AC001875	AM13246-AS	CS002396	AD10212	735
AC002023	AM14888-AS	CS002396	AD10441	735
AC002024	AM14889-AS	CS002396	AD10442	735
AC002085	AM14116-AS	CS002133	AD10637	971
AC002086	AM15155-AS	CS001941	AD10638	971
AC002087	AM14114-AS	CS001941	AD10639	971
AC002217	AM14655-AS	CS002396	AD10879	735

Duplex	AS ID	SS ID	Duplex	Targeted MMP7 Gene Position (Of SEQ ID NO:1)
AC002218	AM14657-AS	CS002396	AD10880	735
AC002219	AM14108-AS	CS002805	AD10815	971
AC002220	AM14108-AS	CS002806	AD10816	971
AC002221	AM14108-AS	CS002807	AD10817	971

[0127] Table 10. Conjugate ID Numbers With Chemically Modified Antisense and Sense Strands (including Linkers and Conjugates)

AC ID Number	Sense Strand (Fully Modified with Conjugated Targeting Ligand) (5' → 3')	SEQ ID NO:	Antisense Strand (5' → 3')	SEQ ID NO:
AC001271	Tri-SM6, 1- α β6-(TA14)gsauguggaGfuUfGfccagauguas(invAb)	618	usAfsasCfaUfcUfgGfcAfcUfcCfaCfaUfsc	363
AC001272	Tri-SM6, 1- α β6-(TA14)gsauguggaGfuUfGfccagauguas(invAb)	618	cPrpusAfsasCfaUfcUfgGfcAfcUfcCfaCfaUfsc	385
AC001273	Tri-SM6, 1- α β6-(TA14)gsauguggaGfuUfGfccagauguas(invAb)	619	cPrpuAfacaucuggcAfcUfcCfcausc	386
AC001513	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucus(invAb)	620	asGfsascauucaaaAfaCfcAfacugsc	395
AC001514	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucus(invAb)	620	asGfsascauucAfaaAfaCfcAfacugsc	396
AC001515	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucus(invAb)	621	asGfsascauucaaaAfaCfcAfacugsc	395
AC001516	Tri-SM6, 1- α β6-(TA14)csauguggauCfGfAfuUfagugucaas(invAb)	622	usUfsgsacacUfaAfuCfGfAfuCfcauscg	393
AC001517	Tri-SM6, 1- α β6-(TA14)csauguggauCfGfAfuUfagugucaas(invAb)	623	usUfsgsacacUfaAfuCfGfAfuCfcauscg	393
AC001875	Tri-SM6, 1- α β6-(TA14)gscagugauGfuAfuCfcaacuauas(invAb)	624	asUfsgsgguuggauAfcAfuCfcauscg	398
AC002217	Tri-SM6, 1- α β6-(TA14)gscagugauGfuAfuCfcaacuauas(invAb)	624	cPrpasUfsaGfguuggauAfcAfuCfcauscgsc	429
AC002218	Tri-SM6, 1- α β6-(TA14)gscagugauGfuAfuCfcaacuauas(invAb)	624	cPrpasUfsagGfuuggauAfcAfuCfcauscgsc	431
AC002219	Tri-SM6, 1- α β6-(TA14)gscguuggUfuUfuUfgaangucas(invAb)	625	cPrpuGfacaucAfaaAfaCfcAfacugsc	406
AC002220	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucas(invAb)	626	cPrpuGfacaucAfaaAfaCfcAfacugsc	406
AC002221	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaanguca(invAb)	627	cPrpuGfacaucAfaaAfaCfcAfacugsc	406
AC001651	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucas(invAb)	628	cPrpuGfacaucAfaaAfaCfcAfacugsc	406
AC001652	Tri-SM6, 1- α β6-(TA14)csauguggauCfGfAfuUfagugucaas(invAb)	622	cPrpuUfgaacUfaAfuCfGfAfuCfcauscg	407
AC002085	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucas(invAb)	628	cPrpusGfsascauucAfaaAfaCfcAfacugsc	424
AC002086	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucus(invAb)	620	cPrpaGfacaucAfaaAfaCfcAfacugsc	436
AC002087	Tri-SM6, 1- α β6-(TA14)gscaguuggUfuUfuUfgaangucus(invAb)	620	cPrpasGfsascauucAfaaAfaCfcAfacugsc	423
AC002023	Tri-SM6, 1- α β6-(TA14)gscagugauGfuAfuCfcaacuauas(invAb)	624	cPrpasUfsgsgguuggauAfcAfuCfcauscgsc	434

AC002024	Tri-SM6. I- α β 6-(TA14)gscagugauGfuAfuCfcaaccuauus(invAb)	624	cPrpaUfagguuggauAfcAfuCfacuugsc	435
----------	---	-----	---------------------------------	-----

[0128] In some embodiments, a MMP7 RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid. In some embodiments, a MMP7 RNAi agent is prepared or provided as a pharmaceutically acceptable salt. In some embodiments, a MMP7 RNAi agent is prepared or provided as a pharmaceutically acceptable sodium or potassium salt. The RNAi agents described herein, upon delivery to a cell expressing an MMP7 gene, inhibit or knockdown expression of one or more MMP7 genes *in vivo* and/or *in vitro*.

Targeting Groups, Linking Groups, Pharmacokinetic/Pharmacodynamic (PK/PD) Modulators, and Delivery Vehicles

[0129] In some embodiments, a MMP7 RNAi agent contains or is conjugated to one or more non-nucleotide groups including, but not limited to, a targeting group, a linking group, a pharmacokinetic/pharmacodynamic (PK/PD) modulator, a delivery polymer, or a delivery vehicle. The non-nucleotide group can enhance targeting, delivery, or attachment of the RNAi agent. The non-nucleotide group can be covalently linked to the 3' and/or 5' end of either the sense strand and/or the antisense strand. In some embodiments, a MMP7 RNAi agent contains a non-nucleotide group linked to the 3' and/or 5' end of the sense strand. In some embodiments, a non-nucleotide group is linked to the 5' end of a MMP7 RNAi agent sense strand. A non-nucleotide group can be linked directly or indirectly to the RNAi agent via a linker/linking group. In some embodiments, a non-nucleotide group is linked to the RNAi agent via a labile, cleavable, or reversible bond or linker.

[0130] In some embodiments, a non-nucleotide group enhances the pharmacokinetic or biodistribution properties of an RNAi agent or conjugate to which it is attached to improve cell- or tissue-specific distribution and cell-specific uptake of the conjugate. In some embodiments, a non-nucleotide group enhances endocytosis of the RNAi agent.

[0131] Targeting groups or targeting moieties enhance the pharmacokinetic or biodistribution properties of a conjugate or RNAi agent to which they are attached to improve cell-specific (including, in some cases, organ specific) distribution and cell-specific (or organ specific) uptake of the conjugate or RNAi agent. A targeting group can be monovalent, divalent, trivalent, tetravalent, or have higher valency for the target to which it is directed. Representative targeting groups include, without limitation, compounds with affinity to cell surface molecule, cell receptor ligands, hapten, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity to cell surface molecules. In some embodiments, a targeting group is linked to an RNAi agent using a linker, such as

a PEG linker or one, two, or three abasic and/or ribitol (abasic ribose) residues, which in some instances can serve as linkers.

[0132] A targeting group, with or without a linker, can be attached to the 5' or 3' end of any of the sense and/or antisense strands disclosed in Tables 2, 3, 4, 5, 6, and 10. A linker, with or without a targeting group, can be attached to the 5' or 3' end of any of the sense and/or antisense strands disclosed in Tables 2, 3, 4, 5, 6, and 10.

[0133] The MMP7 RNAi agents described herein can be synthesized having a reactive group, such as an amino group (also referred to herein as an amine), at the 5'-terminus and/or the 3'-terminus. The reactive group can be used subsequently to attach a targeting moiety using methods typical in the art.

[0134] For example, in some embodiments, the MMP7 RNAi agents disclosed herein are synthesized having an $\text{NH}_2\text{-C}_6$ group at the 5'-terminus of the sense strand of the RNAi agent. The terminal amino group subsequently can be reacted to form a conjugate with, for example, a group that includes an $\alpha\text{v}\beta 6$ integrin targeting ligand. In some embodiments, the MMP7 RNAi agents disclosed herein are synthesized having one or more alkyne groups at the 5'-terminus of the sense strand of the RNAi agent. The terminal alkyne group(s) can subsequently be reacted to form a conjugate with, for example, a group that includes an $\alpha\text{v}\beta 6$ integrin targeting ligand.

[0135] In some embodiments, a targeting group comprises an integrin targeting ligand. In some embodiments, an integrin targeting ligand is an $\alpha\text{v}\beta 6$ integrin targeting ligand. The use of an $\alpha\text{v}\beta 6$ integrin targeting ligand facilitates cell-specific targeting to cells having $\alpha\text{v}\beta 6$ on its respective surface, and binding of the integrin targeting ligand can facilitate entry of the therapeutic agent, such as an RNAi agent, to which it is linked, into cells such as epithelial cells, including pulmonary epithelial cells and renal epithelial cells. Integrin targeting ligands can be monomeric or monovalent (e.g., having a single integrin targeting moiety) or multimeric or multivalent (e.g., having multiple integrin targeting moieties). The targeting group can be attached to the 3' and/or 5' end of the RNAi oligonucleotide using methods known in the art. The preparation of targeting groups, such as $\alpha\text{v}\beta 6$ integrin targeting ligands, is described, for example, in International Patent Application Publication No. WO 2018/085415 and in International Patent Application Publication No. WO 2019/089765, the contents of each of which are incorporated herein in its entirety.

[0136] In some embodiments, targeting groups are linked to the MMP7 RNAi agents without the use of an additional linker. In some embodiments, the targeting group is

designed having a linker readily present to facilitate the linkage to a MMP7 RNAi agent. In some embodiments, when two or more RNAi agents are included in a composition, the two or more RNAi agents can be linked to their respective targeting groups using the same linkers. In some embodiments, when two or more RNAi agents are included in a composition, the two or more RNAi agents are linked to their respective targeting groups using different linkers.

[0137] In some embodiments, a linking group is conjugated to the RNAi agent. The linking group facilitates covalent linkage of the agent to a targeting group, pharmacokinetic modulator, delivery polymer, or delivery vehicle. The linking group can be linked to the 3' and/or the 5' end of the RNAi agent sense strand or antisense strand. In some embodiments, the linking group is linked to the RNAi agent sense strand. In some embodiments, the linking group is conjugated to the 5' or 3' end of an RNAi agent sense strand. In some embodiments, a linking group is conjugated to the 5' end of an RNAi agent sense strand. Examples of linking groups, include but are not limited to: C6-SS-C6, 6-SS-6, reactive groups such as primary amines (e.g., NH₂-C6) and alkynes, alkyl groups, abasic residues/nucleotides, amino acids, tri-alkyne functionalized groups, ribitol, and/or PEG groups. Examples of certain linking groups are provided in Table 11.

[0138] A linker or linking group is a connection between two atoms that links one chemical group (such as an RNAi agent) or segment of interest to another chemical group (such as a targeting group, pharmacokinetic modulator, or delivery polymer) or segment of interest via one or more covalent bonds. A labile linkage contains a labile bond. A linkage can optionally include a spacer that increases the distance between the two joined atoms. A spacer may further add flexibility and/or length to the linkage. Spacers include, but are not limited to, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkenyl groups, and aralkynyl groups; each of which can contain one or more heteroatoms, heterocycles, amino acids, nucleotides, and saccharides. Spacer groups are well known in the art and the preceding list is not meant to limit the scope of the description. In some embodiments, a MMP7 RNAi agent is conjugated to a polyethylene glycol (PEG) moiety, or to a hydrophobic group having 12 or more carbon atoms, such as a cholesterol or palmitoyl group.


[0139] In some embodiments, a MMP7 RNAi agent is linked to one or more pharmacokinetic/pharmacodynamic (PK/PD) modulators. PK/PD modulators can increase circulation time of the conjugated drug and/or increase the activity of the RNAi agent

through improved cell receptor binding, improved cellular uptake, and/or other means. Various PK/PD modulators suitable for use with RNAi agents are known in the art. In some embodiments, the PK/PD modulatory can be cholesterol or cholesteryl derivatives, or in some circumstances a PK/PD modulator can be comprised of alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkenyl groups, or aralkynyl groups, each of which may be linear, branched, cyclic, and/or substituted or unsubstituted. In some embodiments, the location of attachment for these moieties is at the 5' or 3' end of the sense strand, at the 2' position of the ribose ring of any given nucleotide of the sense strand, and/or attached to the phosphate or phosphorothioate backbone at any position of the sense strand.


[0140] Any of the MMP7 RNAi agent nucleotide sequences listed in Tables 2, 3, 4, 5, 6, and 10, whether modified or unmodified, can contain 3' and/or 5' targeting group(s), linking group(s), and/or PK/PD modulator(s). Any of the MMP7 RNAi agent sequences listed in Tables 3, 4, 5, 6, and 10, or are otherwise described herein, which contain a 3' or 5' targeting group, linking group, and/or PK/PD modulator can alternatively contain no 3' or 5' targeting group, linking group, or PK/PD modulator, or can contain a different 3' or 5' targeting group, linking group, or pharmacokinetic modulator including, but not limited to, those depicted in Table 11. Any of the MMP7 RNAi agent duplexes listed in Tables 7A, 7B, 8, 9 and 10, whether modified or unmodified, can further comprise a targeting group or linking group, including, but not limited to, those depicted in Table 11, and the targeting group or linking group can be attached to the 3' or 5' terminus of either the sense strand or the antisense strand of the MMP7 RNAi agent duplex.

[0141] Examples of certain modified nucleotides, capping moieties, and linking groups are provided in Table 11.


Table 11. Structures Representing Various Modified Nucleotides, Capping Moieties, and Linking Groups (wherein $\sim$ indicates the point of connection)




When positioned internally:




When positioned internally:



When positioned at the 3' terminal end:



When positioned at the 3' terminal end:




linkage towards 5' end

(C6-SS-C6)

When positioned internally:


linkage towards 5' end

linkage towards 3' end



(C6-SS-C6)


When positioned at the 3' terminal end:



linkage towards 5' end

(6-SS-6)


When positioned internally:




linkage towards 5' end

linkage towards 3' end


(6-SS-6)




(NH2-C6)




(NH2-C6)s




-C6-




-C6s-




-L6-C6-




-L6-C6s-





-Alk-cyHex-





-Alk-cyHexs-



(TriAlk14)







[0142] Alternatively, other linking groups known in the art may be used. In many instances, linking groups can be commercially acquired or alternatively, are incorporated into commercially available nucleotide phosphoramidites. (See, e.g., International Patent Application Publication No. WO 2019/161213, which is incorporated herein by reference in its entirety).

[0143] In some embodiments, a MMP7 RNAi agent is delivered without being conjugated to a targeting ligand or pharmacokinetic/pharmacodynamic (PK/PD) modulator (referred to as being “naked” or a “naked RNAi agent”).

[0144] In some embodiments, a MMP7 RNAi agent is conjugated to a targeting group, a linking group, a PK modulator, and/or another non-nucleotide group to facilitate delivery of the MMP7 RNAi agent to the cell or tissue of choice, for example, to an epithelial cell *in vivo*. In some embodiments, a MMP7 RNAi agent is conjugated to a targeting group wherein the targeting group includes an integrin targeting ligand. In some embodiments, the integrin targeting ligand is an $\alpha\beta6$ integrin targeting ligand. In some embodiments, a targeting group includes one or more $\alpha\beta6$ integrin targeting ligands.

[0145] In some embodiments, a delivery vehicle may be used to deliver an RNAi agent to a cell or tissue. A delivery vehicle is a compound that improves delivery of the RNAi agent to a cell or tissue. A delivery vehicle can include, or consist of, but is not limited to: a

polymer, such as an amphipathic polymer, a membrane active polymer, a peptide, a melittin peptide, a melittin-like peptide (MLP), a lipid, a reversibly modified polymer or peptide, or a reversibly modified membrane active polyamine.

[0146] In some embodiments, the RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs or other delivery systems available in the art for nucleic acid delivery. The RNAi agents can also be chemically conjugated to targeting groups, lipids (including, but not limited to cholesteryl and cholesteryl derivatives), encapsulating in nanoparticles, liposomes, micelles, conjugating to polymers or DPCs (see, for example WO 2000/053722, WO 2008/022309, WO 2011/104169, and WO 2012/083185, WO 2013/032829, WO 2013/158141, each of which is incorporated herein by reference), by iontophoresis, or by incorporation into other delivery vehicles or systems available in the art such as hydrogels, cyclodextrins, biodegradable nanocapsules, bioadhesive microspheres, or proteinaceous vectors. In some embodiments the RNAi agents can be conjugated to antibodies having affinity for pulmonary epithelial cells. In some embodiments, the RNAi agents can be linked to targeting ligands that have affinity for pulmonary epithelial cells or receptors present on pulmonary epithelial cells.

Pharmaceutical Compositions and Formulations

[0147] The MMP7 RNAi agents disclosed herein can be prepared as pharmaceutical compositions (alternatively referred to as pharmaceutical formulations or medicaments). The pharmaceutical compositions disclosed herein include at least one MMP7 RNAi agent. These pharmaceutical compositions are particularly useful in the inhibition of the expression of MMP7 mRNA in a target cell, a group of cells, a tissue, or an organism. The pharmaceutical compositions can be used to treat a subject having a disease, disorder, or condition that would benefit from reduction in the level of the target mRNA, or inhibition in expression of the target gene. The pharmaceutical compositions can be used to treat a subject at risk of developing a disease or disorder that would benefit from reduction of the level of the target mRNA or an inhibition in expression the target gene. In one embodiment, the method includes administering a MMP7 RNAi agent linked to a targeting ligand as described herein, to a subject to be treated. In some embodiments, one or more pharmaceutically acceptable excipients (including vehicles, carriers, diluents, and/or delivery polymers) are added to the pharmaceutical compositions that include a MMP7

RNAi agent, thereby forming a pharmaceutical formulation or medicament suitable for *in vivo* delivery to a subject, including a human.

[0148] The pharmaceutical compositions that include a MMP7 RNAi agent and methods disclosed herein decrease the level of the target mRNA in a cell, group of cells, group of cells, tissue, organ, or subject, including by administering to the subject a therapeutically effective amount of a herein described MMP7 RNAi agent, thereby inhibiting the expression of MMP7 mRNA in the subject. In some embodiments, the subject has been previously identified or diagnosed as having a disease or disorder that can be mediated at least in part by a reduction in MMP7 expression. In some embodiments, the subject has been previously diagnosed with having one or more pulmonary diseases such as idiopathic pulmonary fibrosis (IPF), asthma (including severe asthma), acute respiratory distress syndrome, lung cancer, chronic inflammation, interstitial lung diseases (ILD), or another type of fibrosis. In some embodiments, the subject has been previously diagnosed with having IPF.

[0149] Embodiments of the present disclosure include pharmaceutical compositions for delivering a MMP7 RNAi agent to a pulmonary epithelial cell *in vivo*. Such pharmaceutical compositions can include, for example, a MMP7 RNAi agent conjugated to a targeting group that comprises an integrin targeting ligand. In some embodiments, the integrin targeting ligand is comprised of an $\alpha\text{v}\beta 6$ integrin ligand.

[0150] In some embodiments, the described pharmaceutical compositions including a MMP7 RNAi agent are used for treating or managing clinical presentations in a subject that would benefit from the inhibition of expression of MMP7. In some embodiments, a therapeutically or prophylactically effective amount of one or more of pharmaceutical compositions is administered to a subject in need of such treatment. In some embodiments, administration of any of the disclosed MMP7 RNAi agents can be used to decrease the number, severity, and/or frequency of symptoms of a disease in a subject.

[0151] In some embodiments, the described MMP7 RNAi agents are optionally combined with one or more additional (i.e., second, third, etc.) therapeutics. A second therapeutic can be another MMP7 RNAi agent (e.g., a MMP7 RNAi agent that targets a different sequence within a MMP7 gene). In some embodiments, a second therapeutic can be an RNAi agent that targets the MMP7 gene. An additional therapeutic can also be a small molecule drug, antibody, antibody fragment, and/or aptamer. The MMP7 RNAi agents, with or without the one or more additional therapeutics, can be combined with one or more excipients to form pharmaceutical compositions.

[0152] The described pharmaceutical compositions that include a MMP7 RNAi agent can be used to treat at least one symptom in a subject having a disease or disorder that would benefit from reduction or inhibition in expression of MMP7 mRNA. In some embodiments, the subject is administered a therapeutically effective amount of one or more pharmaceutical compositions that include a MMP7 RNAi agent thereby treating the symptom. In other embodiments, the subject is administered a prophylactically effective amount of one or more MMP7 RNAi agents, thereby preventing or inhibiting the at least one symptom.

[0153] In some embodiments, one or more of the described MMP7 RNAi agents are administered to a mammal in a pharmaceutically acceptable carrier or diluent. In some embodiments, the mammal is a human.

[0154] The route of administration is the path by which a MMP7 RNAi agent is brought into contact with the body. In general, methods of administering drugs, oligonucleotides, and nucleic acids, for treatment of a mammal are well known in the art and can be applied to administration of the compositions described herein. The MMP7 RNAi agents disclosed herein can be administered via any suitable route in a preparation appropriately tailored to the particular route. Thus, in some embodiments, the herein described pharmaceutical compositions are administered via inhalation, intranasal administration, intratracheal administration, or oropharyngeal aspiration administration. In some embodiments, the pharmaceutical compositions can be administered by injection, for example, intravenously, intramuscularly, intracutaneously, subcutaneously, intraarticularly, intraocularly, or intraperitoneally, or topically.

[0155] The pharmaceutical compositions including a MMP7 RNAi agent described herein can be delivered to a cell, group of cells, tissue, or subject using oligonucleotide delivery technologies known in the art. In general, any suitable method recognized in the art for delivering a nucleic acid molecule (*in vitro* or *in vivo*) can be adapted for use with the compositions described herein. For example, delivery can be by local administration, (e.g., direct injection, implantation, or topical administering), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration. In some embodiments, the compositions are administered via inhalation, intranasal administration, oropharyngeal aspiration administration, or intratracheal administration.

[0156] For example, in some embodiments, it is desired that the MMP7 RNAi agents described herein inhibit the expression of an MMP7 gene in the pulmonary epithelium, for which administration via inhalation (e.g., by an inhaler device, such as a metered-dose inhaler, or a nebulizer such as a jet or vibrating mesh nebulizer, or a soft mist inhaler) is particularly suitable and advantageous

[0157] In some embodiments, the pharmaceutical compositions described herein comprise one or more pharmaceutically acceptable excipients. The pharmaceutical compositions described herein are formulated for administration to a subject.

[0158] As used herein, a pharmaceutical composition includes a pharmacologically effective amount of at least one of the described therapeutic compounds and one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients (excipients) are substances other than the Active Pharmaceutical Ingredient (API, therapeutic product, e.g., MMP7 RNAi agent) that are intentionally included in the drug delivery system. Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage. Excipients can act to a) aid in processing of the drug delivery system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and/or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during stoMMP7 or use. A pharmaceutically acceptable excipient may or may not be an inert substance.

[0159] Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, delivery polymers, detergents, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, surfactants, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.

[0160] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor® ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or

dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0161] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0162] Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.

[0163] Formulations suitable for inhalation administration can be prepared by incorporating the active compound in the desired amount in an appropriate solvent, followed by sterile filtration. In general, formulations for inhalation administration are sterile solutions at physiological pH and have low viscosity (< 5 cP). Salts may be added to the formulation to balance tonicity. In some cases, surfactants or co-solvents can be added to increase active compound solubility and improve aerosol characteristics. In some cases, excipients can be added to control viscosity in order to ensure size and distribution of nebulized droplets.

[0164] In some embodiments, pharmaceutical formulations that include the MMP7 RNAi agents disclosed herein suitable for inhalation administration can be prepared in water for injection (sterile water), or an aqueous sodium phosphate buffer (for example, the MMP7

RNAi agent formulated in 0.5 mM sodium phosphate monobasic, 0.5 mM sodium phosphate dibasic, in water).

[0165] The active compounds can be prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0166] The MMP7 RNAi agents can be formulated in compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0167] A pharmaceutical composition can contain other additional components commonly found in pharmaceutical compositions. Such additional components include, but are not limited to: anti-pruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine, etc.). It is also envisioned that cells, tissues, or isolated organs that express or comprise the herein defined RNAi agents may be used as “pharmaceutical compositions.” As used herein, “pharmacologically effective amount,” “therapeutically effective amount,” or simply “effective amount” refers to that amount of an RNAi agent to produce a pharmacological, therapeutic, or preventive result.

[0168] In some embodiments, the methods disclosed herein further comprise the step of administering a second therapeutic or treatment in addition to administering an RNAi agent disclosed herein. In some embodiments, the second therapeutic is another MMP7 RNAi agent (e.g., a MMP7 RNAi agent that targets a different sequence within the MMP7 target). In other embodiments, the second therapeutic can be a small molecule drug, an antibody, an antibody fragment, and/or an aptamer.

[0169] In some embodiments, described herein are compositions that include a combination or cocktail of at least two MMP7 RNAi agents having different sequences. In some embodiments, the two or more MMP7 RNAi agents are each separately and independently linked to targeting groups. In some embodiments, the two or more MMP7 RNAi agents are each linked to targeting groups that include or consist of integrin targeting ligands. In some embodiments, the two or more MMP7 RNAi agents are each linked to targeting groups that include or consist of $\alpha\beta6$ integrin targeting ligands.

[0170] Described herein are compositions for delivery of MMP7 RNAi agents to pulmonary epithelial cells. Furthermore, compositions for delivery of MMP7 RNAi agents to cells, including renal epithelial cells and/or epithelial cells in the GI or reproductive tract and/or and ocular surface epithelial cells in the eye, *in vivo*, are generally described herein.

[0171] Generally, an effective amount of a MMP7 RNAi agent disclosed herein will be in the range of from about 0.0001 to about 20 mg/kg of body weight/deposited dose, e.g., from about 0.001 to about 5 mg/kg of body weight/deposited dose. In some embodiments, an effective amount of a MMP7 RNAi agent will be in the range of from about 0.01 mg/kg to about 3.0 mg/kg of body weight per deposited dose. In some embodiments, an effective amount of a MMP7 RNAi agent will be in the range of from about 0.03 mg/kg to about 2.0 mg/kg of body weight per deposited dose. In some embodiments, an effective amount of a MMP7 RNAi agent will be in the range of from about 0.01 to about 1.0 mg/kg of deposited dose per body weight. In some embodiments, an effective amount of a MMP7 RNAi agent will be in the range of from about 0.50 to about 1.0 mg/kg of deposited dose per body weight. Calculating the pulmonary deposited dose (PDD) is done in accordance with methods known in the art. (See Wolff R.K., Dorato M.A., *Toxicologic Testing of Inhaled Pharmaceutical Aerosols*, Crit Rev Toxicol., 1993; 23(4):343-369; Tepper *et al.*, International J. Toxicology, 2016, vol. 35(4):376-392). The amount administered will also likely depend on such variables as the overall health status of the patient, the relative biological efficacy of the compound delivered, the formulation of the drug, the presence and types of excipients in the formulation, and the route of administration. Also, it is to be understood that the initial dosage administered can be increased beyond the above upper level to rapidly achieve the desired blood-level or tissue level, or the initial dosage can be smaller than the optimum. In some embodiments, a dose is administered daily. In some embodiments, a dose is administered weekly. In further embodiments, a dose is

administered bi-weekly, tri-weekly, once monthly, or once quarterly (i.e., once every three months).

[0172] For treatment of disease or for formation of a medicament or composition for treatment of a disease, the pharmaceutical compositions described herein including a MMP7 RNAi agent can be combined with an excipient or with a second therapeutic agent or treatment including, but not limited to: a second or other RNAi agent, a small molecule drug, an antibody, an antibody fragment, peptide, and/or an aptamer.

[0173] The described MMP7 RNAi agents, when added to pharmaceutically acceptable excipients or adjuvants, can be packaged into kits, containers, packs, or dispensers. The pharmaceutical compositions described herein can be packaged in dry powder or aerosol inhalers, other metered-dose inhalers, nebulizers, pre-filled syringes, or vials.

Methods of Treatment and Inhibition of MMP7 Expression

[0174] The MMP7 RNAi agents disclosed herein can be used to treat a subject (e.g., a human or other mammal) having a disease or disorder that would benefit from administration of the RNAi agent. In some embodiments, the RNAi agents disclosed herein can be used to treat a subject (e.g., a human) that would benefit from a reduction and/or inhibition in expression of MMP7 mRNA and/or a reduction in MMP7 enzyme levels.

[0175] In some embodiments, the RNAi agents disclosed herein can be used to treat a subject (e.g., a human) having a disease or disorder for which the subject would benefit from reduction in MMP7 enzyme levels, including but not limited to, idiopathic pulmonary fibrosis (IPF), asthma, various other types of fibrosis, chronic inflammation, interstitial lung diseases (ILD), infectious disease (for example, SARS-COV-2), acute lung injury (for example, acute respiratory distress syndrome (ARDS)), pulmonary hypertension, various cancers, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), fatty liver disease, biliary atresia, and chronic kidney disease (CKD). In some embodiments the disease is IPF. In some embodiments the subject has been previously diagnosed with having IPF, asthma, ILD, ARDS, or another type of fibrosis. Treatment of a subject can include therapeutic and/or prophylactic treatment. The subject is administered a therapeutically effective amount of any one or more MMP7 RNAi agents described herein. The subject can be a human, patient, or human patient. The subject may be an adult, adolescent, child, or infant. Administration of a pharmaceutical composition described herein can be to a human being or animal.

[0176] Increased membrane MMP7 enzyme levels are known to contribute to aberrant epithelial cell, fibroblast, and immune cell function and have been linked to fibrosis particularly in pulmonary tissues and cells. In some embodiments, the described MMP7 RNAi agents are used to treat at least one symptom mediated at least in part by a reduction in MMP7 enzyme levels, in a subject. The subject is administered a therapeutically effective amount of any one or more of the described MMP7 RNAi agents. In some embodiments, the subject is administered a prophylactically effective amount of any one or more of the described RNAi agents, thereby treating the subject by preventing or inhibiting the at least one symptom.

[0177] In certain embodiments, the present disclosure provides methods for treatment of diseases, disorders, conditions, or pathological states mediated at least in part by MMP7 gene expression, in a patient in need thereof, wherein the methods include administering to the patient any of the MMP7 RNAi agents described herein.

[0178] In some embodiments, the MMP7 RNAi agents are used to treat or manage a clinical presentation or pathological state in a subject, wherein the clinical presentation or pathological state is mediated at least in part by a reduction in MMP7 expression. The subject is administered a therapeutically effective amount of one or more of the MMP7 RNAi agents or MMP7 RNAi agent-containing compositions described herein. In some embodiments, the method comprises administering a composition comprising a MMP7 RNAi agent described herein to a subject to be treated.

[0179] In a further aspect, the disclosure features methods of treatment (including prophylactic or preventative treatment) of diseases or symptoms that may be addressed by a reduction in MMP7 enzyme levels, the methods comprising administering to a subject in need thereof a MMP7 RNAi agent that includes an antisense strand comprising the sequence of any of the sequences in Table 2, Table 3, or Table 10. Also described herein are compositions for use in such methods.

[0180] The described MMP7 RNAi agents and/or compositions that include MMP7 RNAi agents can be used in methods for therapeutic treatment of disease or conditions caused by enhanced or elevated MMP7 enzyme levels. Such methods include administration of a MMP7 RNAi agent as described herein to a subject, e.g., a human or animal subject.

[0181] In another aspect, the disclosure provides methods for the treatment (including prophylactic treatment) of a pathological state (such as a condition or disease) mediated at least in part by MMP7 expression, wherein the methods include administering to a subject

a therapeutically effective amount of an RNAi agent that includes an antisense strand comprising the sequence of any of the sequences in Table 2, Table 3, or Table 10.

[0182] In some embodiments, methods for inhibiting expression of an MMP7 gene are disclosed herein, wherein the methods include administering to a cell an RNAi agent that includes an antisense strand comprising the sequence of any of the sequences in Table 2, Table 3, or Table 10.

[0183] In some embodiments, methods for the treatment (including prophylactic treatment) of a pathological state mediated at least in part by MMP7 expression are disclosed herein, wherein the methods include administering to a subject a therapeutically effective amount of an RNAi agent that includes a sense strand comprising the sequence of any of the sequences in Table 2, Table 4, Table 5, Table 6, or Table 10.

[0184] In some embodiments, methods for inhibiting expression of an MMP7 gene are disclosed herein, wherein the methods comprise administering to a cell an RNAi agent that includes a sense strand comprising the sequence of any of the sequences in Table 2, Table 4, Table 5, Table 6, or Table 10.

[0185] In some embodiments, methods for the treatment (including prophylactic treatment) of a pathological state mediated at least in part by MMP7 expression are disclosed herein, wherein the methods include administering to a subject a therapeutically effective amount of an RNAi agent that includes a sense strand comprising the sequence of any of the sequences in Table 4, Table 5, Table 6, or Table 10, and an antisense strand comprising the sequence of any of the sequences in Table 3 or Table 10.

[0186] In some embodiments, methods for inhibiting expression of a MMP7 gene are disclosed herein, wherein the methods include administering to a cell an RNAi agent that includes a sense strand comprising the sequence of any of the sequences in Table 4, Table 5, Table 6, or Table 10, and an antisense strand comprising the sequence of any of the sequences in Table 3 or Table 10.

[0187] In some embodiments, methods of inhibiting expression of a MMP7 gene are disclosed herein, wherein the methods include administering to a subject a MMP7 RNAi agent that includes a sense strand consisting of the nucleobase sequence of any of the sequences in Table 4, Table 5, Table 6, or Table 10, and the antisense strand consisting of the nucleobase sequence of any of the sequences in Table 3 or Table 10. In other embodiments, disclosed herein are methods of inhibiting expression of a MMP7 gene, wherein the methods include administering to a subject a MMP7 RNAi agent that includes

a sense strand consisting of the modified sequence of any of the modified sequences in Table 4, Table 5, Table 6, or Table 10, and the antisense strand consisting of the modified sequence of any of the modified sequences in Table 3 or Table 10.

[0188] In some embodiments, methods for inhibiting expression of an MMP7 gene in a cell are disclosed herein, wherein the methods include administering one or more MMP7 RNAi agents comprising a duplex structure of one of the duplexes set forth in Tables 7A, 7B, 8, 9, and 10.

[0189] In some embodiments, the MMP7 gene expression level and/or MMP7 mRNA level in certain pulmonary epithelial cells of subject to whom a described MMP7 RNAi agent is administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99%, relative to the subject's respective level prior to being administered the MMP7 RNAi agent or to a different subject not receiving the MMP7 RNAi agent. In some embodiments, the MMP7 enzyme levels in certain epithelial cells or circulating MMP7 enzyme levels of a subject to whom a described MMP7 RNAi agent is administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99%, relative to the subject prior to being administered the MMP7 RNAi agent or to a different subject not receiving the MMP7 RNAi agent. The gene expression level, enzyme or protein level, and/or mRNA level in the subject may be reduced in a cell, group of cells, serum, and/or tissue of the subject. In some embodiments, the MMP7 enzyme levels in certain subject to whom a described MMP7 RNAi agent has been administered is reduced by at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% relative to the subject prior to being administered the MMP7 RNAi agent or to a subject not receiving the MMP7 RNAi agent.

[0190] A reduction in gene expression, mRNA, and enzyme or protein levels can be assessed by any methods known in the art. Reduction or decrease in MMP7 enzyme levels or MMP7 mRNA levels are sometimes collectively referred to herein as a decrease in, reduction of, or inhibition of MMP7 gene expression. The Examples set forth herein illustrate known methods for assessing inhibition of MMP7.

Cells, Tissues, Organs, and Non-Human Organisms

[0191] Cells, tissues, organs, and non-human organisms that include at least one of the MMP7 RNAi agents described herein are contemplated. The cell, tissue, organ, or non-human organism is made by delivering the RNAi agent to the cell, tissue, organ, or non-human organism.

Additional Illustrative Embodiments

[0192] Provided here are certain additional illustrative embodiments of the disclosed technology. These embodiments are illustrative only and do not limit the scope of the present disclosure or of the claims attached hereto.

[0193] Embodiment 1. An RNAi agent for inhibiting expression of a matrix metalloproteinase 7 gene, comprising:

an antisense strand comprising at least 17 contiguous nucleotides differing by 0 or 1 nucleotides from any one of the sequences provided in Table 2 or Table 3; and

a sense strand comprising a nucleotide sequence that is at least partially complementary to the antisense strand.

[0194] Embodiment 2. The RNAi agent of embodiment 1, wherein the antisense strand comprises nucleotides 2-18 of any one of the sequences provided in Table 2 or Table 3.

[0195] Embodiment 3. The RNAi agent of embodiment 1 or embodiment 2, wherein the sense strand comprises a nucleotide sequence of at least 17 contiguous nucleotides differing by 0 or 1 nucleotides from any one of the sequences provided in Table 2 or Table 4, and wherein the sense strand has a region of at least 85% complementarity over the 17 contiguous nucleotides to the antisense strand.

[0196] Embodiment 4. The RNAi agent of any one of embodiments 1-3, wherein at least one nucleotide of the MMP7 RNAi agent is a modified nucleotide or includes a modified internucleoside linkage.

[0197] Embodiment 5. The RNAi agent of any one of embodiments 1-4, wherein all or substantially all of the nucleotides are modified nucleotides.

[0198] Embodiment 6. The RNAi agent of any one of embodiments 4-5, wherein the modified nucleotide is selected from the group consisting of: 2'-O-methyl nucleotide, 2'-fluoro nucleotide, 2'-deoxy nucleotide, 2',3'-seco nucleotide mimic, locked nucleotide, 2'-F-arabino nucleotide, 2'-methoxyethyl nucleotide, abasic nucleotide,

ribitol, inverted nucleotide, inverted 2'-O-methyl nucleotide, inverted 2'-deoxy nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, vinyl phosphonate-containing nucleotide, cyclopropyl phosphonate-containing nucleotide, and 3'-O-methyl nucleotide.

- [0199] Embodiment 7. The RNAi agent of embodiment 5, wherein all or substantially all of the nucleotides are modified with 2'-O-methyl nucleotides, 2'-fluoro nucleotides, or combinations thereof.
- [0200] Embodiment 8. The RNAi agent of any one of embodiments 1-7, wherein the antisense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 3.
- [0201] Embodiment 9. The RNAi agent of any one of embodiments 1-8, wherein the sense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 4.
- [0202] Embodiment 10. The RNAi agent of embodiment 1, wherein the antisense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 3 and the sense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 4.
- [0203] Embodiment 11. The RNAi agent of any one of embodiments 1-10, wherein the sense strand is between 18 and 30 nucleotides in length, and the antisense strand is between 18 and 30 nucleotides in length.
- [0204] Embodiment 12. The RNAi agent of embodiment 11, wherein the sense strand and the antisense strand are each between 18 and 27 nucleotides in length.
- [0205] Embodiment 13. The RNAi agent of embodiment 12, wherein the sense strand and the antisense strand are each between 18 and 24 nucleotides in length.
- [0206] Embodiment 14. The RNAi agent of embodiment 13, wherein the sense strand and the antisense strand are each 21 nucleotides in length.
- [0207] Embodiment 15. The RNAi agent of embodiment 14, wherein the RNAi agent has two blunt ends.
- [0208] Embodiment 16. The RNAi agent of any one of embodiments 1-15, wherein the sense strand comprises one or two terminal caps.
- [0209] Embodiment 17. The RNAi agent of any one of embodiments 1-16, wherein the sense strand comprises one or two inverted abasic residues.

- [0210] Embodiment 18. The RNAi agent of embodiment 1, wherein the RNAi agent is comprised of a sense strand and an antisense strand that form a duplex having the structure of any one of the duplexes in Table 7A, Table 7B, Table 8, Table 9, or Table 10.
- [0211] Embodiment 19. The RNAi agent of embodiment 18, wherein all or substantially all of the nucleotides are modified nucleotides.
- [0212] Embodiment 20. The RNAi agent of embodiment 1, comprising an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):
- AGACAUUCAAAAACCAACU (SEQ ID NO:175);
UUGACACUAAUCGAUCCAC (SEQ ID NO:123);
UGACAUUCAAAAACCAACU (SEQ ID NO:176);
AGACAUUCAAAAACCAACUGC (SEQ ID NO:674);
UUGACACUAAUCGAUCCACUG (SEQ ID NO:661); or
UGACAUUCAAAAACCAACUGC (SEQ ID NO:679).
- [0213] Embodiment 21. The RNAi agent of embodiment 20, wherein the sense strand consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):
- AGUUGGUUUUUGAAUGUCU (SEQ ID NO:325);
GUGGAUCGAUUAGUGUCA (SEQ ID NO:273);
AGUUGGUUUUUGAAUGUCA (SEQ ID NO:326);
GCAGUUGGUUUUUGAAUGUCU (SEQ ID NO:720);
CAGUGGAUCGAUUAGUGUCA (SEQ ID NO:724); or
GCAGUUGGUUUUUGAAUGUCA (SEQ ID NO:726).
- [0214] Embodiment 22. The RNAi agent of embodiment 20 or 21, wherein all or substantially all of the nucleotides are modified nucleotides.
- [0215] Embodiment 23. The RNAi agent of embodiment 1, comprising an antisense strand that comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):

asGfsascauucAfaaAfaCfcAfacugsc (SEQ ID NO:396);
 usUfsgsacacUfaAfuCfGafuCfcacug (SEQ ID NO:393); or
 cPrpuGfacauucAfaaAfaCfcAfacugsc (SEQ ID NO:406);

wherein a, c, g, and u represent 2'-O-methyl adenosine, 2'-O-methyl cytidine, 2'-O-methyl guanosine, and 2'-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluoro adenosine, 2'-fluoro cytidine, 2'-fluoro guanosine, and 2'-fluoro uridine, respectively; cPrpu represents a 5'-cyclopropyl phosphonate-2'-O-methyl uridine; s represents a phosphorothioate linkage; and wherein all or substantially all of the nucleotides on the sense strand are modified nucleotides.

[0216] Embodiment 24. The RNAi agent of embodiment 1, wherein the sense strand comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):

gscaguuggUfuUfuUfgaaugucu (SEQ ID NO:522);
 csaguggauCfGafuUfagugucuaa (SEQ ID NO:524);
 gscaguuggUfuUfuUfgaauguca (SEQ ID NO:526);

wherein a, c, g, i, and u represent 2'-O-methyl adenosine, 2'-O-methyl cytidine, 2'-O-methyl guanosine, 2'-O-methyl inosine, and 2'-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluoro adenosine, 2'-fluoro cytidine, 2'-fluoro guanosine, and 2'-fluoro uridine, respectively; and s represents a phosphorothioate linkage; and wherein all or substantially all of the nucleotides on the antisense strand are modified nucleotides.

[0217] Embodiment 25. The RNAi agent of any one of embodiments 20-24, wherein the sense strand further includes inverted abasic residues at the 3' terminal end of the nucleotide sequence, at the 5' end of the nucleotide sequence, or at both.


[0218] Embodiment 26. The RNAi agent of any one of embodiments 1-25, wherein the RNAi agent is linked to a targeting ligand.

[0219] Embodiment 27. The RNAi agent of embodiment 26, wherein the targeting ligand has affinity for a cell receptor expressed on an epithelial cell.

[0220] Embodiment 28. The RNAi agent of embodiment 27, wherein the targeting ligand comprises an integrin targeting ligand.


[0221] Embodiment 29. The RNAi agent of embodiment 28, wherein the integrin targeting ligand is an $\alpha v \beta 6$ integrin targeting ligand.

[0222] Embodiment 30. The RNAi agent of embodiment 29, wherein the targeting ligand comprises the structure:



or a pharmaceutically acceptable salt

thereof, or





or a pharmaceutically acceptable salt


thereof,

wherein  indicates the point of connection to the RNAi agent.


[0223] Embodiment 31. The RNAi agent of any one of embodiments 26-29, wherein the targeting ligand has a structure selected from the group consisting of:











2













, and




, wherein --- indicates the point of connection to the RNAi agent.

[0224] Embodiment 32. The RNAi agent of embodiment 31, wherein RNAi agent is conjugated to a targeting ligand having the following structure:



[0225] Embodiment 33. The RNAi agent of any one of embodiments 26-29, wherein the targeting ligand has the following structure:



- [0226] Embodiment 34. The RNAi agent of any one of embodiments 26-33, wherein the targeting ligand is conjugated to the sense strand.
- [0227] Embodiment 35. The RNAi agent of embodiment 34, wherein the targeting ligand is conjugated to the 5' terminal end of the sense strand.
- [0228] Embodiment 36. A composition comprising the RNAi agent of any one of embodiments 1-35, wherein the composition further comprises a pharmaceutically acceptable excipient.
- [0229] Embodiment 37. The composition of embodiment 36, further comprising a second RNAi agent capable of inhibiting the expression of matrix metalloproteinase 7 gene expression.
- [0230] Embodiment 38. The composition of any one of embodiments 36-37, further comprising one or more additional therapeutics.
- [0231] Embodiment 39. The composition of any one of embodiments 36-38, wherein the composition is formulated for administration by inhalation.
- [0232] Embodiment 40. The composition of embodiment 39, wherein the composition is delivered by a metered-dose inhaler, jet nebulizer, vibrating mesh nebulizer, or soft mist inhaler.
- [0233] Embodiment 41. The composition of any of embodiments 36-40, wherein the RNAi agent is a sodium salt.
- [0234] Embodiment 42. The composition of any of embodiments 36-41, wherein the pharmaceutically acceptable excipient is water for injection.
- [0235] Embodiment 43. The composition of any of embodiments 36-41, wherein the pharmaceutically acceptable excipient is a buffered saline solution.
- [0236] Embodiment 44. A method for inhibiting expression of a MMP7 gene in a cell, the method comprising introducing into a cell an effective amount of an RNAi agent of any one of embodiments 1-33 or the composition of any one of embodiments 36-43.
- [0237] Embodiment 45. The method of embodiment 44, wherein the cell is within a subject.
- [0238] Embodiment 46. The method of embodiment 45, wherein the subject is a human subject.

- [0239] Embodiment 47. The method of any one of embodiments 44-46, wherein following the administration of the RNAi agent the matrix metalloproteinase 7 gene expression is inhibited by at least about 30%.
- [0240] Embodiment 48. A method of treating one or more symptoms or diseases associated with enhanced or elevated membrane MMP7 activity levels, the method comprising administering to a human subject in need thereof a therapeutically effective amount of the composition of any one of embodiments 36-43.
- [0241] Embodiment 49. The method of embodiment 48, wherein the disease is a respiratory or pulmonary disease.
- [0242] Embodiment 50. The method of embodiment 48, wherein the disease is selected from the group consisting of: idiopathic pulmonary fibrosis (IPF), another type of pulmonary fibrosis, asthma, chronic inflammation, interstitial lung diseases (ILD), SARS-COV-2 or another type of infectious disease in the airway, acute respiratory distress syndrome (ARDS) or another type of acute lung injury, pulmonary hypertension, lung cancer, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), fatty liver disease, biliary atresia, and chronic kidney disease (CKD).
- [0243] Embodiment 51. The method of embodiment 50, wherein the disease is idiopathic pulmonary fibrosis (IPF).
- [0244] Embodiment 54. The method of any one of embodiments 44-51, wherein the RNAi agent is administered at a deposited dose of about 0.01 mg/kg to about 5.0 mg/kg of body weight of the subject.
- [0245] Embodiment 55. The method of any one of embodiments 44-54, wherein the RNAi agent is administered at a deposited dose of about 0.03 mg/kg to about 2.0 mg/kg of body weight of the subject.
- [0246] Embodiment 56. The method of any one of embodiments 44-55, wherein the RNAi agent is administered in two or more doses.
- [0247] Embodiment 57. Use of the RNAi agent of any one of embodiments 1-35, for the treatment of a disease, disorder, or symptom that is mediated at least in part by membrane MMP7 activity and/or MMP7 gene expression.
- [0248] Embodiment 58. Use of the composition according to any one of embodiments 36-43, for the treatment of a disease, disorder, or symptom that is mediated at least in part

by matrix metallopeptidase 7 activity and/or matrix metallopeptidase 7 gene expression.

[0249] Embodiment 59. Use of the composition according to any one of embodiments 36-43, for the manufacture of a medicament for treatment of a disease, disorder, or symptom that is mediated at least in part by matrix metallopeptidase 7 and/or matrix metallopeptidase 7 gene expression.

[0250] Embodiment 60. The use of any one of embodiments 57-59, wherein the disease is pulmonary inflammation.

[0251] Embodiment 61. A method of making an RNAi agent of any one of embodiments 1-35, comprising annealing a sense strand and an antisense strand to form a double-stranded ribonucleic acid molecule.

[0252] Embodiment 62. The method of embodiment 61, wherein the sense strand comprises a targeting ligand.

[0253] Embodiment 63. The method of embodiment 62, comprising conjugating a targeting ligand to the sense strand.

[0254] The above provided embodiments and items are now illustrated with the following, non-limiting examples.

EXAMPLES

Example 1. Synthesis of MMP7 RNAi Agents.

[0256] MMP7 RNAi agent duplexes disclosed herein were synthesized in accordance with the following:

[0257] A. *Synthesis.* The sense and antisense strands of the MMP7 RNAi agents were synthesized according to phosphoramidite technology on solid phase used in oligonucleotide synthesis. Depending on the scale, a MerMade96E® (Bioautomation), a MerMade12® (Bioautomation), or an OP Pilot 100 (GE Healthcare) was used. Syntheses were performed on a solid support made of controlled pore glass (CPG, 500 Å or 600Å, obtained from Prime Synthesis, Aston, PA, USA). All RNA and 2'-modified RNA phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, WI, USA). Specifically, the 2'-O-methyl phosphoramidites that were used included the following: (5'-O-dimethoxytrityl-N⁶-(benzoyl)-2'-O-methyl-adenosine-3'-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, 5'-O-dimethoxy-trityl-N⁴-(acetyl)-2'-O-methyl-cytidine-3'-O-(2-cyanoethyl-N,N-diisopropyl-amino) phosphoramidite, (5'-O-dimethoxytrityl-N²-(isobutyryl)-2'-O-methyl-guanosine-3'-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, and 5'-O-dimethoxytrityl-2'-O-methyl-uridine-3'-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite. The 2'-deoxy-2'-fluoro-phosphoramidites carried the same protecting groups as the 2'-O-methyl RNA amidites. 5'-dimethoxytrityl-2'-O-methyl-inosine-3'-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidites were purchased from Glen Research (Virginia). The inverted abasic (3'-O-dimethoxytrityl-2'-deoxyribose-5'-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidites were purchased from ChemGenes (Wilmington, MA, USA). The following UNA phosphoramidites were used: 5'-(4,4'-Dimethoxytrityl)-N⁶-(benzoyl)-2',3'-seco-adenosine, 2'-benzoyl-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, 5'-(4,4'-Dimethoxytrityl)-N-acetyl-2',3'-seco-cytosine, 2'-benzoyl-3'-[(2-cyanoethyl)-(N,N-diiso-propyl)]-phosphoramidite, 5'-(4,4'-Dimethoxytrityl)-N-isobutyryl-2',3'-seco-guanosine, 2'-benzoyl-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, and 5'-(4,4'-Dimethoxy-trityl)-2',3'-seco-uridine, 2'-benzoyl-3'-[(2-cyanoethyl)-(N,N- diiso-propyl)]-phosphoramidite. TFA aminolink phosphoramidites were also commercially purchased (ThermoFisher). Linker L6 was purchased as propargyl-PEG5-NHS from BroadPharm (catalog # BP-20907) and coupled to the NH₂-C₆ group from an aminolink phosphoramidite to form -L6-C₆-, using standard coupling conditions. The linker Alk-

cyHex was similarly commercially purchased from Lumiprobe (alkyne phosphoramidite, 5'-terminal) as a propargyl-containing compound phosphoramidite compound to form the linker -Alk-cyHex-. In each case, phosphorothioate linkages were introduced as specified using the conditions set forth herein. The cyclopropyl phosphonate phosphoramidites were synthesized in accordance with International Patent Application Publication No. WO 2017/214112 (*see also* Altenhofer et. al., Chem. Communications (Royal Soc. Chem.), 57(55):6808-6811 (July 2021)).

[0258] Tri-alkyne-containing phosphoramidites were dissolved in anhydrous dichloromethane or anhydrous acetonitrile (50 mM), while all other amidites were dissolved in anhydrous acetonitrile (50 mM) and molecular sieves (3Å) were added. 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-Ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) was used as activator solution. Coupling times were 10 minutes (RNA), 90 seconds (2' O-Me), and 60 seconds (2' F). In order to introduce phosphorothioate linkages, a 100 mM solution of 3-phenyl 1,2,4-dithiazoline-5-one (POS, obtained from PolyOrg, Inc., Leominster, MA, USA) in anhydrous acetonitrile was employed.

[0259] Alternatively, tri-alkyne moieties were introduced post-synthetically (see section E, below). For this route, the sense strand was functionalized with a 5' and/or 3' terminal nucleotide containing a primary amine. TFA aminolink phosphoramidite was dissolved in anhydrous acetonitrile (50 mM) and molecular sieves (3Å) were added. 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-Ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) was used as activator solution. Coupling times were 10 minutes (RNA), 90 seconds (2' O-Me), and 60 seconds (2' F). In order to introduce phosphorothioate linkages, a 100 mM solution of 3-phenyl 1,2,4-dithiazoline-5-one (POS, obtained from PolyOrg, Inc., Leominster, MA, USA) in anhydrous acetonitrile was employed.


[0260] *B. Cleavage and deprotection of support bound oligomer.* After finalization of the solid phase synthesis, the dried solid support was treated with a 1:1 volume solution of 40 wt. % methylamine in water and 28% to 31% ammonium hydroxide solution (Aldrich) for 1.5 hours at 30°C. The solution was evaporated and the solid residue was reconstituted in water (see below).

[0261] *C. Purification.* Crude oligomers were purified by anionic exchange HPLC using a TSKgel SuperQ-5PW 13µm column and Shimadzu LC-8 system. Buffer A was 20 mM Tris, 5 mM EDTA, pH 9.0 and contained 20% Acetonitrile and buffer B was the same

as buffer A with the addition of 1.5 M sodium chloride. UV traces at 260 nm were recorded. Appropriate fractions were pooled then run on size exclusion HPLC using a GE Healthcare XK 16/40 column packed with Sephadex G-25 fine with a running buffer of 100mM ammonium bicarbonate, pH 6.7 and 20% Acetonitrile or filtered water. Alternatively, pooled fractions were desalted and exchanged into an appropriate buffer or solvent system via tangential flow filtration.

[0262] *D. Annealing.* Complementary strands were mixed by combining equimolar RNA solutions (sense and antisense) in 1× PBS (Phosphate-Buffered Saline, 1×, Corning, Cellgro) to form the RNAi agents. Some RNAi agents were lyophilized and stored at −15 to −25°C. Duplex concentration was determined by measuring the solution absorbance on a UV-Vis spectrometer in 1× PBS. The solution absorbance at 260 nm was then multiplied by a conversion factor (0.050 mg/(mL·cm)) and the dilution factor to determine the duplex concentration.

[0263] *E. Conjugation of Tri-alkyne linker.* In some embodiments a tri-alkyne linker is conjugated to the sense strand of the RNAi agent on resin as a phosphoramidite (see Example 1G for the synthesis of an example tri-alkyne linker phosphoramidite and Example 1A for the conjugation of the phosphoramidite.). In other embodiments, a tri-alkyne linker may be conjugated to the sense strand following cleavage from the resin, described as follows: either prior to or after annealing, in some embodiments, the 5' or 3' amine functionalized sense strand is conjugated to a tri-alkyne linker. An example tri-alkyne linker structure that can be used in forming the constructs disclosed herein is as




follows:

follows: . To conjugate the tri-alkyne linker to the annealed duplex, amine-functionalized duplex was dissolved in 90% DMSO/10% H₂O, at ~50-70 mg/mL. 40 equivalents triethylamine was added, followed by 3

equivalents tri-alkyne-PNP. Once complete, the conjugate was precipitated twice in a solvent system of 1x phosphate buffered saline/acetonitrile (1:14 ratio), and dried.

[0264] F. *Synthesis of Targeting Ligand SM6.1*


((S)-3-(4-(4-((14-azido-3,6,9,12-tetraoxatetradecyl)oxy)naphthalen-1-yl)phenyl)-3-(2-(4-((4-methylpyridin-2-yl)amino)butanamido)acetamido)propanoic acid)




[0265] Compound 5 (tert-Butyl(4-methylpyridin-2-yl)carbamate) (0.501 g, 2.406 mmol, 1 equiv.) was dissolved in DMF (17 mL). To the mixture was added NaH (0.116 mg, 3.01 mmol, 1.25 eq, 60 % dispersion in oil) The mixture stirred for 10 min before adding Compound 20 (Ethyl 4-Bromobutyrate (0.745 g, 3.82 mmol, 0.547 mL)) (Sigma 167118). After 3 hours the reaction was quenched with ethanol (18 mL) and concentrated. The concentrate was dissolved in DCM (50 mL) and washed with saturated aq. NaCl solution (1 x 50 mL), dried over Na₂SO₄, filtered and concentrated. The product was purified on silica column, gradient 0-5% Methanol in DCM.




[0266] Compound 21 was dissolved (0.80 g, 2.378 mmol) in 100 mL of Acetone : 0.1 M NaOH [1:1]. The reaction was monitored by TLC (5% ethyl acetate in hexane). The organics were concentrated away, and the residue was acidified to pH 3-4 with 0.3 M Citric Acid (40 mL). The product was extracted with DCM (3 x 75 mL). The organics were pooled, dried over Na₂SO₄, filtered and concentrated. The product was used without further purification.



[0267] To a solution of Compound 22 (1.1 g, 3.95 mmol, 1 equiv.), Compound 45 (595 mg, 4.74 mmol, 1.2 equiv.), and TBTU (1.52 g, 4.74 mmol, 1.2 equiv.) in anhydrous DMF (10 mL) was added diisopropylethylamine (2.06 mL, 11.85 mmol, 3 equiv.) at 0 °C. The reaction mixture was warmed to room temperature and stirred 3 hours. The reaction was quenched by saturated NaHCO₃ solution (10 mL). The aqueous phase was extracted with ethyl acetate (3 x 10 mL) and the organic phase was combined, dried over anhydrous Na₂SO₄, and concentrated. The product was separated by CombiFlash® using silica gel as the stationary phase. LC-MS: calculated [M+H]⁺ 366.20, found 367.




[0268] To a solution of compound 61 (2 g, 8.96 mmol, 1 equiv.), and compound 62 (2.13 mL, 17.93 mmol, 2 equiv.) in anhydrous DMF (10 mL) was added K₂CO₃ (2.48 g, 17.93 mmol, 2 equiv.) at 0 °C. The reaction mixture was warmed to room temperature and stirred overnight. The reaction was quenched by water (10 mL). The aqueous phase was extracted with ethyl acetate (3 x 10 mL) and the organic phase was combined, dried over anhydrous Na₂SO₄, and concentrated. The product was separated by CombiFlash® using silica gel as the stationary phase.




[0269] To a solution of compound 60 (1.77 g, 4.84 mmol, 1 equiv.) in THF (5 mL) and H₂O (5 mL) was added lithium hydroxide monohydrate (0.61 g, 14.53 mmol, 3 equiv.) portion-wise at 0 °C. The reaction mixture was warmed to room temperature. After stirring at room

temperature for 3 hours, the reaction mixture was acidified by HCl (6 N) to pH 3.0. The aqueous phase was extracted with ethyl acetate (3 x 20 mL) and the organic layer was combined, dried over Na₂SO₄, and concentrated. LC-MS: calculated [M+H]⁺ 352.18, found 352.




[0270] To a solution of compound 63 (1.88 g, 6.0 mmol, 1.0 equiv.) in anhydrous THF (20 mL) was added n-BuLi in hexane (3.6 mL, 9.0 mmol, 1.5 equiv.) drop-wise at -78 °C. The reaction was kept at -78 °C for another 1 hour. Triisopropylborate (2.08 mL, 9.0 mmol, 1.5 equiv.) was then added into the mixture at -78 °C. The reaction was then warmed up to room temperature and stirred for another 1 hour. The reaction was quenched by saturated NH₄Cl solution (20 mL) and the pH was adjusted to 3. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the organic phase was combined, dried over Na₂SO₄, and concentrated.




[0271] Compound 12 (300 mg, 0.837 mmol, 1.0 equiv.), Compound 65 (349 mg, 1.256 mmol, 1.5 equiv.), XPhos Pd G2 (13 mg, 0.0167 mmol, 0.02 equiv.), and K₃PO₄ (355 mg, 1.675 mmol, 2.0 equiv.) were mixed in a round-bottom flask. The flask was sealed with a screw-cap septum, and then evacuated and backfilled with nitrogen (this process was repeated a total of 3 times). Then, THF (8 mL) and water (2 mL) were added via syringe. The mixture was bubbled with nitrogen for 20 min and the reaction was kept at room

temperature for overnight. The reaction was quenched with water (10 mL), and the aqueous phase was extracted with ethyl acetate (3×10 mL). The organic phase was dried over Na_2SO_4 , concentrated, and purified via CombiFlash® using silica gel as the stationary phase and was eluted with 15% EtOAc in hexane. LC-MS: calculated $[\text{M}+\text{H}]^+$ 512.24, found 512.56.




[0272] Compound 66 (858 mg, 1.677 mmol, 1.0 equiv.) was cooled by ice bath. HCl in dioxane (8.4 mL, 33.54 mmol, 20 equiv.) was added into the flask. The reaction was warmed to room temperature and stirred for another 1 hr. The solvent was removed by rotary evaporator and the product was directly used without further purification. LC-MS: calculated $[\text{M}+\text{H}]^+$ 412.18, found 412.46.




[0273] To a solution of compound 64 (500 mg, 1.423 mmol, 1 equiv.), compound 67 (669 mg, 1.494 mmol, 1.05 equiv.), and TBTU (548 mg, 0.492 mmol, 1.2 equiv.) in anhydrous DMF (15 mL) was added diisopropylethylamine (0.744 mL, 4.268 mmol, 3 equiv.) at 0 °C. The reaction mixture was warmed to room temperature and stirred for another 1 hr. The reaction was quenched by saturated NaHCO_3 aqueous solution (10 mL) and the product was extracted with ethyl acetate (3×20 mL). The organic phase was combined, dried over


Na₂SO₄, and concentrated. The product was purified by CombiFlash® using silica gel as the stationary phase and was eluted with 3-4% methanol in DCM. The yield was 96.23%. LC-MS: calculated [M+H]⁺ 745.35, found 746.08.



[0274] To a solution of compound 68 (1.02 g, 1.369 mmol, 1 equiv.) in ethyl acetate (10 mL) was added 10% Pd/C (0.15 g, 50% H₂O) at room temperature. The reaction mixture was warmed to room temperature and the reaction was monitored by LC-MS. The reaction was kept at room temperature overnight. The solids were filtered through Celite® and the solvent was removed by rotary evaporator. The product was directly used without further purification. LC-MS: [M+H]⁺ 655.31, found 655.87.




[0275] To a solution of compound 69 (100 mg, 0.152 mmol, 1 equiv.) and azido-PEG₅-OTs (128 mg, 0.305 mmol, 2 equiv.) in anhydrous DMF (2 mL) was added K₂CO₃ (42 mg, 0.305 mmol, 2 equiv.) at 0 °C. The reaction mixture was stirred for 6 hours at 80 °C. The reaction was quenched by saturated NaHCO₃ solution and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The organic phase was combined, dried over Na₂SO₄, and concentrated. LC-MS: calculated [M+H]⁺ 900.40, found 901.46.



[0276] To a solution of compound 72 (59 mg, 0.0656 mmol, 1.0 equiv.) in THF (2 mL) and water (2 mL) was added lithium hydroxide (5 mg, 0.197 mmol, 3.0 equiv.) at room temperature. The mixture was stirred at room temperature for another 1 hr. The pH was adjusted to 3.0 by HCl (6N) and the aqueous phase was extracted with EtOAc (3 x 10 mL). The organic phase was combined, dried over Na₂SO₄, and concentrated. TFA (0.5 mL) and DCM (0.5 mL) was added into the residue and the mixture was stirred at room temperature for another 3 hr. The solvent was removed by rotary evaporator. LC-MS: calculated [M+H]⁺ 786.37, found 786.95.


[0277] *G. Synthesis of TriAlk 14*

[0278] TriAlk14 and (TriAlk14)s as shown in Table 11, above, may be synthesized using the synthetic route shown below. Compound 14 may be added to the sense strand as a phosphoramidite using standard oligonucleotide synthesis techniques, or compound 22 may be conjugated to the sense strand comprising an amine in an amide coupling reaction.




[0279] To a 3-L jacketed reactor was added 500 mL DCM and **4** (75.0 g, 0.16 mol). The internal temperature of the reaction was cooled to 0 °C and TBTU (170.0 g, 0.53 mol) was added. The suspension was then treated with the amine **5** (75.5 g, 0.53 mol) dropwise keeping the internal temperature less than 5 °C. The reaction was then treated with DIPEA (72.3 g, 0.56 mol) slowly, keeping the internal temperature less than 5 °C. After the addition was complete, the reaction was warmed up to 23 °C over 1 hour, and allowed to

stir for 3 hours. A 10% kicker charge of all three reagents were added and allowed to stir an additional 3 hours. The reaction was deemed complete when <1% of **4** remained. The reaction mixture was washed with saturated ammonium chloride solution (2 x 500 mL) and once with saturated sodium bicarbonate solution (500 mL). The organic layer was then dried over sodium sulfate and concentrated to an oil. The mass of the crude oil was 188 g which contained 72% **6** by QNMR. The crude oil was carried to the next step. Calculated mass for $C_{46}H_{60}N_4O_{11}$ = 845.0 m/z. Found $[M+H]^+$ = 846.0.




[0280] The 121.2 g of crude oil containing 72 wt% compound **6** (86.0 g, 0.10 mol) was dissolved in DMF (344 mL) and treated with TEA (86 mL, 20 v/v%), keeping the internal temperature below 23 °C. The formation of dibenzofulvene (DBF) relative to the consumption of Fmoc-amine **6** was monitored via HPLC method 1 (Figure 2) and the reaction was complete within 10 hours. To the solution was added glutaric anhydride (12.8 g, 0.11 mol) and the intermediate amine **7** was converted to compound **8** within 2 hours. Upon completion, the DMF and TEA were removed at 30 °C under reduced pressure resulting in 100 g of a crude oil. Due to the high solubility of compound **7** in water, an aqueous workup could not be used, and chromatography is the only way to remove DBF, TMU, and glutaric anhydride. The crude oil (75 g) was purified on a Teledyne ISCO Combi-flash® purification system in three portions. The crude oil (25 g) was loaded onto a 330 g silica column and eluted from 0 – 20% methanol/DCM over 30 minutes resulting

in 42 g of compound **8** (54% yield over 3 steps). Calculated mass for $C_{36}H_{55}N_4O_{12}$ = 736.4 m/z. Found $[M+H] = 737.0$.




[0281] Compound **8** (42.0 g, 0.057 mol) was co-stripped with 10 volumes of acetonitrile prior to use to remove any residual methanol from chromatography solvents. The oil was redissolved in DMF (210 mL) and cooled to 0 °C. The solution was treated with 4-nitrophenol (8.7 g, 0.063 mol) followed by EDC-hydrochloride (12.0 g, 0.063 mol) and found to reach completion within 10 hours. The solution was cooled to 0 °C and 10 volumes ethyl acetate was added followed by 10 volumes saturated ammonium chloride solution, keeping the internal temperature below 15 °C. The layers were allowed to separate and the ethyl acetate layer was washed with brine. The combined aqueous layers were extracted twice with 5 volumes ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated to an oil. The crude oil (55 g) was purified on a Teledyne ISCO Combi-Flash® purification system in three portions. The crude oil (25 g) was loaded onto a 330 g silica column and eluted from 0 – 10% methanol/DCM over 30 minutes resulting in 22 g of pure **9** (**Compound 22**) (50% yield). Calculated mass for $C_{42}H_{59}N_5O_{14}$ = 857.4 m/z. Found $[M+H] = 858.0$.



[0282] A solution of ester **9** (49.0 g, 57.1 mmol) and 6-amino-1-hexanol (7.36 g, 6.28 mmol) in dichloromethane (3 volumes) was treated with triethylamine (11.56g, 111.4

mmol) dropwise. The reaction was monitored by observing the disappearance of compound **9** on HPLC Method 1 and was found to be complete in 10 minutes. The crude reaction mixture was diluted with 5 volumes dichloromethane and washed with saturated ammonium chloride (5 volumes) and brine (5 volumes). The organic layer was dried over sodium sulfate and concentrated to an oil. The crude oil was purified on a Teledyne ISCO Combi-flash® purification system using a 330 g silica column. The 4-nitrophenol was eluted with 100% ethyl acetate and **10** was flushed from the column using 20% methanol/DCM resulting in a colorless oil (39 g, 81% yield). Calculated mass for $C_{42}H_{69}N_5O_{12}$ = 836.0 m/z. Found $[M+H] = 837.0$.



[0283] Alcohol **10** was co-stripped twice with 10 volumes of acetonitrile to remove any residual methanol from chromatography solvents and once more with dry dichloromethane (KF < 60 ppm) to remove trace water. The alcohol **10** (2.30 g, 2.8 mmol) was dissolved in 5 volumes dry dichloromethane (KF < 50 ppm) and treated with diisopropylammonium tetrazolide (188 mg, 1.1 mmol). The solution was cooled to 0 °C and treated with 2-cyanoethyl N,N,N',N'-tetraisopropylphosphoramidite (1.00 g, 3.3 mmol) dropwise. The solution was removed from ice-bath and stirred at 20 °C. The reaction was found to be complete within 3 – 6 hours. The reaction mixture was cooled to 0 °C and treated with 10 volumes of a 1:1 solution of saturated ammonium bicarbonate/brine and then warmed to ambient over 1 minute and allowed to stir an additional 3 minutes at 20 °C. The biphasic mixture was transferred to a separatory funnel and 10 volumes of dichloromethane was added. The organic layer was separated and washed with 10 volumes of saturated sodium bicarbonate solution to hydrolyze unreacted bis-phosphorous reagent. The organic layer was dried over sodium sulfate and concentrated to an oil resulting in 3.08 g of 94 wt% Compound 14. Calculated mass for C₅₁H₈₆N₇O₁₃P = 1035.6 m/z. Found [M+H] = 1036.

[0284] *H. Conjugation of Targeting Ligands.* Either prior to or after annealing, the 5' or 3' tridentate alkyne functionalized sense strand is conjugated to targeting ligands. The following example describes the conjugation of targeting ligands to the annealed duplex: Stock solutions of 0.5M Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), 0.5M of

Cu(II) sulfate pentahydrate ($\text{Cu(II)SO}_4 \cdot 5\text{H}_2\text{O}$) and 2M solution of sodium ascorbate were prepared in deionized water. A 75 mg/mL solution in DMSO of targeting ligand was made. In a 1.5 mL centrifuge tube containing tri-alkyne functionalized duplex (3mg, 75 μL , 40mg/mL in deionized water, $\sim 15,000$ g/mol), 25 μL of 1M Hepes pH 8.5 buffer is added. After vortexing, 35 μL of DMSO was added and the solution is vortexed. Targeting ligand was added to the reaction (6 equivalents/duplex, 2 equivalents/alkyne, $\sim 15\mu\text{L}$) and the solution is vortexed. Using pH paper, pH was checked and confirmed to be pH ~ 8 . In a separate 1.5 mL centrifuge tube, 50 μL of 0.5M THPTA was mixed with 10 μL of 0.5M $\text{Cu(II)SO}_4 \cdot 5\text{H}_2\text{O}$, vortexed, and incubated at room temp for 5 min. After 5 min, THPTA/Cu solution (7.2 μL , 6 equivalents 5:1 THPTA:Cu) was added to the reaction vial, and vortexed. Immediately afterwards, 2M ascorbate (5 μL , 50 equivalents per duplex, 16.7 per alkyne) was added to the reaction vial and vortexed. Once the reaction was complete (typically complete in 0.5-1h), the reaction was immediately purified by non-denaturing anion exchange chromatography.

Example 2. *MMP7-SEAP Mouse Model.*

[0285] To assess the potency of the RNAi agents, an *MMP7-SEAP* mouse model was used. Six to eight week old female C57BL/6 albino mice were transiently transfected *in vivo* with plasmid by hydrodynamic tail vein injection, administered at least 15 days prior to administration of an *MMP7* RNAi agent or control. The plasmid contains the *MMP7* cDNA sequence (GenBank NM_002423.5 (SEQ ID NO:1)) inserted into the 3' UTR of the SEAP (secreted human placental alkaline phosphatase) reporter gene. 50 μg of the plasmid containing the *MMP7* cDNA sequence in Ringer's Solution in a total volume of 10% of the animal's body weight was injected into mice via the tail vein to create *MMP7-SEAP* model mice. The solution was injected through a 27-gauge needle in 5-7 seconds as previously described (Zhang G et al., "High levels of foreign gene expression in hepatocytes after tail vein injection of naked plasmid DNA." Human Gene Therapy 1999 Vol. 10, p1735-1737.). Inhibition of expression of *MMP7* by an *MMP7* RNAi agent results in concomitant inhibition of SEAP expression, which is measured by the Phospha-Light™ SEAP Reporter Gene Assay System (Invitrogen). Prior to treatment, SEAP expression levels in serum were measured and the mice were grouped according to average SEAP levels.

Analyses: SEAP levels may be measured at various times, both before and after administration of *MMP7* RNAi agents.

i) Serum collection: Mice were anesthetized with 2-3% isoflurane and blood samples were collected from the submandibular area into serum separation tubes (Sarstedt AG & Co., Nümbrecht, Germany). Blood was allowed to coagulate at ambient temperature for 20 min. The tubes were centrifuged at 8,000 ×g for 3 min to separate the serum and stored at 4°C.

ii) Serum SEAP levels: Serum was collected and measured by the Phospha-Light™ SEAP Reporter Gene Assay System (Invitrogen) according to the manufacturer's instructions. Serum SEAP levels for each animal was normalized to the control group of mice injected with saline in order to account for the non-treatment related decline in *MMP7* expression with this model. First, the SEAP level for each animal at a time point was divided by the pre-treatment level of expression in that animal ("pre-treatment") in order to determine the ratio of expression "normalized to pre-treatment". Expression at a specific time point was then normalized to the control group by dividing the "normalized to pre-treatment" ratio for an individual animal by the average "normalized to pre-treatment" ratio of all mice in the normal saline control group. Alternatively, in some Examples set forth herein, the serum SEAP levels for each animal were assessed by normalizing to pre-treatment levels only.

Example 3. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0286] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 µl per 20g body weight containing either 3.0 mg/kg (mpk) of an *MMP7* RNAi agent or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 12.

[0287] **Table 12.** *MMP7* RNAi Agent and Dosing for Example 3

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 3.0 mg/kg AD08797	Single injection on day 1
Group 3 3.0 mg/kg AD08798	Single injection on day 1

Group 4 3.0 mg/kg AD08801	Single injection on day 1
Group 5 3.0 mg/kg AD08802	Single injection on day 1
Group 6 3.0 mg/kg AD08803	Single injection on day 1
Group 7 3.0 mg/kg AD08804	Single injection on day 1
Group 8 3.0 mg/kg AD08805	Single injection on day 1
Group 9 3.0 mg/kg AD08815	Single injection on day 1
Group 10 3.0 mg/kg AD08816	Single injection on day 1
Group 11 3.0 mg/kg AD08823	Single injection on day 1

[0288] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 13, with Average SEAP reflecting the normalized average value of SEAP:

Table 13. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 3.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.509	1.000	0.414
Group 2 3.0 mg/kg AD08797	0.217	0.044	0.187	0.112
Group 3 3.0 mg/kg AD08798	0.259	0.070	0.189	0.048
Group 4 3.0 mg/kg AD08801	0.265	0.073	0.401	0.155
Group 5 3.0 mg/kg AD08802	0.237	0.036	0.216	0.082
Group 6 3.0 mg/kg AD08803	0.125	0.044	0.104	0.070
Group 7 3.0 mg/kg AD08804	0.227	0.103	0.195	0.063
Group 8 3.0 mg/kg AD08805	0.145	0.098	0.129	0.143
Group 9 3.0 mg/kg AD08815	0.150	0.014	0.069	0.028
Group 10 3.0 mg/kg AD08816	0.643	0.716	0.288	0.119
Group 11 3.0 mg/kg AD08823	0.129	0.026	0.075	0.030

	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.581	1.000	0.464
Group 2 3.0 mg/kg AD08797	0.221	0.021	0.381	0.082
Group 3 3.0 mg/kg AD08798	0.227	0.066	0.377	0.170
Group 4 3.0 mg/kg AD08801	0.434	0.109	0.577	0.108
Group 5 3.0 mg/kg AD08802	0.220	0.082	0.279	0.136
Group 6 3.0 mg/kg AD08803	0.075	0.050	0.081	0.039
Group 7 3.0 mg/kg AD08804	0.169	0.034	0.299	0.083
Group 8 3.0 mg/kg AD08805	0.223	0.317	0.414	0.568
Group 9 3.0 mg/kg AD08815	0.057	0.028	0.111	0.068
Group 10 3.0 mg/kg AD08816	0.247	0.075	0.375	0.212
Group 11 3.0 mg/kg AD08823	0.092	0.070	0.093	0.089

[0289] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 11) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 4. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0290] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 3.0 mg/kg (mpk) of an *MMP7* RNAi agent or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 14.

[0291] **Table 14.** *MMP7* RNAi Agent and Dosing for Example 4.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 3.0 mg/kg AD08799	Single injection on day 1
Group 3 3.0 mg/kg AD08800	Single injection on day 1
Group 4 3.0 mg/kg AD08806	Single injection on day 1
Group 5 3.0 mg/kg AD08807	Single injection on day 1

Group 6 3.0 mg/kg AD08808	Single injection on day 1
Group 7 3.0 mg/kg AD08813	Single injection on day 1
Group 8 3.0 mg/kg AD08814	Single injection on day 1
Group 9 3.0 mg/kg AD08817	Single injection on day 1
Group 10 3.0 mg/kg AD08818	Single injection on day 1

[0292] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 15, with Average SEAP reflecting the normalized average value of SEAP:

Table 15. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 4.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.112	1.000	0.402
Group 2 3.0 mg/kg AD08799	0.300	0.054	0.731	0.182
Group 3 3.0 mg/kg AD08800	0.208	0.079	0.237	0.165
Group 4 3.0 mg/kg AD08806	0.215	0.063	0.282	0.173
Group 5 3.0 mg/kg AD08807	0.168	0.060	0.166	0.099
Group 6 3.0 mg/kg AD08808	0.143	0.042	0.143	0.111
Group 7 3.0 mg/kg AD08813	0.192	0.072	0.088	0.029
Group 8 3.0 mg/kg AD08814	0.154	0.060	0.339	0.152
Group 9 3.0 mg/kg AD08817	0.430	0.097	0.369	0.206
Group 10 3.0 mg/kg AD08818	0.160	0.073	0.127	0.043
Group ID	Day 22		Day 29	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.323	1.000	0.364

Group 2 3.0 mg/kg AD08799	0.818	0.164	0.730	0.279
Group 3 3.0 mg/kg AD08800	0.194	0.130	0.384	0.240
Group 4 3.0 mg/kg AD08806	0.454	0.378	0.502	0.424
Group 5 3.0 mg/kg AD08807	0.155	0.074	0.287	0.137
Group 6 3.0 mg/kg AD08808	0.116	0.106	0.192	0.171
Group 7 3.0 mg/kg AD08813	0.077	0.053	0.151	0.113
Group 8 3.0 mg/kg AD08814	0.307	0.139	0.463	0.356
Group 9 3.0 mg/kg AD08817	0.313	0.085	0.456	0.138
Group 10 3.0 mg/kg AD08818	0.087	0.047	0.148	0.086

[0293] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 10) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 5. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0294] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 3.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1 mpk of an *MMP7* RNAi agent, 0.3 mpk an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 16.

[0295] **Table 16.** *MMP7* RNAi Agent and Dosing for Example 5.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 3.0 mg/kg AD08809	Single injection on day 1
Group 3 3.0 mg/kg AD08811	Single injection on day 1
Group 4 3.0 mg/kg AD08812	Single injection on day 1
Group 5 3.0 mg/kg AD08819	Single injection on day 1
Group 6 3.0 mg/kg AD08820	Single injection on day 1
Group 7 3.0 mg/kg AD08821	Single injection on day 1
Group 8 3.0 mg/kg AD08822	Single injection on day 1
Group 9 3.0 mg/kg AD08815	Single injection on day 1

Group 10 1.0 mg/kg AD08815	Single injection on day 1
Group 11 0.3 mg/kg AD08815	Single injection on day 1

[0296] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 17, with Average SEAP reflecting the normalized average value of SEAP:

Table 17. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 5.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.264	1.000	0.478
Group 2 3.0 mg/kg AD08809	0.807	0.283	0.853	0.441
Group 3 3.0 mg/kg AD08811	0.177	0.046	0.111	0.076
Group 4 3.0 mg/kg AD08812	0.704	0.342	0.567	0.143
Group 5 3.0 mg/kg AD08819	0.549	0.079	0.405	0.083
Group 6 3.0 mg/kg AD08820	0.133	0.022	0.046	0.020
Group 7 3.0 mg/kg AD08821	0.148	0.061	0.051	0.028
Group 8 3.0 mg/kg AD08822	0.111	0.025	0.048	0.018
Group 9 3.0 mg/kg AD08815	0.193	0.043	0.097	0.043
Group 10 1.0 mg/kg AD08815	0.630	0.139	0.299	0.087
Group 11 0.3 mg/kg AD08815	0.789	0.185	0.493	0.157
Group ID	Day 22		Day 29	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.556	1.000	0.398
Group 2 3.0 mg/kg AD08809	0.797	0.396	0.920	0.517
Group 3 3.0 mg/kg AD08811	0.118	0.099	0.202	0.137

Group 4 3.0 mg/kg AD08812	0.994	0.384	0.565	0.079
Group 5 3.0 mg/kg AD08819	0.375	0.045	0.652	0.148
Group 6 3.0 mg/kg AD08820	0.040	0.022	0.087	0.065
Group 7 3.0 mg/kg AD08821	0.038	0.025	0.050	0.023
Group 8 3.0 mg/kg AD08822	0.038	0.016	0.085	0.030
Group 9 3.0 mg/kg AD08815	0.078	0.030	0.156	0.065
Group 10 1.0 mg/kg AD08815	0.395	0.074	0.650	0.179
Group 11 0.3 mg/kg AD08815	0.625	0.152	0.819	0.291

[0297] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 11) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 6. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0298] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 2.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 18.

[0299] **Table 18.** *MMP7* RNAi Agent and Dosing for Example 5.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 2.0 mg/kg AD08815	Single injection on day 1
Group 3 1.0 mg/kg AD08815	Single injection on day 1
Group 4 2.0 mg/kg AD08823	Single injection on day 1
Group 5 1.0 mg/kg AD08823	Single injection on day 1
Group 6 2.0 mg/kg AD08803	Single injection on day 1
Group 7 1.0 mg/kg AD08803	Single injection on day 1

[0300] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The

injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each of groups 1-6 were tested (n=4), and three (3) mice were tested in group 7 (n=3.) Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 19, with Average SEAP reflecting the normalized average value of SEAP:

Table 19. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 6.

	Day 8		Day 15	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.637	1.000	0.354
Group 2 2.0 mg/kg AD08815	0.261	0.086	0.169	0.099
Group 3 1.0 mg/kg AD08815	0.307	0.198	0.435	0.277
Group 4 2.0 mg/kg AD08823	0.230	0.172	0.140	0.042
Group 5 1.0 mg/kg AD08823	0.543	0.250	0.266	0.079
Group 6 2.0 mg/kg AD08803	0.617	0.294	0.204	0.109
Group 7 1.0 mg/kg AD08803	0.320	0.145	0.283	0.063
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.235	1.000	0.302
Group 2 2.0 mg/kg AD08815	0.157	0.143	0.256	0.092
Group 3 1.0 mg/kg AD08815	0.343	0.171	0.522	0.233
Group 4 2.0 mg/kg AD08823	0.212	N/A*	0.294	0.155
Group 5 1.0 mg/kg AD08823	0.291	0.107	0.502	0.205
Group 6 2.0 mg/kg AD08803	0.087	0.042	0.179	0.092
Group 7 1.0 mg/kg AD08803	0.309	0.371	0.211	N/A*

*Only one mouse from the group was tested on the indicated day.

[0301] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 7) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 7. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0302] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 2.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1.0 mpk of an *MMP7* RNAi agent, 0.5 mpk an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 20.

[0303] **Table 20.** MMP7 RNAi Agent and Dosing for Example 7.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 2.0 mg/kg AD08808	Single injection on day 1
Group 3 1.0 mg/kg AD08808	Single injection on day 1
Group 4 0.5 mg/kg AD08808	Single injection on day 1
Group 5 2.0 mg/kg AD08818	Single injection on day 1
Group 6 1.0 mg/kg AD08818	Single injection on day 1
Group 7 0.5 mg/kg AD08818	Single injection on day 1

[0304] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 21, with Average SEAP reflecting the normalized average value of SEAP:

Table 21. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 7.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.199	1.000	0.169
Group 2 2.0 mg/kg AD08808	0.281	0.137	0.373	0.417
Group 3 1.0 mg/kg AD08808	0.432	0.087	0.547	0.191
Group 4 0.5 mg/kg AD08808	0.646	0.331	0.589	0.217

Group 5 2.0 mg/kg AD08818	0.403	0.158	0.462	0.442
Group 6 1.0 mg/kg AD08818	0.793	0.229	0.623	0.256
Group 7 0.5 mg/kg AD08818	0.649	0.092	0.669	0.266
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.229	1.000	0.135
Group 2 2.0 mg/kg AD08808	0.056	0.020	0.049	N/A*
Group 3 1.0 mg/kg AD08808	0.355	0.176	0.434	0.080
Group 4 0.5 mg/kg AD08808	0.649	0.559	0.639	0.102
Group 5 2.0 mg/kg AD08818	0.286	0.294	0.298	0.313
Group 6 1.0 mg/kg AD08818	0.485	0.102	0.404	0.243
Group 7 0.5 mg/kg AD08818	0.531	0.271	0.845	0.635

*Only one mouse was tested on this day.

[0305] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 7) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 8. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0306] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 2.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 22.

[0307] **Table 22.** *MMP7* RNAi Agent and Dosing for Example 8.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 2.0 mg/kg AD08813	Single injection on day 1
Group 3 1.0 mg/kg AD08813	Single injection on day 1
Group 4 2.0 mg/kg AD08811	Single injection on day 1
Group 5 1.0 mg/kg AD08811	Single injection on day 1

Group 6 2.0 mg/kg AD08820	Single injection on day 1
Group 7 1.0 mg/kg AD08820	Single injection on day 1
Group 8 2.0 mg/kg AD08821	Single injection on day 1
Group 9 1.0 mg/kg AD08821	Single injection on day 1
Group 10 2.0 mg/kg AD08822	Single injection on day 1
Group 11 1.0 mg/kg AD08822	Single injection on day 1

[0308] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 23, with Average SEAP reflecting the normalized average value of SEAP:

Table 23. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 8.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.270	1.000	0.275
Group 2 2.0 mg/kg AD08813	0.268	0.129	0.102	0.023
Group 3 1.0 mg/kg AD08813	0.485	0.139	0.447	0.181
Group 4 2.0 mg/kg AD08811	0.158	0.063	0.121	0.066
Group 5 1.0 mg/kg AD08811	0.223	0.079	0.277	0.135
Group 6 2.0 mg/kg AD08820	0.134	0.054	ND**	ND**
Group 7 1.0 mg/kg AD08820	0.282	0.151	0.138	0.084
Group 8 2.0 mg/kg AD08821	0.124	0.079	0.036	N/A*
Group 9 1.0 mg/kg AD08821	0.607	0.226	0.121	0.061
Group 10 2.0 mg/kg AD08822	0.860	0.320	0.058	N/A*
Group 11 1.0 mg/kg AD08822	0.558	0.193	0.194	0.099
	Day 22		Day 29	

Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.408	1.000	0.388
Group 2 2.0 mg/kg AD08813	0.137	0.089	0.168	0.060
Group 3 1.0 mg/kg AD08813	0.355	0.133	0.338	0.095
Group 4 2.0 mg/kg AD08811	0.177	0.072	0.249	0.083
Group 5 1.0 mg/kg AD08811	0.311	0.086	0.417	0.170
Group 6 2.0 mg/kg AD08820	0.024	0.026	0.055	0.036
Group 7 1.0 mg/kg AD08820	0.110	0.060	0.195	0.062
Group 8 2.0 mg/kg AD08821	0.028	N/A*	0.084	N/A*
Group 9 1.0 mg/kg AD08821	0.172	0.051	0.143	0.116
Group 10 2.0 mg/kg AD08822	0.093	0.030	0.082	N/A*
Group 11 1.0 mg/kg AD08822	0.131	0.047	0.319	0.125

*Only one mouse was tested on the day indicated **No mice were tested on the day indicated

[0309] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 11) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 9. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0310] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.5 mg/kg (mpk) of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 24.

[0311] **Table 24.** *MMP7* RNAi Agent and Dosing for Example 9.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.5 mg/kg AD08815	Single injection on day 1
Group 3 1.5 mg/kg AD09243	Single injection on day 1
Group 4 1.5 mg/kg AD09244	Single injection on day 1
Group 5 1.5 mg/kg AD09245	Single injection on day 1

Group 6 1.5 mg/kg AD09246	Single injection on day 1
Group 7 1.5 mg/kg AD09247	Single injection on day 1
Group 8 1.5 mg/kg AD09248	Single injection on day 1

[0312] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 25, with Average SEAP reflecting the normalized average value of SEAP:

Table 25. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 8.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.440	1.000	0.145
Group 2 1.5 mg/kg AD08815	0.569	0.186	0.152	0.065
Group 3 1.5 mg/kg AD09243	0.282	0.154	0.075	0.049
Group 4 1.5 mg/kg AD09244	0.535	0.169	0.270	0.122
Group 5 1.5 mg/kg AD09245	0.659	0.190	0.211	0.140
Group 6 1.5 mg/kg AD09246	0.528	0.100	0.199	0.110
Group 7 1.5 mg/kg AD09247	0.613	0.227	0.269	0.086
Group 8 1.5 mg/kg AD09248	1.047**	1.439	0.259	0.079
Group ID	Day 22		Day 29	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.436	1.000	0.530
Group 2 1.5 mg/kg AD08815	0.195	0.071	0.576	0.425
Group 3 1.5 mg/kg AD09243	0.095	N/A*	0.400	0.291
Group 4 1.5 mg/kg AD09244	0.203	0.147	0.479	0.357
Group 5 1.5 mg/kg AD09245	0.161	0.012	0.406	0.278

Group 6 1.5 mg/kg AD09246	0.190	0.167	0.426	0.258
Group 7 1.5 mg/kg AD09247	0.233	0.106	0.359	0.122
Group 8 1.5 mg/kg AD09248	0.280	0.192	0.411	0.136

*Only one mouse was tested on the day indicated **On Day 8, one animal in group 8 had a high signal

[0313] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 8) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points (with the exception of Group 8 on day 8), which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 10. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0314] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 2.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 26.

[0315] **Table 26.** *MMP7* RNAi Agent and Dosing for Example 10.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 2.0 mg/kg AD08815	Single injection on day 1
Group 3 1.0 mg/kg AD08815	Single injection on day 1
Group 4 2.0 mg/kg AD08821	Single injection on day 1
Group 5 1.0 mg/kg AD08821	Single injection on day 1
Group 6 2.0 mg/kg AD08808	Single injection on day 1
Group 7 1.0 mg/kg AD08808	Single injection on day 1
Group 8 2.0 mg/kg AD08813	Single injection on day 1
Group 9 1.0 mg/kg AD08813	Single injection on day 1

[0316] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested

(n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 27, with Average SEAP reflecting the normalized average value of SEAP:

Table 27. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 10.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.468	1.000	0.469
Group 2 2.0 mg/kg AD08815	0.170	0.102	0.177	0.195
Group 3 1.0 mg/kg AD08815	0.365	0.193	0.330	0.161
Group 4 2.0 mg/kg AD08821	0.109	0.054	0.069	0.061
Group 5 1.0 mg/kg AD08821	0.134	0.045	0.115	0.046
Group 6 2.0 mg/kg AD08808	0.115	0.034	0.107	0.023
Group 7 1.0 mg/kg AD08808	0.178	0.057	0.209	0.130
Group 8 2.0 mg/kg AD08813	0.167	0.047	0.108	0.065
Group 9 1.0 mg/kg AD08813	0.224	0.028	0.190	0.091
Group ID	Day 22		Day 29	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.300	1.000	0.297
Group 2 2.0 mg/kg AD08815	0.158	0.131	0.226	0.232
Group 3 1.0 mg/kg AD08815	0.439	0.277	0.457	0.383
Group 4 2.0 mg/kg AD08821	0.095	0.074	0.110	0.092
Group 5 1.0 mg/kg AD08821	0.289	0.259	0.412	0.331
Group 6 2.0 mg/kg AD08808	0.179	0.077	0.373	0.294
Group 7 1.0 mg/kg AD08808	0.299	0.124	0.397	0.201
Group 8 2.0 mg/kg AD08813	0.133	0.083	0.244	0.217
Group 9 1.0 mg/kg AD08813	0.324	0.149	0.360	0.134

[0317] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 9) showed reduction in SEAP as compared to the saline control (Group 1) across all

measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 11. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0318] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 28.

[0319] **Table 28.** *MMP7* RNAi Agent and Dosing for Example 11.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD08808	Single injection on day 1
Group 3 1.0 mg/kg AD09330	Single injection on day 1
Group 4 1.0 mg/kg AD09331	Single injection on day 1
Group 5 1.0 mg/kg AD09332	Single injection on day 1
Group 6 1.0 mg/kg AD09333	Single injection on day 1
Group 7 1.0 mg/kg AD08821	Single injection on day 1
Group 8 1.0 mg/kg AD09349	Single injection on day 1
Group 9 1.0 mg/kg AD09350	Single injection on day 1
Group 10 1.0 mg/kg AD09351	Single injection on day 1
Group 11 1.0 mg/kg AD09352	Single injection on day 1

[0320] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 29, with Average SEAP reflecting the normalized average value of SEAP:

Table 29. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 11.

	Day 8		Day 15	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.440	1.000	0.419
Group 2 1.0 mg/kg AD08808	0.756	0.932	0.745	0.928
Group 3 1.0 mg/kg AD09330	0.457	0.186	0.444	0.178
Group 4 1.0 mg/kg AD09331	0.475	0.193	0.470	0.191
Group 5 1.0 mg/kg AD09332	0.380	0.198	0.367	0.184
Group 6 1.0 mg/kg AD09333	0.357	0.142	0.384	0.165
Group 7 1.0 mg/kg AD08821	0.304	0.110	0.314	0.110
Group 8 1.0 mg/kg AD09349	0.258	0.117	0.261	0.117
Group 9 1.0 mg/kg AD09350	0.362	0.082	0.365	0.079
Group 10 1.0 mg/kg AD09351	0.419	0.260	0.407	0.242
Group 11 1.0 mg/kg AD09352	0.281	0.049	0.281	0.031
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.345	1.000	0.415
Group 2 1.0 mg/kg AD08808	0.569	0.538	0.534	0.485
Group 3 1.0 mg/kg AD09330	0.361	0.155	0.408	0.188
Group 4 1.0 mg/kg AD09331	0.310	0.124	0.299	0.139
Group 5 1.0 mg/kg AD09332	0.323	0.208	0.348	0.206
Group 6 1.0 mg/kg AD09333	0.329	0.165	0.243	0.112
Group 7 1.0 mg/kg AD08821	0.257	0.173	0.304	0.219
Group 8 1.0 mg/kg AD09349	0.276	0.260	0.152	0.147
Group 9 1.0 mg/kg AD09350	0.300	0.092	0.134	0.030
Group 10 1.0 mg/kg AD09351	0.307	0.215	0.327	0.298
Group 11 1.0 mg/kg AD09352	0.212	0.078	0.173	0.058

[0321] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 11) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 12. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0322] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 30.

[0323] **Table 30.** MMP7 RNAi Agent and Dosing for Example 12.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD08813	Single injection on day 1
Group 3 1.0 mg/kg AD09334	Single injection on day 1
Group 4 1.0 mg/kg AD09335	Single injection on day 1
Group 5 1.0 mg/kg AD09336	Single injection on day 1
Group 6 1.0 mg/kg AD09337	Single injection on day 1
Group 7 1.0 mg/kg AD08811	Single injection on day 1
Group 8 1.0 mg/kg AD09354	Single injection on day 1
Group 9 1.0 mg/kg AD09355	Single injection on day 1
Group 10 1.0 mg/kg AD09356	Single injection on day 1
Group 11 1.0 mg/kg AD09357	Single injection on day 1
Group 12 1.0 mg/kg AD09358	Single injection on day 1

[0324] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, and day 22, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 31, with Average SEAP reflecting the normalized average value of SEAP:

Table 31. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 12.

	Day 8	Day 15

Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.303	1.000	0.313
Group 2 1.0 mg/kg AD08813	0.889	0.357	0.342	0.166
Group 3 1.0 mg/kg AD09334	0.924	0.368	0.587	0.256
Group 4 1.0 mg/kg AD09335	0.869	0.269	0.680	0.414
Group 5 1.0 mg/kg AD09336	0.826	0.233	0.468	0.146
Group 6 1.0 mg/kg AD09337	0.850	0.176	0.483	0.195
Group 7 1.0 mg/kg AD08811	0.454	0.147	0.249	0.185
Group 8 1.0 mg/kg AD09354	0.833	0.353	0.678	0.349
Group 9 1.0 mg/kg AD09355	0.715	0.174	0.485	0.191
Group 10 1.0 mg/kg AD09356	1.182	0.280	0.428	0.351
Group 11 1.0 mg/kg AD09357	0.897	0.384	0.491	0.224
Group 12 1.0 mg/kg AD09358	0.701	0.237	0.465	0.126
Day 22				
Group ID	Avg SEAP	Std Dev (+/-)		
Group 1 (Saline)	1.000	0.460		
Group 2 1.0 mg/kg AD08813	0.495	0.322		
Group 3 1.0 mg/kg AD09334	0.574	0.266		
Group 4 1.0 mg/kg AD09335	0.563	0.335		
Group 5 1.0 mg/kg AD09336	0.721	0.282		
Group 6 1.0 mg/kg AD09337	0.603	0.300		
Group 7 1.0 mg/kg AD08811	0.982	0.517		
Group 8 1.0 mg/kg AD09354	0.386	0.268		
Group 9 1.0 mg/kg AD09355	0.615	0.152		
Group 10 1.0 mg/kg AD09356	1.188	0.560		
Group 11 1.0 mg/kg AD09357	0.862	0.427		
Group 12 1.0 mg/kg AD09358	0.828	0.248		

[0325] Each of the *MMP7* RNAi agents in each of the dosing groups except for Group 10 (i.e., Groups 2 through 9 and 11 and 12) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 13. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0326] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 32.

[0327] **Table 32.** MMP7 RNAi Agent and Dosing for Example 13.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD08803	Single injection on day 1
Group 3 1.0 mg/kg AD09441	Single injection on day 1
Group 4 1.0 mg/kg AD09442	Single injection on day 1
Group 5 1.0 mg/kg AD09443	Single injection on day 1
Group 6 1.0 mg/kg AD09444	Single injection on day 1
Group 7 1.0 mg/kg AD08823	Single injection on day 1
Group 8 1.0 mg/kg AD09445	Single injection on day 1
Group 9 1.0 mg/kg AD09446	Single injection on day 1
Group 10 1.0 mg/kg AD09447	Single injection on day 1
Group 11 1.0 mg/kg AD09448	Single injection on day 1

[0328] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 33, with Average SEAP reflecting the normalized average value of SEAP:

Table 33. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 13.

	Day 8	Day 15

Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.210	1.000	0.188
Group 2 1.0 mg/kg AD08803	0.383	0.125	0.387	0.143
Group 3 1.0 mg/kg AD09441	0.785	0.192	0.695	0.185
Group 4 1.0 mg/kg AD09442	0.780	0.285	0.820	0.321
Group 5 1.0 mg/kg AD09443	0.749	0.353	0.733	0.493
Group 6 1.0 mg/kg AD09444	0.451	0.208	0.342	0.094
Group 7 1.0 mg/kg AD08823	0.249	0.064	0.189	0.079
Group 8 1.0 mg/kg AD09445	0.260	0.095	0.135	0.103
Group 9 1.0 mg/kg AD09446	0.162	0.056	0.162	0.086
Group 10 1.0 mg/kg AD09447	0.177	0.030	0.126	0.049
Group 11 1.0 mg/kg AD09448	0.360	0.139	0.273	0.126
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.376	1.000	0.429
Group 2 1.0 mg/kg AD08803	0.418	0.101	ND*	ND*
Group 3 1.0 mg/kg AD09441	0.826	0.393	ND*	ND*
Group 4 1.0 mg/kg AD09442	1.186	0.656	ND*	ND*
Group 5 1.0 mg/kg AD09443	0.940	0.656	ND*	ND*
Group 6 1.0 mg/kg AD09444	0.568	0.230	ND*	ND*
Group 7 1.0 mg/kg AD08823	0.295	0.169	0.655	0.373
Group 8 1.0 mg/kg AD09445	0.307	0.262	0.519	0.397
Group 9 1.0 mg/kg AD09446	0.173	0.113	0.338	0.238
Group 10 1.0 mg/kg AD09447	0.182	0.061	0.299	0.081
Group 11 1.0 mg/kg AD09448	0.545	0.352	0.699	0.384

*Mice from Groups 2-6 were euthanized prior to day 29

[0329] Each of the *MMP7* RNAi agents in each of the dosing groups, except for Group 4 on day 22 (i.e., Groups 2, 3 and 5 through 11), showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 14. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0330] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 3.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1.0 mpk of an *MMP7* RNAi agent, 0.3 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 34.

[0331] **Table 34.** *MMP7* RNAi Agent and Dosing for Example 14.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 0.3 mg/kg AD08821	Single injection on day 1
Group 3 1.0 mg/kg AD08821	Single injection on day 1
Group 4 3.0 mg/kg AD08821	Single injection on day 1
Group 5 0.3 mg/kg AD09350	Single injection on day 1
Group 6 1.0 mg/kg AD09350	Single injection on day 1
Group 7 3.0 mg/kg AD09350	Single injection on day 1
Group 8 0.3 mg/kg AD09352	Single injection on day 1
Group 9 1.0 mg/kg AD09352	Single injection on day 1
Group 10 3.0 mg/kg AD09352	Single injection on day 1

[0332] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 35, with Average SEAP reflecting the normalized average value of SEAP:

Table 35. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 14.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.482	1.000	0.382

Group 2 0.3 mg/kg AD08821	0.681	0.235	0.655	0.419
Group 3 1.0 mg/kg AD08821	0.291	0.063	0.251	0.164
Group 4 3.0 mg/kg AD08821	0.136	0.051	0.084	0.076
Group 5 0.3 mg/kg AD09350	0.507	0.066	0.685	0.130
Group 6 1.0 mg/kg AD09350	0.250	0.090	0.211	0.093
Group 7 3.0 mg/kg AD09350	0.098	0.036	0.044	0.019
Group 8 0.3 mg/kg AD09352	0.861	0.180	0.948	0.401
Group 9 1.0 mg/kg AD09352	0.295	0.142	0.203	0.100
Group 10 3.0 mg/kg AD09352	0.166	0.043	0.004	0.005
Day 22				
Group ID	Avg SEAP	Std Dev (+/-)		
Group 1 (Saline)	1.000	0.514		
Group 2 0.3 mg/kg AD08821	0.511	0.302		
Group 3 1.0 mg/kg AD08821	0.168	0.103		
Group 4 3.0 mg/kg AD08821	0.047	0.024		
Group 5 0.3 mg/kg AD09350	0.426	0.083		
Group 6 1.0 mg/kg AD09350	0.105	0.073		
Group 7 3.0 mg/kg AD09350	0.026	0.014		
Group 8 0.3 mg/kg AD09352	0.660	0.103		
Group 9 1.0 mg/kg AD09352	0.154	0.082		
Group 10 3.0 mg/kg AD09352	0.024	0.006		

[0333] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 10) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 15. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0334] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 3.0 mg/kg (mpk) of an *MMP7* RNAi agent, 1.0 mpk of an *MMP7* RNAi

agent, 0.3 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 36.

[0335] Table 36. *MMP7* RNAi Agent and Dosing for Example 15.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 0.3 mg/kg AD08808	Single injection on day 1
Group 3 1.0 mg/kg AD08808	Single injection on day 1
Group 4 3.0 mg/kg AD08808	Single injection on day 1
Group 5 0.3 mg/kg AD09332	Single injection on day 1
Group 6 1.0 mg/kg AD09332	Single injection on day 1
Group 7 3.0 mg/kg AD09332	Single injection on day 1
Group 8 0.3 mg/kg AD09333	Single injection on day 1
Group 9 1.0 mg/kg AD09333	Single injection on day 1
Group 10 3.0 mg/kg AD09333	Single injection on day 1

[0336] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 37, with Average SEAP reflecting the normalized average value of SEAP:

Table 37. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 15.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.334	1.000	0.473
Group 2 0.3 mg/kg AD08808	0.679	0.506	0.503	0.164
Group 3 1.0 mg/kg AD08808	0.365	0.134	0.316	0.158
Group 4 3.0 mg/kg AD08808	0.116	0.069	0.099	0.084

Group 5 0.3 mg/kg AD09332	0.482	0.124	0.337	0.264
Group 6 1.0 mg/kg AD09332	0.342	0.177	0.244	0.091
Group 7 3.0 mg/kg AD09332	0.139	0.100	0.066	0.075
Group 8 0.3 mg/kg AD09333	0.562	0.377	0.502	0.250
Group 9 1.0 mg/kg AD09333	0.305	0.108	0.191	0.055
Group 10 3.0 mg/kg AD09333	0.125	0.020	0.037	0.020
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.310	1.000	0.619
Group 2 0.3 mg/kg AD08808	1.407	2.130	0.907	0.778
Group 3 1.0 mg/kg AD08808	0.308	0.131	0.333	0.270
Group 4 3.0 mg/kg AD08808	0.095	0.062	0.127	0.083
Group 5 0.3 mg/kg AD09332	1.652	2.697	0.471	0.259
Group 6 1.0 mg/kg AD09332	0.298	0.121	0.275	0.313
Group 7 3.0 mg/kg AD09332	0.065	0.052	0.070	0.045
Group 8 0.3 mg/kg AD09333	0.635	0.240	0.687	0.321
Group 9 1.0 mg/kg AD09333	0.236	0.129	0.289	0.219
Group 10 3.0 mg/kg AD09333	0.075	0.052	0.061	0.039

[0337] Each of the *MMP7* RNAi agents in each of the dosing groups, except for Groups 2 and 5 on day 22, showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 16. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0338] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mg/kg (mpk) of an *MMP7* RNAi agent, 0.5 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 38.

[0339] **Table 38.** *MMP7* RNAi Agent and Dosing for Example 16.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD08811	Single injection on day 1
Group 3 0.5 mg/kg AD08811	Single injection on day 1
Group 4 1.0 mg/kg AD08823	Single injection on day 1
Group 5 0.5 mg/kg AD08823	Single injection on day 1
Group 6 1.0 mg/kg AD09246	Single injection on day 1
Group 7 0.5 mg/kg AD09246	Single injection on day 1
Group 8 1.0 mg/kg AD09247	Single injection on day 1
Group 9 0.5 mg/kg AD09247	Single injection on day 1

[0340] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, and day 22, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 39, with Average SEAP reflecting the normalized average value of SEAP:

Table 39. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 16.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.737	1.000	0.652
Group 2 1.0 mg/kg AD08811	0.982	1.098	1.114	1.386
Group 3 0.5 mg/kg AD08811	2.107	1.950	2.015	1.885
Group 4 1.0 mg/kg AD08823	0.831	0.728	0.750	0.643
Group 5 0.5 mg/kg AD08823	0.818	0.371	0.802	0.459
Group 6 1.0 mg/kg AD09246	0.347	0.223	0.257	0.173
Group 7 0.5 mg/kg AD09246	0.592	0.649	0.535	0.640
Group 8 1.0 mg/kg AD09247	0.240	0.265	0.214	0.225
Group 9 0.5 mg/kg AD09247	1.108	0.878	2.426	1.497

Group ID	Day 22	
	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.663
Group 2 1.0 mg/kg AD08811	1.699	2.201
Group 3 0.5 mg/kg AD08811	3.642	3.831
Group 4 1.0 mg/kg AD08823	0.918	0.907
Group 5 0.5 mg/kg AD08823	0.966	0.480
Group 6 1.0 mg/kg AD09246	0.441	0.439
Group 7 0.5 mg/kg AD09246	0.795	0.983
Group 8 1.0 mg/kg AD09247	0.285	0.300
Group 9 0.5 mg/kg AD09247	0.868	0.630

[0341] Each of the *MMP7* RNAi agents in each of the dosing groups 4 through 8 showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 17. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0342] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 40.

[0343] **Table 40.** *MMP7* RNAi Agent and Dosing for Example 17.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD08821	Single injection on day 1
Group 3 1.0 mg/kg AD09890	Single injection on day 1
Group 4 1.0 mg/kg AD09891	Single injection on day 1
Group 5 1.0 mg/kg AD09352	Single injection on day 1
Group 6 1.0 mg/kg AD09908	Single injection on day 1
Group 7 1.0 mg/kg AD09909	Single injection on day 1

Group 8 1.0 mg/kg AD09330	Single injection on day 1
Group 9 1.0 mg/kg AD09892	Single injection on day 1
Group 10 1.0 mg/kg AD09332	Single injection on day 1
Group 11 1.0 mg/kg AD09894	Single injection on day 1
Group 12 1.0 mg/kg AD09895	Single injection on day 1
Group 13 1.0 mg/kg AD08801	Single injection on day 1
Group 14 1.0 mg/kg AD09896	Single injection on day 1
Group 15 1.0 mg/kg AD09897	Single injection on day 1
Group 16 1.0 mg/kg AD09898	Single injection on day 1
Group 17 1.0 mg/kg AD09899	Single injection on day 1
Group 18 1.0 mg/kg AD08811	Single injection on day 1
Group 19 1.0 mg/kg AD08823	Single injection on day 1

[0344] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 41, with Average SEAP reflecting the normalized average value of SEAP:

Table 41. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 17.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.429	1.000	0.282
Group 2 1.0 mg/kg AD08821	0.204	0.056	0.201	0.080
Group 3 1.0 mg/kg AD09890	0.179	0.120	0.204	0.117
Group 4 1.0 mg/kg AD09891	0.142	0.062	0.149	0.088
Group 5 1.0 mg/kg AD09352	0.178	0.069	0.185	0.105
Group 6 1.0 mg/kg AD09908	0.211	0.070	0.148	0.062
Group 7 1.0 mg/kg AD09909	0.162	0.068	0.096	0.062

Group 8 1.0 mg/kg AD09330	0.445	0.199	0.558	0.290
Group 9 1.0 mg/kg AD09892	0.295	0.130	0.480	0.263
Group 10 1.0 mg/kg AD09332	0.318	0.135	0.273	0.142
Group 11 1.0 mg/kg AD09894	0.218	0.106	0.190	0.127
Group 12 1.0 mg/kg AD09895	0.120	0.035	0.127	0.063
Group 13 1.0 mg/kg AD08801	0.387	0.037	0.533	0.206
Group 14 1.0 mg/kg AD09896	0.414	0.162	0.648	0.330
Group 15 1.0 mg/kg AD09897	0.682	0.497	0.740	0.487
Group 16 1.0 mg/kg AD09898	0.559	0.196	0.746	0.256
Group 17 1.0 mg/kg AD09899	0.316	0.069	0.415	0.191
Group 18 1.0 mg/kg AD08811	0.270	0.062	0.367	0.054
Group 19 1.0 mg/kg AD08823	0.213	0.057	0.291	0.079
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.354	1.000	0.137
Group 2 1.0 mg/kg AD08821	0.192	0.102	0.244	0.174
Group 3 1.0 mg/kg AD09890	0.212	0.107	0.345	0.218
Group 4 1.0 mg/kg AD09891	0.148	0.092	0.149	0.133
Group 5 1.0 mg/kg AD09352	0.165	0.089	0.299	0.201
Group 6 1.0 mg/kg AD09908	0.118	0.055	0.184	0.108
Group 7 1.0 mg/kg AD09909	0.152	0.110	0.225	0.172
Group 8 1.0 mg/kg AD09330	0.552	0.273	0.722	0.362
Group 9 1.0 mg/kg AD09892	0.477	0.257	0.851	0.596
Group 10 1.0 mg/kg AD09332	0.251	0.148	0.461	0.322
Group 11 1.0 mg/kg AD09894	0.214	0.156	0.276	0.243
Group 12 1.0 mg/kg AD09895	0.122	0.048	0.154	0.067
Group 13 1.0 mg/kg AD08801	0.423	0.060	0.555	0.107
Group 14 1.0 mg/kg AD09896	0.667	0.280	0.762	0.393
Group 15 1.0 mg/kg AD09897	0.574	0.336	0.941	0.413
Group 16 1.0 mg/kg AD09898	0.795	0.460	0.952	0.381
Group 17 1.0 mg/kg AD09899	0.437	0.230	0.487	0.290
Group 18 1.0 mg/kg AD08811	0.381	0.067	0.610	0.196

Group 19 1.0 mg/kg AD08823	0.158	0.049	0.241	0.051
-----------------------------------	-------	-------	-------	-------

[0345] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 19) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 18. In Vivo testing of *MMP7* RNAi Agents in *MMP7*-SEAP Mice.

[0346] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 42.

[0347] **Table 42.** *MMP7* RNAi Agent and Dosing for Example 18.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD08811	Single injection on day 1
Group 3 1.0 mg/kg AD09354	Single injection on day 1
Group 4 1.0 mg/kg AD09356	Single injection on day 1
Group 5 1.0 mg/kg AD09357	Single injection on day 1
Group 6 1.0 mg/kg AD09358	Single injection on day 1
Group 7 1.0 mg/kg AD09900	Single injection on day 1
Group 8 1.0 mg/kg AD09901	Single injection on day 1
Group 9 1.0 mg/kg AD09902	Single injection on day 1
Group 10 1.0 mg/kg AD09903	Single injection on day 1

[0348] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 43, with Average SEAP reflecting the normalized average value of SEAP:

Table 43. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 18.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.177	1.000	0.343
Group 2 1.0 mg/kg AD08811	0.322	0.148	0.341	0.274
Group 3 1.0 mg/kg AD09354	0.508	0.197	0.411	0.144
Group 4 1.0 mg/kg AD09356	0.561	0.222	0.528	0.171
Group 5 1.0 mg/kg AD09357	0.414	0.150	0.335	0.167
Group 6 1.0 mg/kg AD09358	0.298	0.029	0.207	0.093
Group 7 1.0 mg/kg AD09900	0.356	0.208	0.111	0.096
Group 8 1.0 mg/kg AD09901	0.581	0.053	0.360	0.077
Group 9 1.0 mg/kg AD09902	0.404	0.242	0.273	0.174
Group 10 1.0 mg/kg AD09903	0.492	0.221	0.317	0.194
Group ID	Day 22		Day 29	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.356	1.000	0.328
Group 2 1.0 mg/kg AD08811	0.493	0.227	0.623	0.316
Group 3 1.0 mg/kg AD09354	0.478	0.244	0.535	0.241
Group 4 1.0 mg/kg AD09356	0.654	0.341	0.622	0.304
Group 5 1.0 mg/kg AD09357	0.999	0.550	0.429	0.295
Group 6 1.0 mg/kg AD09358	0.398	0.475	0.241	0.108
Group 7 1.0 mg/kg AD09900	0.195	0.155	0.273	0.213
Group 8 1.0 mg/kg AD09901	0.358	0.146	0.354	0.220
Group 9 1.0 mg/kg AD09902	0.318	0.248	0.273	0.149
Group 10 1.0 mg/kg AD09903	0.375	0.241	0.399	0.230

[0349] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 10) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 19. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0350] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 0.75 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 44.

[0351] **Table 44.** MMP7 RNAi Agent and Dosing for Example 19.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 0.75 mg/kg AD08811	Single injection on day 1
Group 3 0.75 mg/kg AD10284	Single injection on day 1
Group 4 0.75 mg/kg AD09900	Single injection on day 1
Group 5 0.75 mg/kg AD10285	Single injection on day 1
Group 6 0.75 mg/kg AD09358	Single injection on day 1
Group 7 0.75 mg/kg AD10286	Single injection on day 1
Group 8 0.75 mg/kg AD10287	Single injection on day 1
Group 9 0.75 mg/kg AD10288	Single injection on day 1
Group 10 0.75 mg/kg AD10290	Single injection on day 1
Group 11 0.75 mg/kg AD10291	Single injection on day 1
Group 12 0.75 mg/kg AD10292	Single injection on day 1

[0352] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, day 22, and day 29, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 45, with Average SEAP reflecting the normalized average value of SEAP:

Table 45. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 19.

	Day 8	Day 15

Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.149	1.000	0.109
Group 2 0.75 mg/kg AD08811	0.439	0.147	0.447	0.150
Group 3 0.75 mg/kg AD10284	0.362	0.124	0.517	0.229
Group 4 0.75 mg/kg AD09900	0.473	0.107	0.363	0.204
Group 5 0.75 mg/kg AD10285	0.354	0.117	0.298	0.143
Group 6 0.75 mg/kg AD09358	0.573	0.280	0.315	0.155
Group 7 0.75 mg/kg AD10286	0.392	0.198	0.257	0.213
Group 8 0.75 mg/kg AD10287	0.448	0.166	0.259	0.083
Group 9 0.75 mg/kg AD10288	0.304	0.126	0.196	0.086
Group 10 0.75 mg/kg AD10290	0.360	0.138	0.166	0.074
Group 11 0.75 mg/kg AD10291	0.354	0.188	0.273	0.144
Group 12 0.75 mg/kg AD10292	0.914	1.247	0.661	0.865
	Day 22		Day 29	
Group ID	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)
Group 1 (Saline)	1.000	0.273	1.000	0.300
Group 2 0.75 mg/kg AD08811	0.445	0.083	0.357	0.171
Group 3 0.75 mg/kg AD10284	0.448	0.173	0.203	0.192
Group 4 0.75 mg/kg AD09900	0.330	0.133	0.263	0.110
Group 5 0.75 mg/kg AD10285	0.284	0.086	0.207	0.095
Group 6 0.75 mg/kg AD09358	0.512	0.266	0.403	0.188
Group 7 0.75 mg/kg AD10286	0.313	0.133	0.250	0.178
Group 8 0.75 mg/kg AD10287	0.310	0.065	0.224	0.026
Group 9 0.75 mg/kg AD10288	0.214	0.183	0.203	0.161
Group 10 0.75 mg/kg AD10290	0.158	0.073	0.111	0.059
Group 11 0.75 mg/kg AD10291	0.274	0.108	0.331	0.193
Group 12 0.75 mg/kg AD10292	0.676	0.892	0.702	0.726

[0353] Each of the *MMP7* RNAi agents in each of the dosing groups (i.e., Groups 2 through 12) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 20. In Vivo testing of MMP7 RNAi Agents in MMP7-SEAP Mice.

[0354] The *MMP7*-SEAP mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous injection of 200 μ l per 20g body weight containing either 1.0 mg/kg (mpk) of an *MMP7* RNAi agent, 0.5 mpk of an *MMP7* RNAi agent, or saline without an *MMP7* RNAi agent to be used as a control, according to the following Table 46.

[0355] **Table 46.** MMP7 RNAi Agent and Dosing for Example 20.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Single injection on day 1
Group 2 1.0 mg/kg AD09358	Single injection on day 1
Group 3 0.5 mg/kg AD09358	Single injection on day 1
Group 4 1.0 mg/kg AD10288	Single injection on day 1
Group 5 0.5 mg/kg AD10288	Single injection on day 1
Group 6 1.0 mg/kg AD10290	Single injection on day 1
Group 7 0.5 mg/kg AD10290	Single injection on day 1
Group 8 1.0 mg/kg AD09909	Single injection on day 1
Group 9 0.5 mg/kg AD09909	Single injection on day 1

[0356] Each of the *MMP7* RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5'-terminal end of the sense strand, as shown in Tables 5 and 7B. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n=4). Serum was collected on day 8, day 15, and day 22, and SEAP expression levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment are shown in the following Table 47, with Average SEAP reflecting the normalized average value of SEAP:

Table 47. Average SEAP normalized to pre-treatment and saline control in *MMP7*-SEAP mice from Example 20.

Group ID	Day 8		Day 15	
	Avg SEAP	Std Dev (+/-)	Avg SEAP	Std Dev (+/-)

Group 1 (Saline)	1.000	0.087	1.000	0.128
Group 2 1.0 mg/kg AD09358	0.494	0.178	0.479	0.264
Group 3 0.5 mg/kg AD09358	0.577	0.182	0.659	0.287
Group 4 1.0 mg/kg AD10288	0.333	0.144	0.307	0.242
Group 5 0.5 mg/kg AD10288	0.510	0.218	0.569	0.252
Group 6 1.0 mg/kg AD10290	0.273	0.069	0.303	0.226
Group 7 0.5 mg/kg AD10290	0.571	0.303	0.447	0.351
Group 8 1.0 mg/kg AD09909	0.129	0.075	0.054	0.019
Group 9 0.5 mg/kg AD09909	0.290	0.129	0.164	0.093
Day 22				
Group ID	Avg SEAP	Std Dev (+/-)		
Group 1 (Saline)	1.000	0.205		
Group 2 1.0 mg/kg AD09358	0.523	0.296		
Group 3 0.5 mg/kg AD09358	0.963	0.452		
Group 4 1.0 mg/kg AD10288	0.403	0.392		
Group 5 0.5 mg/kg AD10288	0.471	0.213		
Group 6 1.0 mg/kg AD10290	0.301	0.155		
Group 7 0.5 mg/kg AD10290	0.517	0.564		
Group 8 1.0 mg/kg AD09909	0.051	0.011		
Group 9 0.5 mg/kg AD09909	0.198	0.152		

[0357] Each of the *MMP7* RNAi agents in all of the dosing groups (i.e., Groups 2 through 9) showed reduction in SEAP as compared to the saline control (Group 1) across all measured time points, which as described herein, indicates inhibition of *MMP7* in the *MMP7*-SEAP mouse model.

Example 21. In Vivo Inhaled Aerosolized Administration of MMP7 RNAi Agents in Cynomolgus Monkeys.

[0358] On study day 1, male cynomolgus monkeys were administered a single deposited dose level of 1 mg/kg of the *MMP7* RNAi agent AC001514, AC001651, or AC001516 (see Tables 8, 6, and 3 for structural information.). Twelve anesthetized male non-human primates (NHPs) were exposed to either aerosolized Isotonic Saline (control article),

AC001514, AC001516 or AC001651 (test articles) using an endotracheal inhalation delivery system. All animals received a single inhalation exposure. In this study, aerosols generated using Aeroneb Solo nebulizers were delivered using a Harvard ventilation pump. The exposure duration for each of these tests was 8 minutes. Dose exposures *in vivo* were estimated by collecting aerosol on a filter at the end of the endotracheal tube in a separate *in vitro* test. One filter test was performed before and after each *in vivo* exposure. The filters were analyzed by gravimetric and chemical methods. A UV spectrometric method using SpectraMax i3x was deployed for the chemical analysis of the filters to determine the amount of test article administered over the course of the exposure.

[0359] The average deposited doses of saline control, AC001514, AC001516 and AC001651 were 0.0, 1.04, 1.12 and 1.21 mg/kg, respectively. Target deposited doses for each of the three test articles for this study were 1.0 mg/kg. The MMP7 RNAi agent was conjugated to a tridentate small molecule $\alpha\beta6$ epithelial cell targeting ligand (Tri-SM6.1, *see* Table 11) at the 5' terminal end of the sense strand, formulated in isotonic saline. The dosing groups were as follows:

[0360] **Table 48.** MMP7 RNAi Agent and Dosing for Example 21.

Group ID	AC Duplex Number
Group 1 (isotonic saline)	N/A
Group 2 (1.0 mg/kg target deposited dose Tri-SM6.1- $\alpha\beta6$ -AD09667)	AC001514
Group 3 (1.0 mg/kg target deposited dose Tri-SM6.1- $\alpha\beta6$ -AD09887)	AC001651
Group 4 (1.0 mg/kg target deposited dose Tri-SM6.1- $\alpha\beta6$ -AD09669)	AC001516

[0361] Three (3) monkeys were dosed per group. Bronchoalveolar lavage (BAL) and endobronchial brushings were collected at baseline and two weeks after a single inhalation exposure. All animals were euthanized just after blood and BAL sample collection to collect tissue of interest. Monkeys were sacrificed on study day 15, and total RNA was isolated from lung samples following collection and homogenization. The data in Table 49 shows mRNA expression sampled from the right cranial lobe, the right middle lobe, and the right

caudal lobe. Cynomolgus monkey MMP7 mRNA expression was quantitated by probe-based quantitative PCR, normalized to Cynomolgus monkey ARL1 expression, and expressed as fraction of vehicle control group (geometric mean, +/- 95% confidence interval).

[0362] Table 49. Average Relative Cynomolgus Monkey *MMP7* mRNA Expression at Sacrifice in Example 21.

Right Cranial Lobe									
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.354	0.547	1.000	0.438	0.780	1.000	0.412	0.699
Group 2 (1.0 mg/kg AC001514)	0.778	0.379	0.740	0.264	0.180	0.562	0.412	0.161	0.265
Group 3 (1.0 mg/kg AC001651)	0.115	0.049	0.085	0.202	0.093	0.173	0.461	0.278	0.703
Group 4 (1.0 mg/kg AC001516)	0.181	0.098	0.215	0.173	0.112	0.321	0.466	0.294	0.796
Right Middle Lobe									
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.227	0.293	1.000	0.466	0.874	1.000	0.366	0.577
Group 2 (1.0 mg/kg AC001514)	0.537	0.081	0.096	0.362	0.172	0.328	0.548	0.163	0.231
Group 3 (1.0 mg/kg AC001651)	0.358	0.078	0.099	0.071	0.016	0.020	0.188	0.053	0.074
Group 4 (1.0 mg/kg AC001516)	0.265	0.158	0.392	0.574	0.288	0.579	0.682	0.372	0.817
Right Caudal Lobe									
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.459	0.848	1.000	0.425	0.739	1.000	0.359	0.561

Group 2 (1.0 mg/kg AC001514)	1.180	0.184	0.219	0.565	0.043	0.047	0.583	0.136	0.177
Group 3 (1.0 mg/kg AC001651)	0.259	0.081	0.118	0.137	0.071	0.147	0.149	0.044	0.062
Group 4 (1.0 mg/kg AC001516)	0.580	0.347	0.863	0.843	0.358	0.622	0.664	0.416	1.111

[0363] As shown in the data in Table 49 above, RNAi agents AC001514, AC001651 and AC001516 showed substantial inhibition across various regions and lobes of the lung demonstrating the ability to robustly silence MMP7 expression in non-human primates.

[0364] Cynomolgus monkey MMP7 protein expression in the lung tissues and BAL was quantitated by Western blot using iBright imaging system (Thermofisher), shown in the following Table 50.

[0365] **Table 50.** Average Relative Cynomolgus Monkey MMP7 Protein Expression at Sacrifice in Example 21.

	MMP7 Protein expression in lung tissue (Right Accessory Lobe)		MMP7 protein expression in the BAL	
Group ID	Avg MMP7	Std Dev (+/-)	Avg MMP7	Std Dev (+/-)
Group 1 (isotonic saline)	1.00	0.519	1.00	0.613
Group 2 (1.0 mg/kg AC001514)	N/A		N/A	
Group 3 (1.0 mg/kg AC001651)	0.181	0.031	0.171	0.145
Group 4 (1.0 mg/kg AC001516)	N/A		N/A	

[0366] As shown in the data in Table 50 above, RNAi agent AC001651 silences MMP7 expression, showing over 80% reduction in protein expression in both lung tissues and BAL in non-human primates.

Example 22. AAV6.2FF-CAG-hMMP7.UTRs AAV Mouse Model.

[0367] The following procedure was used to evaluate MMP7 RNAi agents in an AAV mouse model. To evaluate certain MMP7 RNAi agents, a AAV6.2FF-CAG-hMMP7.UTRs (Adeno-associated virus) mouse model was used. The transgenic sequence included human

MMP7 CDS with 3'UTR. Six- to eight-week-old female C57BL/6 mice were transduced with human MMP7 using AAV with serotype 6.2FF. Mice were intratracheally administered at least 10 days prior to mutiple intracheal administration of MMP7 RNAi agents or control. Two types of AAV, AAV6.2FF-CAG-hMMP7.UTRs and AAV6.2FF-CAG-eGFP were used. The genome of the AAV6.2FF-CAG-hMMP7.UTRs construct contains the 17-1119 region of the human MMP7 cDNA sequence (GenBank NM_002423.5). AAV6.2FF-CAG-eGFP was co-dosed with AAV6.2FF-CAG-hMMP7.UTRs. eGFP was used as endogenous control to normalize human MMP7 mRNA expression by qPCR. 2E10 to 4E10 GC of the respective virus mixed in PBS in a total volume of 50 µL was intratracheally (IT) delivered into mice to create AAV-hMMP7 model mice. Lung tissues and bronchoalveolar lavage fluid (BALF) were collected 2-3 weeks after the administration of RNAi agents.

[0368] The human MMP7 mRNA and protein level expressions were measured in the lung tissues by qPCR and Western Blot. Human MMP7 protein expression in bronchoalveolar lavage fluid (BALF) was measured by ELISA.

[0369] At day 1 and Day 3, each mouse was given an intratracheal (IT) administration of 50 µL AAV solutions containing 1 GC (genome copy) of AAV6.2FF-CAG-eGFP and 2 GC of AAV6.2FF-CAG-hMMP7.UTRs in PBS or vehicle control (PBS). At Day 13, 15, and 17, each mouse was given intratracheal administration of 50 µL of different dose levels of MMP7 RNAi agents formulated in isotonic saline, or vehicle control (isotonic saline with no RNAi agent), according to the following Table 51.

Table 51. Targeted Positions and Dosing Groups of Example 22.

Group	Targeted MMP7 Gene Position (within SEQ ID NO: 1, GenBank NM_002423.5)	AAV dose	RNAi Agent and Dose	Dosing Regimen
1	N/A	PBS	Saline (no RNAi agent)	Mutiple IT doses of PBS on Day 1, 3; Mutiple IT doses of saline on day 13, 15, 17

2	N/A	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	Saline (no RNAi agent)	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of saline on day 13, 15, 17
3	971	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	3 mg/kg AC001651	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of RNAi agent on day 13, 15, 17
4	971	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	1.5 mg/kg AC001651	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of RNAi agent on day 13, 15, 17
5	971	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	0.75 mg/kg AC001651	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of RNAi agent on day 13, 15, 17
6	735	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	3 mg/kg AC002023	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of RNAi agent on day 13, 15, 17
7	735	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	1.5 mg/kg AC002023	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of RNAi agent on day 13, 15, 17
8	735	1GC of AAV6.2FF-CAG-eGFP and 2GC of AAV6.2FF-CAG-hMMP7.UTRs	0.75 mg/kg AC002023	Mutiple IT doses of AAV on Day 1, 3; Mutiple IT doses of RNAi agent on day 13, 15, 17

[0370] Each of the MMP7 RNAi agents included modified nucleotides that were conjugated at the 5' terminal end of the sense strand to an $\alpha v\beta 6$ integrin targeting ligand having the modified sequences as set forth in the duplex structures herein. (See Tables 3, 4, 5, 6, 7A, 7B, 8, 9, 10, and 11 for specific modifications and structure information related to the MMP7 RNAi agents, including Tri-SM6.1- $\alpha v\beta 6$). The MMP7 RNAi agents in Groups 3-8 each included nucleotide sequences that were designed to inhibit expression of a MMP7 gene by targeting specific positions of MMP7 mRNA as set forth in Table 50, above. (See, e.g., SEQ ID NO:1 and Table 2 for the MMP7 mRNA sequence referenced.)

[0371] Four (4) mice in each group were tested (n=4). MMP7 expression levels were determined pursuant to the procedure set forth above. Dose response of MMP7 RNAi agent AC001516 was observed in AAV6.2FF-CAG-hMMP7.UTRs mouse model. Data from the experiment are shown in the following Table 52:

Table S2. Average MMP7 Normalized to Control in AAV-hMMP7 Mice from Example 22.

Group ID	Day 31 Lung tissue mRNA		Day 31 BALF protein		Day 31 Lung tissue protein	
	Avg MMP7	Std Dev (+/-)	Avg MMP7	Std Dev (+/-)	Avg MMP7	Std Dev (+/-)
Group 1 (Saline vehicle)	N/A		N/A		N/A	
Group 2 (Saline vehicle)	1.00	0.266	1.000	0.217	1.00	0.563
Group 3 (3 mg/kg AC001651)	0.319	0.159	0.174	0.061	0.358	0.077
Group 4 (1.5 mg/kg AC001651)	0.424	0.126	0.224	0.020	0.404	0.048
Group 5 (0.75 mg/kg AC001651)	0.606	0.105	0.440	0.155	0.524	0.083
Group 6 (3 mg/kg AC002023)	0.945	0.216	0.866	0.249	0.780	0.195
Group 7 (1.5 mg/kg AC002023)	1.100	0.119	1.046	0.734	N/A	
Group 8 (0.75 mg/kg AC002023)	1.100	0.186	0.753	0.364	N/A	

[0372] As shown in Table 52, above, the RNAi agent of Group 3 (targeting position 971) was active and showed reductions of approximately 68% on day 31 (0.159) at mRNA level in the lung tissues; 83% reduction of secreted human MMP7 protein and 64% reduction of human MMP7 protein in lung tissues.

Example 23. Proof of concept efficacy studies using rodent-specific MMP7 RNAi agent in rat bleomycin-induced injury model.

[0373] It has been demonstrated that MMP7 knockout mice are protected against bleomycin-mediated lung injury (*Proc Natl Acad Sci USA*. 2002;99:6292–6297). To evaluate MMP7 RNAi agents, several proof of concept efficacy studies were developed using rodent-specific MMP7 RNAi agent in a rat bleomycin-induced injury model. MMP7 expression in a mouse bleomycin injury model was evaluated, and MMP7 mRNA levels were found to be not increased in lung tissues after bleomycin-induced injury. Furthermore, MMP7 expression transiently increased in rat lung tissues after bleomycin-induced injury. MMP7 expression peaked at 7-10 days after bleomycin-induced injury and decreased to baseline levels over 4-week period after injury.

[0374] One rat-specific RNAi agent was selected after screening and optimization in a rat bleomycin-induced injury model. Bleomycin was used to induce injury in rat. After injury, the RNAi agent was administered to the rat via 1.4 mg/kg single inhalation or multiple 3.0 mg/kg intratracheal doses. In the 2 to 4 weeks after the bleomycin-induced injury, the RNAi agent achieved 60-90% gene silencing of MMP7. Silencing MMP7 in the lung significantly attenuated lung injury in rat bleomycin model with reduced pulmonary fibrosis Ashcroft histology scores, reduced collagen deposition, decreased inflammatory response with reduced eosinophils and neutrophils in lavage fluid, decreased translatable fibrotic gene expression including Col1a2, Col5a1, Grem1, Cthrc1, Muc16. Furthermore, silencing MMP7 significantly improved pulmonary function with increased functional compliance, preserved blood oxygen content, less body weight loss and reduced mortality. MMP7 silencing by rodent-specific RNAi agent effectively protects lung from fibrosis development in intratracheal bleomycin injury model in rats.

Example 24. Passive uptake of MMP7 RNAi agents in human precision cut lung slices (PCLS).

Precision cut tissue slices (PCLS) represent an *ex vivo* model and tool for studying the structure and function of the lung in its native 3D environment, allowing for examination of the natural interactions between cells, molecules, and the extracellular matrix (ECM) *ex vivo* (Alsafadi H. N. et al, *Am J Respir Cell Mol Biol* 62(6): 681-691 (2020)). PCLS can be generated from various anatomical locations of the lung (distal and proximal), and from different species, including rodents, pigs, monkeys, and humans. However, the effectiveness of passive uptake of RNAi agents in human PCLS is still unclear. To validate the RNAi agent potency for silencing human MMP7 mRNA, fresh agarose inflated lung slices from healthy human donors were used for examination.

[0375] Saline or MMP7 RNAi agents were added to cell media, with daily media changes. The PCLS were cultured in the media from Day 1 to Day 7 and harvested at Day 8. mRNA expression of MMP7 and potential off target genes MAP3K9, MTF2, NUP107 were quantitated by qPCR normalized by endogenous control PPIA. Effective passive uptake of MMP7 RNAi agents was observed. Little off target effects was detected. MMP7 RNAi agent was administered according to the following Table 53. Data from the qPCR experiment are shown in the following Table 54.

[0376] Test Groups 11 and 12 were dosed with 1 μ M AC002026. AC002026 is an RNAi agent duplex with the same modified antisense and sense strand sequences as those of AC001514. However, the AC002026 sense strand is conjugated to an inactive enantiomer of the α v β 6 integrin targeting ligand. Due to the difference in stereochemistry, this chemically modified analogue of α v β 6 integrin targeting ligand is unable to effectively bind to α v β 6 integrin, and therefore unable to effectively support cellular intake of the AC002026 RNAi agent.

Table 53. Dosing groups and dosing regimen of MMP7 RNAi agents from Example 24.

Group ID	Dosing Regimen
Group 1 (isotonic saline)	Treatment daily in the cell media for 7 days
Group 2 AC001514 1 μ M	Treatment daily in the cell media for 7 days
Group 3 AC001514 0.3 μ M	Treatment daily in the cell media for 7 days
Group 4 AC001514 0.1 μ M	Treatment daily in the cell media for 7 days

Group 5 AC001651 1 μ M	Treatment daily in the cell media for 7 days
Group 6 AC001651 0.3 μ M	Treatment daily in the cell media for 7 days
Group 7 AC001651 0.1 μ M	Treatment daily in the cell media for 7 days
Group 8 AC002023 1 μ M	Treatment daily in the cell media for 7 days
Group 9 AC002023 0.3 μ M	Treatment daily in the cell media for 7 days
Group 10 AC002023 0.1 μ M	Treatment daily in the cell media for 7 days
Group 11 AC002026 1 μ M	Treatment daily in the cell media for 7 days
Group 12 AC002026 1 μ M	Treatment daily in the cell media for 7 days

Table S4. mRNA Expression normalized to human endogenous control PPIA_h in human PCLS from Example 24.

Group ID	Avg MMP7	Std Dev (+/-)	Avg MTF2	Std Dev (+/-)	Avg MAP3K9	Std Dev (+/-)	Avg NUP107	Std Dev (+/-)
Group 1 (isotonic saline)	1.000	0.698	1.000	0.288	1.000	0.252	1.000	0.479
Group 2 AC001514 1 μ M	0.414	1.132	1.196	0.610	1.394	0.631	0.904	0.779
Group 3 AC001514 0.3 μ M	0.616	0.960	1.003	0.569	1.091	0.655	0.637	0.579
Group 4 AC001514 0.1 μ M	0.470	0.509	0.680	1.065	0.847	0.489	0.466	1.327
Group 5 AC001651 1 μ M	0.104	0.736	0.917	0.543	0.755	0.335	0.483	1.143
Group 6 AC001651 0.3 μ M	0.102	0.284	1.575	0.492	1.221	0.867	0.675	0.633
Group 7 AC001651 0.1 μ M	0.184	0.900	1.125	0.477	1.228	0.183	0.507	0.610
Group 8 AC002023 1 μ M	0.769	1.522	0.888	0.703	1.500	0.417	0.601	0.589
Group 9 AC002023 0.3 μ M	0.760	0.566	0.727	0.734	0.983	0.286	0.563	0.740
Group 10 AC002023 0.1 μ M	0.651	0.961	0.918	0.408	1.565	0.505	0.606	0.473
Group 11 AC002026 1 μ M	0.702	0.706	0.544	0.446	0.972	0.473	0.376	0.789
Group 12 AC002026 1 μ M	0.603	1.081	0.863	0.757	0.972	0.472	0.713	1.106

[0377] Passive uptake of MMP7 RNAi agents was observed. As shown above in Table 54, the MMP7 RNAi agent uptake resulted in up to 82-90% MMP7 silencing from the most potent RNAi agent AC001651. This potency result is of similar rank order as the *in vivo* SEAP studies.

[0378] Concurrently, few off target effects were observed. The RNAi agents, upon dosing, caused only minor cytotoxic effects even at the highest dosing concentration. Such cytotoxicity and cell viability were demonstrated via MTT colorimetric assay for cell metabolic and mitochondrial activity. MTT assay showed MMP7 RNAi agent exhibiting comparable optical density (OD) as that of the control at 168 hours after dosing, as shown in Figure 3.

Example 25. In Vivo Inhaled Aerosolized Administration of MMP7 RNAi Agents in Cynomolgus Monkeys.

[0379] On study day 1, male cynomolgus monkeys were administered a single deposited dose level of 0.24 mg/kg, 0.66 mg/kg, 1.10 mg/kg, or 1.71 mg/kg of the MMP7 RNAi agent AC001651 (see Tables 8, 6, and 3 for structural information.) or isotonic saline. Three (3) animals per group (n=3), anesthetized male non-human primates (NHPs) were exposed to either aerosolized Isotonic Saline (control article) or AC001651 (test articles) via inhalation using the face mask inhalation exposure system on Day 1. In this study, aerosols generated using a Hudson Updraft II compressed air jet nebulizer and delivered to animals by face mask inhalation. Concentration in test atmospheres were determined by gravimetric analysis of filter samples (47-mm fiber film filters, 0.5 micron, GF/A) collected during all exposures at a nominal flow. After collection, the filters were removed from the filter holders and weighed. Additionally, the contents of the filters were analyzed chemically by absorbance measurement on a SpectraMax i3x spectrophotometer. AC001651 formulation samples were analyzed for concentration at the time of filter analysis.

[0380] Target deposited doses for each of the three test articles for this study were 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg and 2.0 mg/kg, respectively. The average deposited doses of saline control and AC001651 were 0.0, 0.24, 0.66, 1.10 and 1.71 mg/kg, respectively. The MMP7 RNAi agent was conjugated to a tridentate small molecule $\alpha\beta6$ epithelial cell targeting ligand (Tri-SM6.1, see Table 11) at the 5' terminal end of the sense strand, formulated in isotonic saline. The dosing groups were as follows:

[0381] Table 55. MMP7 RNAi Agent and Dosing for Example 25.

Group ID	AC Duplex Number
Group 1 (isotonic saline)	N/A
Group 2 (0.25 mg/kg target deposited dose Tri-SM6.1- α v β 6-AD09887) (Average Pulmonary Deposited Dose PDD: 0.24 mg/kg)	AC001651
Group 3 (0.5 mg/kg target deposited dose Tri-SM6.1- α v β 6-AD09887) (Average Pulmonary Deposited Dose PDD: 0.66 mg/kg)	AC001651
Group 4 (1.0 mg/kg target deposited dose Tri-SM6.1- α v β 6-AD09887) (Average Pulmonary Deposited Dose PDD: 1.10 mg/kg)	AC001651
Group 5 (2.0 mg/kg target deposited dose Tri-SM6.1- α v β 6-AD09887) (Average Pulmonary Deposited Dose PDD: 1.71 mg/kg)	AC001651

[0382] Three (3) monkeys were dosed per group. Bronchoalveolar lavage (BAL) fluid samples were collected at baseline on Day 1 and two weeks after a single inhalation exposure on Day 14. All animals were euthanized just after blood and BAL sample collection to collect tissue of interest. Monkeys were sacrificed on study day 14, and total RNA was isolated from lung samples following collection and homogenization. The data in Table 56 shows mRNA expression sampled from the right caudal lobe, the right cranial lobe, the right middle lobe, and the left caudal lobe. Cynomolgus monkey *MMP7* mRNA expression was quantitated by probe-based quantitative PCR, normalized to Cynomolgus monkey *GAPDH* mRNA expression, and the vehicle control group (geometric mean, +/- geometric SD).

[0383] Table 56. Average Relative Cynomolgus Monkey *MMP7* mRNA Expression at Sacrifice in Example 25.

	Right Caudal Lobe								
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.630	1.700	1.000	0.540	1.176	1.000	0.514	1.060
Group 2 (0.24 mg/kg AC001651)	1.113	0.269	0.354	0.609	0.078	0.089	1.099	0.238	0.304
Group 3 (0.66)	0.311	0.144	0.267	0.262	0.090	0.137	0.437	0.128	0.181

mg/kg AC001651)									
Group 4 (1.10 mg/kg AC001651)	0.259	0.067	0.091	0.240	0.105	0.188	0.310	0.141	0.258
Group 5 (1.71 mg/kg AC001651)	0.583	0.313	0.674	0.251	0.111	0.200	0.359	0.167	0.313
Right Cranial Lobe									
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.522	1.091	1.000	0.426	0.742	1.000	0.439	0.782
Group 2 (0.24 mg/kg AC001651)	0.630	0.126	0.157	0.965	0.280	0.395	1.416	0.313	0.401
Group 3 (0.66 mg/kg AC001651)	0.390	0.150	0.243	0.448	0.210	0.395	0.385	0.077	0.097
Group 4 (1.10 mg/kg AC001651)	0.216	0.093	0.162	0.221	0.087	0.142	0.193	0.054	0.075
Group 5 (1.71 mg/kg AC001651)	0.222	0.131	0.318	0.307	0.133	0.236	0.559	0.316	0.728
Right Middle Lobe									
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.572	1.336	1.000	0.425	0.741	1.000	0.443	0.796
Group 2 (0.24 mg/kg AC001651)	1.011	0.127	0.146	0.544	0.095	0.114	0.349	0.138	0.227
Group 3 (0.66 mg/kg AC001651)	0.337	0.107	0.157	0.301	0.066	0.084	0.217	0.033	0.039
Group 4 (1.10 mg/kg AC001651)	0.339	0.131	0.214	0.207	0.099	0.190	0.143	0.072	0.146

Group 5 (1.71 mg/kg AC001651)	0.236	0.118	0.238	0.224	0.096	0.169	0.265	0.097	0.154
Left Caudal Lobe									
	Hilar Region			Middle Region			Peripheral Region		
	Average	Low (error)	High (error)	Average	Low (error)	High (error)	Average	Low (error)	High (error)
Group 1 (isotonic saline)	1.000	0.579	1.376	1.000	0.504	1.014	1.000	0.461	0.856
Group 2 (0.24 mg/kg AC001651)	1.460	0.162	0.182	1.208	0.150	0.171	0.996	0.280	0.390
Group 3 (0.66 mg/kg AC001651)	0.464	0.205	0.366	0.438	0.131	0.186	0.513	0.269	0.564
Group 4 (1.10 mg/kg AC001651)	0.252	0.119	0.226	0.355	0.182	0.373	0.222	0.101	0.186
Group 5 (1.71 mg/kg AC001651)	0.400	0.190	0.363	0.366	0.154	0.265	0.364	0.164	0.298

[0384] As shown in the data in Table 56 above, RNAi agent AC001651 showed substantial inhibition across various regions and lobes of the lung demonstrating the ability to robustly silence MMP7 expression in non-human primates.

[0385] Cynomolgus monkey MMP7 protein expression in the lung tissues was quantitated by Western blot using iBright imaging system (Thermo Fisher), shown in the following Table 57.

[0386] Table 57. Average Relative Cynomolgus Monkey MMP7 Protein Expression at Sacrifice in Example 25.

	MMP7 Protein expression in lung tissue (Right Caudal Lobe)	
Group ID	Avg MMP7	Std Dev (+/-)
Group 1 (isotonic saline)	1.000	0.772
Group 2 (0.24 mg/kg PDD AC001651)	0.778	0.258
Group 3 (0.66 mg/kg PDD AC001651)	0.394	0.166
Group 4 (1.10 mg/kg PDD AC001651)	0.309	0.160
Group 5 (1.71 mg/kg PDD AC001651)	0.399	0.206

[0387] As shown in the data in Table 57 above, RNAi agent AC001651 silences MMP7 expression, showing average ~69% reduction in protein expression at 1.10 mg/kg deposited dose in lung tissues in non-human primates. PDD=pulmonary deposited dose.

[0388] MMP7 mRNA expression in BAL exosome in cynomolgus monkeys treated with single deposited dose of 0.24 mg/kg, 0.66 mg/kg, 1.10 mg/kg, or 1.71 mg/kg PDD of RNAi agent AC001651 was quantified via qPCR. The data are normalized to baseline Day -7 and GAPDH and the vehicle control group (GMEAN +/- with geometric standard deviation. The data is shown below in Table 58.

[0389] **Table 58.** MMP7 mRNA expression in BAL exosome, relative to GAPDH.

	Baseline (Day -7)		Day 14	
Group ID	Avg MMP7	Std Dev (+/-)	Avg MMP7	Std Dev (+/-)
Group 1 (isotonic saline)	1.000	1.045	2.071	0.717
Group 2 (0.24 mg/kg PDD AC001651)	1.000	1.416	1.252	1.110
Group 3 (0.66 mg/kg PDD AC001651)	1.000	0.806	0.428	1.406
Group 4 (1.10 mg/kg PDD AC001651)	1.000	0.407	0.358	0.779
Group 5 (1.71 mg/kg PDD AC001651)	1.000	0.473	0.432	0.470

[0390] As shown in the data in Table 58 above, RNAi agent AC001651 robustly silences MMP7 expression, showing average ~64% reduction in MMP7 mRNA in BAL exosomes at 1.10 mg/kg deposited dose in non-human primates.

[0391] Cynomolgus monkey MMP7 protein expression in BAL was quantitated by Western blot using iBright imaging system (Thermo Fisher), shown in the following Table 59.

[0392] **Table 59.** MMP7 protein expression in BAL.

Group ID	Baseline (Day -7)		Day 14	
	Avg MMP7	Std Dev (+/-)	Avg MMP7	Std Dev (+/-)
Group 1 (isotonic saline)	1.000	N/A	0.933	0.698
Group 2 (0.24 mg/kg PDD AC001651)	1.000	N/A	0.617	0.020
Group 3 (0.66 mg/kg PDD AC001651)	1.000	N/A	0.218	0.161
Group 4 (1.10 mg/kg PDD AC001651)	1.000	N/A	0.593	0.552
Group 5 (1.71 mg/kg PDD AC001651)	1.000	N/A	0.299	0.131

[0393] As shown in the data in Table 59 above, RNAi agent AC001651 robustly silences MMP7 expression, showing average ~78% reduction in protein expression in BAL at 0.66 mg/kg deposited dose in non-human primates.

OTHER EMBODIMENTS

[0394] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims:

1. An RNAi agent for inhibiting expression of a matrix metalloproteinase 7 gene, comprising:
 - an antisense strand comprising at least 17 contiguous nucleotides differing by 0 or 1 nucleotides from any one of the sequences provided in Table 2 or Table 3; and
 - a sense strand comprising a nucleotide sequence that is at least partially complementary to the antisense strand.
2. The RNAi agent of claim 1, wherein the antisense strand comprises nucleotides 2-18 of any one of the sequences provided in Table 2 or Table 3.
3. The RNAi agent of claim 1 or claim 2, wherein the sense strand comprises a nucleotide sequence of at least 17 contiguous nucleotides differing by 0 or 1 nucleotides from any one of the sequences provided in Table 2 or Table 4, and wherein the sense strand has a region of at least 85% complementarity over the 17 contiguous nucleotides to the antisense strand.
4. The RNAi agent of any one of claims 1-3, wherein at least one nucleotide of the MMP7 RNAi agent is a modified nucleotide or includes a modified internucleoside linkage.
5. The RNAi agent of any one of claims 1-4, wherein all or substantially all of the nucleotides are modified nucleotides.
6. The RNAi agent of any one of claims 4-5, wherein the modified nucleotide is selected from the group consisting of: 2'-O-methyl nucleotide, 2'-fluoro nucleotide, 2'-deoxy nucleotide, 2',3'-seco nucleotide mimic, locked nucleotide, 2'-F-arabino nucleotide, 2'-methoxyethyl nucleotide, abasic nucleotide, ribitol, inverted nucleotide, inverted 2'-O-methyl nucleotide, inverted 2'-deoxy nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, vinyl phosphonate-containing nucleotide, cyclopropyl phosphonate-containing nucleotide, and 3'-O-methyl nucleotide.
7. The RNAi agent of claim 5, wherein all or substantially all of the nucleotides are modified with 2'-O-methyl nucleotides, 2'-fluoro nucleotides, or combinations thereof.
8. The RNAi agent of any one of claims 1-7, wherein the antisense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 3.

9. The RNAi agent of any one of claims 1-8, wherein the sense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 4.
10. The RNAi agent of claim 1, wherein the antisense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 3 and the sense strand comprises the nucleotide sequence of any one of the modified sequences provided in Table 4.
11. The RNAi agent of any one of claims 1-10, wherein the sense strand is between 18 and 30 nucleotides in length, and the antisense strand is between 18 and 30 nucleotides in length.
12. The RNAi agent of claim 11, wherein the sense strand and the antisense strand are each between 18 and 27 nucleotides in length.
13. The RNAi agent of claim 12, wherein the sense strand and the antisense strand are each between 18 and 24 nucleotides in length.
14. The RNAi agent of claim 13, wherein the sense strand and the antisense strand are each 21 nucleotides in length.
15. The RNAi agent of claim 14, wherein the RNAi agent has two blunt ends.
16. The RNAi agent of any one of claims 1-15, wherein the sense strand comprises one or two terminal caps.
17. The RNAi agent of any one of claims 1-16, wherein the sense strand comprises one or two inverted abasic residues.
18. The RNAi agent of claim 1, wherein the RNAi agent is comprised of a sense strand and an antisense strand that form a duplex having the structure of any one of the duplexes in Table 7A, Table 7B, Table 8, Table 9, or Table 10.
19. The RNAi agent of claim 18, wherein all or substantially all of the nucleotides are modified nucleotides.
20. The RNAi agent of claim 1, comprising an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):

AGACAUUCAAAAACCAACU (SEQ ID NO:175);

UUGACACUAAUCGAUCCAC (SEQ ID NO:123);

UGACAUUCAAAAACCAACU (SEQ ID NO:176);

AGACAUUCAAAAACCAACUGC (SEQ ID NO:674);

UUGACACUAAUCGAUCCACUG (SEQ ID NO:661); or

UGACAUUCAAAAACCAACUGC (SEQ ID NO:679).

21. The RNAi agent of claim 20, wherein the sense strand consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):

AGUUGGUUUUUGAAUGUCU (SEQ ID NO:325);

GUGGAUCGAUUAGUGUCA (SEQ ID NO:273);

AGUUGGUUUUUGAAUGUCA (SEQ ID NO:326);

GCAGUUGGUUUUUGAAUGUCU (SEQ ID NO:720);

CAGUGGAUCGAUUAGUGUCA (SEQ ID NO:724); or

GCAGUUGGUUUUUGAAUGUCA (SEQ ID NO:726).

22. The RNAi agent of claim 20 or 21, wherein all or substantially all of the nucleotides are modified nucleotides.

23. The RNAi agent of claim 1, comprising an antisense strand that comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):

asGfsascauucAfaaAfaCfcAfacugsc (SEQ ID NO:396);

usUfsgsacacUfaAfuCfGafuCfcacusg (SEQ ID NO:393); or

cPrpuGfacauucAfaaAfaCfcAfacugsc (SEQ ID NO:406);

wherein a, c, g, and u represent 2'-O-methyl adenosine, 2'-O-methyl cytidine, 2'-O-methyl guanosine, and 2'-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluoro adenosine, 2'-fluoro cytidine, 2'-fluoro guanosine, and 2'-fluoro uridine, respectively; cPrpu represents a 5'-cyclopropyl phosphonate-2'-O-methyl uridine; s represents a phosphorothioate linkage; and wherein all or substantially all of the nucleotides on the sense strand are modified nucleotides.

24. The RNAi agent of claim 1, wherein the sense strand comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):


gscaguuggUfuUfuUfgaaugucu (SEQ ID NO:522);

csaguggauCfGafuUfagugucuaa (SEQ ID NO:524);

gscaguuggUfuUfuUfgaauuca (SEQ ID NO:526);


wherein a, c, g, i, and u represent 2'-O-methyl adenosine, 2'-O-methyl cytidine, 2'-O-methyl guanosine, 2'-O-methyl inosine, and 2'-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluoro adenosine, 2'-fluoro cytidine, 2'-fluoro guanosine, and 2'-fluoro uridine, respectively; and s represents a phosphorothioate linkage; and wherein all or substantially all of the nucleotides on the antisense strand are modified nucleotides.

25. The RNAi agent of any one of claims 20-24, wherein the sense strand further includes inverted abasic residues at the 3' terminal end of the nucleotide sequence, at the 5' end of the nucleotide sequence, or at both.
26. The RNAi agent of any one of claims 1-25, wherein the RNAi agent is linked to a targeting ligand.
27. The RNAi agent of claim 26, wherein the targeting ligand has affinity for a cell receptor expressed on an epithelial cell.
28. The RNAi agent of claim 27, wherein the targeting ligand comprises an integrin targeting ligand.
29. The RNAi agent of claim 28, wherein the integrin targeting ligand is an $\alpha v\beta 6$ integrin targeting ligand.
30. The RNAi agent of claim 29, wherein the targeting ligand comprises the structure:



or a pharmaceutically acceptable salt

thereof, or





or a pharmaceutically acceptable salt


thereof,

wherein $\ddot{}$ indicates the point of connection to the RNAi agent.


31. The RNAi agent of any one of claims 26-29, wherein the targeting ligand has a structure selected from the group consisting of:











9













and




wherein  indicates the point of connection to the RNAi agent.

32. The RNAi agent of claim 31, wherein RNAi agent is conjugated to a targeting ligand having the following structure:



33. The RNAi agent of any one of claims 26-29, wherein the targeting ligand has the following structure:



34. The RNAi agent of any one of claims 26-33, wherein the targeting ligand is conjugated to the sense strand.
35. The RNAi agent of claim 34, wherein the targeting ligand is conjugated to the 5' terminal end of the sense strand.
36. A composition comprising the RNAi agent of any one of claims 1-35, wherein the composition further comprises a pharmaceutically acceptable excipient.
37. The composition of claim 36, further comprising a second RNAi agent capable of inhibiting the expression of matrix metalloproteinase 7 gene expression.
38. The composition of any one of claims 36-37, further comprising one or more additional therapeutics.
39. The composition of any one of claims 36-38, wherein the composition is formulated for administration by inhalation.
40. The composition of claim 39, wherein the composition is delivered by a metered-dose inhaler, jet nebulizer, vibrating mesh nebulizer, or soft mist inhaler.
41. The composition of any of claims 36-40, wherein the RNAi agent is a sodium salt.
42. The composition of any of claims 36-41, wherein the pharmaceutically acceptable excipient is water for injection.
43. The composition of any of claims 36-41, wherein the pharmaceutically acceptable excipient is a buffered saline solution.
44. A method for inhibiting expression of a MMP7 gene in a cell, the method comprising introducing into a cell an effective amount of an RNAi agent of any one of claims 1-33 or the composition of any one of claims 36-43.
45. The method of claim 44, wherein the cell is within a subject.
46. The method of claim 45, wherein the subject is a human subject.
47. The method of any one of claims 44-46, wherein following the administration of the RNAi agent the matrix metalloproteinase 7 gene expression is inhibited by at least about 30%.
48. A method of treating one or more symptoms or diseases associated with enhanced or elevated membrane MMP7 activity levels, the method comprising administering to a human subject in need thereof a therapeutically effective amount of the composition of any one of claims 36-43.

49. The method of claim 48, wherein the disease is idiopathic pulmonary fibrosis (IPF), asthma, another type of fibrosis, chronic inflammation, interstitial lung diseases (ILD), SARS-COV-2 or another type of infectious disease, acute respiratory distress syndrome (ARDS) or another type of acute lung injury, pulmonary hypertension, cancer, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), fatty liver disease, biliary atresia, and chronic kidney disease (CKD).
50. The method of claim 49, wherein the disease is idiopathic pulmonary fibrosis (IPF).
51. The method of any one of claims 44-50, wherein the RNAi agent is administered at a deposited dose of about 0.01 mg/kg to about 5.0 mg/kg of body weight of the subject.
52. The method of any one of claims 44-51, wherein the RNAi agent is administered at a deposited dose of about 0.03 mg/kg to about 2.0 mg/kg of body weight of the subject.
53. The method of any of claims 44-52, wherein the RNAi agent is administered in two or more doses.
54. Use of the RNAi agent of any one of claims 1-35, for the treatment of a disease, disorder, or symptom that is mediated at least in part by membrane MMP7 activity and/or MMP7 gene expression.
55. Use of the composition according to any one of claims 36-43, for the treatment of a disease, disorder, or symptom that is mediated at least in part by matrix metalloproteinase 7 activity and/or matrix metalloproteinase 7 gene expression.
56. Use of the composition according to any one of claims 36-43, for the manufacture of a medicament for treatment of a disease, disorder, or symptom that is mediated at least in part by matrix metalloproteinase 7 and/or matrix metalloproteinase 7 gene expression.
57. The use of any one of claims 54-56, wherein the disease is pulmonary inflammation.
58. A method of making an RNAi agent of any one of claims 1-35, comprising annealing a sense strand and an antisense strand to form a double-stranded ribonucleic acid molecule.
59. The method of claim 58, wherein the sense strand comprises a targeting ligand.
60. The method of claim 59, comprising conjugating a targeting ligand to the sense strand.






FIG. 1



2
K
G
D
L

**FIG. 3**

